The University of Notre Dame Australia

ResearchOnline@ND
Theses
2018

Effect of a nurse-led lymphoma survivorship model of care: A pragmatic
phase II pilot randomised controlled trial
Karen Taylor
The University of Notre Dame Australia

Follow this and additional works at: https://researchonline.nd.edu.au/theses
Part of the Nursing Commons
COMMONWEALTH OF AUSTRALIA
Copyright Regulations 1969
WARNING
The material in this communication may be subject to copyright under the Act. Any further copying or communication of this
material by you may be the subject of copyright protection under the Act.
Do not remove this notice.
Publication Details
Taylor, K. (2018). Effect of a nurse-led lymphoma survivorship model of care: A pragmatic phase II pilot randomised controlled trial
(Doctor of Philosophy (College of Nursing)). University of Notre Dame Australia. https://researchonline.nd.edu.au/theses/206

This dissertation/thesis is brought to you by
ResearchOnline@ND. It has been accepted for inclusion in
Theses by an authorized administrator of ResearchOnline@ND.
For more information, please contact
researchonline@nd.edu.au.

Effect of a Nurse-led Lymphoma Survivorship
Model of Care: A Pragmatic Phase II Pilot
Randomised Controlled Trial

Karen M Taylor
Master of Nursing
Graduate Diploma in Oncology Nursing (Distinction)
Bachelor of Nursing (Post Registration)
Registered Nurse

School of Nursing and Midwifery
University of Notre Dame Australia
Fremantle Campus

This thesis is submitted for the degree of Doctor of Philosophy

2018

Table of Contents
Table of Contents .................................................................................................. i
List of Figures ..................................................................................................... vii
List of Tables ..................................................................................................... viii
Abstract .................................................................................................................. x
List of Publications ............................................................................................ xii
Other Survivorship Research Published Journal Articles ...................................... xiv
Invited Non-Peer Reviewed Papers and Presentations ........................................... xv
Conference Presentations ......................................................................................... xvi
Awards and Recognition .......................................................................................... xix

Statement of Contribution by Others............................................................... xx
Acknowledgements .......................................................................................... xxi
Chapter One — Introduction ............................................................................... 1
1.0 Introduction ..................................................................................................... 2
The Problem.................................................................................................................. 2
Aim and Objectives ...................................................................................................... 7
Design............................................................................................................................ 7
Research Questions ...................................................................................................... 8
Components of the RCT..............................................................................................11
Overview of the Thesis ...............................................................................................12
Glossary of Terms........................................................................................................15

Chapter Two — Phase One ................................................................................ 19
2.0 Literature Reviews ........................................................................................ 20
2.1 Models of Survivorship Care....................................................................... 22
Abstract ........................................................................................................................23

i

Introduction .................................................................................................................24
Method .........................................................................................................................27
Results ..........................................................................................................................30
Data Analysis and Presentation .................................................................................33
Discussion ....................................................................................................................43
Conclusion ...................................................................................................................45
Literature Review Update ..........................................................................................47

2.2 Survivorship Care Plans and Treatment Summaries ............................... 50
Abstract ........................................................................................................................51
Introduction .................................................................................................................52
Method .........................................................................................................................55
Data Analysis and Presentation .................................................................................62
Discussion ....................................................................................................................66
Conclusion and Implications for Nursing .................................................................70
Future Research ...........................................................................................................71
Literature Review Update ..........................................................................................72

2.3 Needs Assessment Measures ....................................................................... 74
Abstract ........................................................................................................................75
Introduction .................................................................................................................76
Method .........................................................................................................................79
Data Analysis ...............................................................................................................87
Results ..........................................................................................................................88
Discussion ....................................................................................................................92
Conclusion ...................................................................................................................95
Literature Review Update ..........................................................................................96
Chapter Summary .......................................................................................................97

Chapter Three — Conceptual Framework ....................................................... 99
3.0 Conceptual Framework .............................................................................. 100
Conceptual Framework ............................................................................................ 100

ii

Chapter Summary ..................................................................................................... 106

Chapter Four — Phase Two ............................................................................. 107
4.0 Intervention Development......................................................................... 108
Haematology Survivorship Research Advisory Committee (HSRAC) ................. 108
Survivorship Care Plan and Treatment Summary ................................................. 109
Measures .................................................................................................................... 112
Resource Pack ............................................................................................................ 114
General Practitioner (GP) Evaluation ...................................................................... 116
Chapter Summary ..................................................................................................... 118

Chapter Five — Methodology ......................................................................... 119
5.0 Protocol and Methods ................................................................................. 120
Abstract ...................................................................................................................... 121
Introduction ............................................................................................................... 122
Aim ............................................................................................................................. 126
Research Questions ................................................................................................... 127
Methods ..................................................................................................................... 128
Data Analysis ............................................................................................................. 138
Discussion .................................................................................................................. 140
Ethics .......................................................................................................................... 142
Chapter Summary ..................................................................................................... 143

Chapter Six — Results ...................................................................................... 144
6.0 Results of Phase Three and Phase Four.................................................... 145
6.1 Results of the Pragmatic Pilot Randomised Controlled Trial ............... 146
Statistical Techniques ................................................................................................ 146
Results ........................................................................................................................ 149

6.2 Results of the General Practitioner Evaluation ....................................... 171
Statistical Techniques ................................................................................................ 171

iii

Results ........................................................................................................................ 171

6.3 Results of Qualitative Interviews ............................................................. 175
Abstract ...................................................................................................................... 176
Introduction ............................................................................................................... 177
Methods ..................................................................................................................... 179
Data Analysis ............................................................................................................. 181
Results ........................................................................................................................ 182
Discussion .................................................................................................................. 193
Conclusion ................................................................................................................. 196

6.4 Results of Test–retest of the SF-SUNS Analysis ..................................... 197
Abstract ...................................................................................................................... 198
Introduction ............................................................................................................... 199
Methods ..................................................................................................................... 203
Data Analysis ............................................................................................................. 205
Results ........................................................................................................................ 206
Discussion .................................................................................................................. 210
Conclusion ................................................................................................................. 212
Chapter Summary ..................................................................................................... 213

Chapter Seven — Discussion .......................................................................... 215
7.0 Discussion .................................................................................................... 216
Summary of the Phase One Literature Reviews ..................................................... 219
Discussion of Phase Three Pragmatic Randomised Controlled Trial.................... 223
Discussion of the Phase Four General Practitioner Evaluations ............................ 232
Summary of the Phase Four Qualitative Interviews ............................................... 233
Summary of the Test–retest Reliability Analysis .................................................... 234
Limitations of the Research ...................................................................................... 235
Strengths of the Research .......................................................................................... 238
Chapter Summary ..................................................................................................... 240

Chapter Eight — Conclusion ........................................................................... 242

iv

8.0 Implications and Recommendations ........................................................ 243
Implications ............................................................................................................... 243
Recommendations ..................................................................................................... 245

References .......................................................................................................... 249
Appendix A ........................................................................................................ 285
A.1 Models of Survivorship Care Provision in Adult Patients with Haematological
Cancer: An Integrative Review ................................................................................ 285
A.2 Survivorship Care Plans and Treatment Summaries in Adult Patients with
Hematologic Cancer: An Integrative Literature Review ........................................ 300
A.3 Systematic Review of the Tools Used to Assess the Informational and
Practical Needs of Acute Leukaemia and Lymphoma Survivors .......................... 311
A.4 Protocol for Care After Lymphoma (CALy) Trial: A Phase II Pilot
Randomised Controlled Trial of a Lymphoma Nurse-led Model of Survivorship
Care ............................................................................................................................ 320
A.5 Qualitative Results from a Phase II Pilot Randomised Controlled Trial of a
Lymphoma Nurse-led Model of Survivorship Care............................................... 331
A.6 Test–Retest Reliability of the Short‑ Form Survivor Unmet Needs Survey ... 338

Appendix B ........................................................................................................ 346
B.1 A Qualitative Study of the Post-treatment Experiences and Support Needs of
Survivors of Lymphoma ........................................................................................... 346
B.2 Living with Multiple Myeloma: A Focus Group Study of Unmet Needs and
Preferences for Survivorship Care ........................................................................... 354

Appendix C ........................................................................................................ 365
Joint Authors’ Declarations ...................................................................................... 365

Appendix D........................................................................................................ 371
Patient Information and Consent Form ................................................................... 371

Appendix E ........................................................................................................ 378

v

Assessment Measures ............................................................................................... 378
E.1 Demographic Questionnaire .............................................................................. 378
E.2 Short-Form Survivor Unmet Needs Survey ...................................................... 380
E.3 Depression Anxiety Stress Scale ........................................................................ 384
E.4 Mini Mental Adjustment to Cancer Scale .......................................................... 385
E.5 Patient Empowerment Scale............................................................................... 387

Appendix F......................................................................................................... 389
F.1 Lymphoma Survivorship Care Plan and Treatment Summary ....................... 389
F.2 Content Validity Evaluation Form ..................................................................... 393

Appendix G........................................................................................................ 399
Control Group Letter ................................................................................................ 399

Appendix H........................................................................................................ 400
GP Letters and Evaluation ........................................................................................ 400

Appendix I ......................................................................................................... 404
Interview Questions .................................................................................................. 404

Appendix J ......................................................................................................... 407
J.1 Checklist for Nurse-led Lymphoma Survivorship Clinic Appointment ......... 407
J.2 Motivational Chart ............................................................................................... 408

Appendix K ........................................................................................................ 409
K.1 SPIRIT Checklist for Protocol ............................................................................ 409
K.2 CONSORT Statement for Pragmatic RCT......................................................... 412

Appendix L ........................................................................................................ 415
Quantitative Analysis Tables.................................................................................... 415

vi

List of Figures
Figure 1.1. Overall study design. ........................................................................11
Figure 2.1.1. Flowchart of literature search results. ..........................................29
Figure 2.2.1. Flowchart of literature search results. ..........................................61
Figure 2.3.1. Flowchart of literature search results. ..........................................81
Figure 3.1.1. Conceptual diagram of the nurse-led lymphoma survivorship
model of care ...................................................................................................... 105
Figure 5.1.1. Trial flow chart. ............................................................................129
Figure 6.1.1. CONSORT flow diagram for pragmatic RCT. ........................... 149

vii

List of Tables
Table 2.1.2 Existing or Proposed Models of Cancer Survivorship Care ..........31
Table 2.1.3 Methodological Characteristics of Models of Haematological
Cancer Survivorship Care (n=6) .........................................................................38
Box 2.2.1 Components for Haematological Survivorship Care Plan and
Treatment Summary ............................................................................................56
Table 2.2.1 Levels of Evidence ............................................................................61
Table 2.2.2 Methodological Characteristics of Haematological Cancer
Survivorship Care Plans and Treatment Summaries (n=4) ..............................63
Table 2.3.1 Inclusion and Exclusion Criteria......................................................80
Table 2.3.2 Methodological Characteristics of Selected Articles (n=9) ............83
Table 2.3.3 Comparison of Assessment Tools....................................................89
Table 5.1.1 Outcomes Assessment Instruments ..............................................134
Table 6.1.1 Demographic Characteristics for RCT Participants (n=60) .......... 151
Table 6.1.2 Top Five Concerns and Health Goals Identified from SCPTS ....155
Table 6.1.3 Linear Mixed Model Results of SF-SUNS Domains ..................... 159
Table 6.1.4 Linear Mixed Model Results of the DASS21................................. 162
Table 6.1.5 Linear Mixed Model Significant Results of Mini-MAC ............... 165
Table 6.1.6 Linear Mixed Model Results of PES ..............................................168
Table 6.1.7 Assessment Measure Items that Demonstrated a Statistically
Significant Difference between Control and Intervention Groups ................ 169
Table 6.2.1 Responses to Use of SCPTS (n=18) ................................................ 172
Table 6.2.2 Description of GP Responses (n=16)..............................................173
Table 6.3.1 Demographic Characteristics for Interview Participants (n=10) . 183
Table 6.4.1 Baseline Participant Demographic and Disease Characteristics
(n=40) ................................................................................................................... 206
Table 6.4.2 Item Test–retest Reliability and Internal Consistency (n=40) ...... 208
Table 1 Reliability of Assessment Measures .................................................... 415

viii

Table 2 Intervention Group Wilcoxon Signed Rank Test ............................... 416
Table 3 Linear Mixed Model Results of SF-SUNS Total Scale........................ 418
Table 4 Linear Mixed Model Results of Mini-MAC Domains ....................... 419
Table 5 Descriptive Data of the Multi-item Measures by Group at Each Time
Point and Between Time Points ........................................................................420
Table 6 Age Differences Across Measures at Each Time Point within the
Control and Intervention Groups ..................................................................... 422
Table 7 Gender Differences Across Measures at Each Time Point within the
Control and Intervention Groups ..................................................................... 425
Table 8 Lymphoma Differences Across Measures at Each Time Point within
the Control and Intervention Groups............................................................... 428

ix

Abstract
Background
Cancer survivorship is recognised as an integral component of the cancer
continuum. Robust evidence on how best to deliver tailored survivorship
care is limited, particularly for individuals affected by rarer cancers such as
lymphoma, a potentially curable haematological cancer. These survivors may
face long-term and late effects affecting quality of life due to the
aggressiveness of the disease and treatment that may not be adequately
addressed in current follow-up models of care.

Aim
To develop and pilot test a nurse-led model of survivorship care intervention
that utilises an individualised survivorship care plan and treatment
summary (SCPTS),

motivational interviewing,

tailored support

and

resources with lymphoma patients who have completed active treatment.

Method
A four-phase prospective study was undertaken: Phase One consisted of
integrative/systematic reviews; Phase Two focused on development of the
survivorship model of care; Phase Three comprised a pragmatic randomised
controlled trial (RCT) to test the intervention; and Phase Four elicited
qualitative feedback from intervention participants and their general
practitioners’ (GP). A published pilot pragmatic RCT protocol was
implemented and participants were randomised to a control group (n=30) or
intervention group (n=30). Four patient reported outcome measures were
administered to both groups at three time points; baseline (Time 1), 3 months
(Time 2) and six months (Time 3).

x

Data Analysis
Descriptive, univariate and multivariate statistical techniques were applied
to quantitative data. Content analysis was performed on qualitative
interview data and GP evaluations.

Results
Three comprehensive integrative/systematic reviews were undertaken,
published (survivorship models of care, SCPTS, survivorship needs
assessment measures) and informed the development of a unique and
concise evidence-based SCPTS and other model of care (intervention)
components. The intervention comprised three face-to-face appointments
over six months to deliver the lymphoma survivorship model of care.
Intervention participants reported increased self-empowerment and less
unmet needs. Test–retest reliability analysis was performed and published
for the Short-Form Survivor Unmet Needs Survey (n=40). Ten intervention
participants interviewed at completion of the RCT reported a positive
experience of the model of care. Feedback from 18/28 (64%) GPs confirmed
the SCPTS was a useful tool for patient consultations.

Conclusion
Findings add to a limited body of knowledge in lymphoma survivorship care
and nurse-led models of care. They highlight the importance and perceived
value of providing individualised, tailored support to lymphoma survivors
from treatment completion. The evidence produced from this study provides
baseline data to support future rigorous testing of nurse-led models of
lymphoma survivorship care with larger samples.

xi
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CHAPTER 1. INTRODUCTION

Chapter One — Introduction

“When I finished treatment, it was a bit like an anti-climax, it was – okay you
have finished treatment, see you later. I felt like I had just been forgotten”
Female_NHL

1

CHAPTER 1. INTRODUCTION

1.0 Introduction
This thesis consists of six related papers that provide a comprehensive
account of the development and testing of a pilot nurse-led lymphoma
survivorship model of care.

This chapter provides a brief background to lymphoma cancer, the issues
survivors face and the need to develop better models of follow-up care for
lymphoma patients who finish curative-intent treatment. An overview of the
purpose of this study, the research questions that guided all aspects of this
study are then presented. The chapter concludes with an overview of the
structure of the thesis and a glossary of terms.

The Problem
Lymphoma is a blood cancer originating from B and T cells in the lymphatic
system which undergo a malignant change. Although there are around 30
different types, they can be categorised into two main types; non-Hodgkin
lymphoma (NHL) or Hodgkin lymphoma (HL) (Cancer Australia, 2018).

In Australia, HL is considered a rarer cancer, accounting for only 0.5% of all
cancer diagnosed. It is estimated about 683 cases will be diagnosed, with
mortality around 30 cases in 2018 (Australian Institute of Health and
Welfare, 2017). Five-year relative survival at diagnosis is 87.5% (Australian
Institute of Health and Welfare, 2017). It is the most common cancer of the
adolescent and young adult population, with over a third of all incidences in
the 15–30-year age group. Unlike other types of lymphoma, HL is diagnosed
when the presence of what are termed Reed-Sternberg cells are seen in the
biopsy material (Kuppers & Hansmann, 2005).
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The majority (80%) of NHL arises from B cells and is the most common type
of lymphoma, especially in those over 50 years of age where incidence
increase with age (Australian Institute of Health and Welfare, 2017). An
estimated 5,720 cases will be diagnosed, and an estimated 1,443 deaths in
2018. Five-year relative survival at diagnosis is approximately 74%
(Australian Institute of Health and Welfare, 2017).

Combined, lymphomas represent the sixth most common cancer diagnosis in
Australia and worldwide (Cancer Australia, 2018; Howlader et al., 2016) and
tend to occur more frequently in men (Australian Institute of Health and
Welfare, 2017). Incidence and survival in Australia are increasing. An
estimated 6,232 cases were diagnosed in 2017, equating to 4.6% of all cancer
cases (Australian Institute of Health and Welfare, 2017). Conversely, an
estimated 1,481 people will have died from lymphoma, equating to 3.1% of
all cancer deaths in 2017. Improved survival rates have been attributed
predominantly to developments in treatment and supportive care options.
These include chemotherapy and/or radiotherapy and may involve
haematopoietic stem cell transplantation or immunotherapy or targeted
therapies (Carey et al., 2012). An estimated 76% of those diagnosed survive at
least five years; this is a marked increase from 52% in the mid-1980s.

With increased remission and survival rates, many survivors are living with
issues and concerns, called unmet needs, due to the aggressive nature of the
cancer and the intensity of treatment (Carey et al., 2012; Sant et al., 2014).
These long-term and late effects may have an ongoing impact on health and
quality of life (QoL) (Leeuwen & Ng, 2017; Oerlemans, Mols, Nijziel, Lybeert,
& van de Poll-Franse, 2011; Sarker et al., 2017). Difficulties faced by
lymphoma survivors may relate to: fatigue; poor nutritional intake;
decreased exercise capacity; cognition impairment; fear of recurrence;

3
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depression and anxiety; fertility issues; relationship stress; financial concerns;
employment issues; and difficulty in obtaining particular types of insurance,
for example health and/or travel insurance (Arboe et al., 2017; Bryant et al.,
2015; Daniels, Oerlemans, Krol, Creutzberg, & van de Poll-Franse, 2014;
Daniels, Oerlemans, Krol, van de Poll-Franse, & Creutzberg, 2013; de Lima et
al., 2017; Hall et al., 2016; Jones et al., 2015; Kreissl et al., 2016; Krolak,
Collins, Weiss, Harris, & Van der Jagt, 2017; Leeuwen & Ng, 2017; Linendoll
et al., 2016; Magyari et al., 2017; Mojs, Warchol-Biedermann, & Samborski,
2017; Oerlemans et al., 2014; van de Wal, van de Poll-Franse, Prins, &
Gielissen, 2016; Zimmer et al., 2015). Furthermore, health can be
compromised by an increased risk of developing other diseases such as
cardiovascular disease and second cancers (Leeuwen & Ng, 2017; Schaapveld
et al., 2015). These are often experienced earlier than the general population
(Panek-Hudson, 2013), an escalating problem in those diagnosed at a
younger age (Grinyer, 2010; Hemminki, Lenner, Sundquist, & Bermejo, 2008),
which is further elevated if treatment involves radiotherapy (Ng, LaCasce, &
Travis, 2011; Travis et al., 2012). Survivor lifestyle behaviours, such as
smoking, can likewise have an effect on secondary disease development (Ng
et al., 2011). It is important that health care providers, survivors and their
families have an awareness of potential late effects, to ensure timely and
appropriate follow-up (Ng et al., 2011).

Regardless of what is currently known about the issues faced by lymphoma
survivors, compared with other more common cancers such as breast,
prostate and colorectal, this cancer remains understudied in survivorship
literature. This gap in the published literature is important to address as
inadequate service provision at treatment completion may be leading to
unmet needs along the survivorship continuum (De Leeuw & Larsson, 2013).
When this research was proposed in 2014, no RCTs were identified that
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related to adult lymphoma survivor cohorts. Since that time there has been
one

published

RCT

reporting

a

12-week

exercise

intervention

in

haematological cancer survivors (mainly lymphoma n=33, 89%), assessing
cancer-related fatigue (Furzer et al., 2016).

The lack of published evidence-based guidelines for the ongoing
management of cancer survivors has previously been acknowledged in the
cancer literature (Phillips & Currow, 2010; Rechis, Arvey, & Beckjord, 2013).
Current follow-up care for lymphoma patients has traditionally been led by
the haematologist (Taylor, Chan, & Monterosso, 2015), with a focus largely
on recurrence surveillance (Molassiotis et al., 2017) that overlooks needsbased tailored support and information (Earle & Ganz, 2012; Jefford et al.,
2008). Likewise, no consensus exists on whether other health care providers,
such as nurses or GPs could deliver holistic care to transition survivors into
the survivorship phase upon treatment completion.

Cancer nurses have established expertise in the areas of health promotion,
information, support and resource provision (Jackson, Scheid, & Rolnick,
2013). Findings from recent studies have supported nurse-led models of
survivorship care that utilised the existing skills of experienced cancer nurses
(Beaver et al., 2012; Gates, Seymour, & Krishnasamy, 2015; Howell et al.,
2012; Jefford et al., 2016; John & Armes, 2013; Maly, Liang, Liu, Griggs, &
Ganz, 2017). An important aspect of these models was the administration of
survivor-specific and patient-centred assessment measures to accurately
ascertain and address concerns or issues that are important to the survivor.
Equally it is proposed these measures may empower survivors to seek out
information and support to manage their concerns and ongoing symptoms,
and to adopt healthy lifestyle behaviours (Fitch, 2008; Ganz, Casillas, &
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Hahn, 2008; McDowell, Occhipinti, Ferguson, Dunn, & Chambers, 2010;
Stricker et al., 2011).

Patient empowerment or activation (Klemanski, Browning, & Kue, 2016) in
this context, indicates the degree to which an individual comprehends that
he or she has a role in managing health and health care. It likewise includes
the extent to which the individual feels capable of fulfilling that role
(Hibbard, Mahoney, Stock, & Tusler, 2007). It could be argued that selfefficacy is an important indicator of a successful transition into survivorship
(Rosenberg et al., 2016).

National

and

international

professional

cancer

organisations

have

recommended the use of survivorship care plans and treatment summaries
(SCPTS) as an important aspect in the facilitation of holistic survivorship
follow-up care (Clinical Oncology Society of Australia, 2016; MacMillan
Cancer Support & NHS Improvement, 2010; McCabe, Bhatia, et al., 2013).
The provision of a written, individualised SCPTS should increase the amount
of information that is communicated to the survivor and other health
professionals such as the GP who may be responsible for future ongoing care
of survivors. A treatment summary succinctly documents an individual’s
disease and treatment information, along with potential late effects and
recommended

management.

The

survivorship

care

plan

is

then

individualised to each patient and should guide personalised follow-up care
with recommendations, screening guidelines, information and healthy
lifestyle promotion and support (Alfano, Ganz, Rowland, & Hahn, 2012;
Grant & Economou, 2008; Hausman, Ganz, Sellers, & Rosenquist, 2011;
Hewitt, Greenfield, & Stovall, 2005; Jabson & Bowen, 2013; Panek-Hudson,
2013; Taylor & Monterosso, 2015).
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Aim and Objectives
The purpose of this research was to develop and empirically test an
evidence-based nurse-led lymphoma survivorship model of care to transition
lymphoma survivors into the survivorship phase, using a pilot pragmatic
randomised controlled trial (RCT). This research aimed to facilitate the
participant randomised to the intervention group to normal functioning
sooner and to produce a reduction in perceived unmet informational,
practical and emotional needs or concerns and an increase in participant selfmanagement compared with those randomly assigned to the current
standard of care (usual care). This research will furthermore provide baseline
data to support hypothesis development, and the calculation of sample sizes
for future multisite randomised controlled trials. It thereby fills a gap in
lymphoma survivorship care where evidence-based research and outcome
evaluation of models of care is lacking (Irwin, Klemp, Glennon, & Frazier,
2011).

Design
The thesis comprised a four-phase prospective study that incorporated
quantitative and qualitative research methodology (Figure 1.1). The main
focus of this thesis was the phase II pilot pragmatic randomised controlled
trial (RCT). Pragmatic RCTs are customarily conducted in the “real-world”
setting where patients receive their usual care (Thorpe et al., 2009). In this
case, participants were recruited from the haematology department of a large
tertiary cancer centre in Perth, Western Australia. As is the case with
pragmatic RCTs, recruitment is offered to potentially all eligible patients
receiving care in the participating location. Intervention delivery and
participant follow-up are closely aligned to usual care to understand the realworld implications of the intervention and to determine the effects of the
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intervention in conditions where it would normally be applied (Thorpe et al.,
2009). Qualitative research was undertaken to complement the quantitative
findings of this study and occurred concurrently with the pragmatic RCT.
The qualitative interviews were undertaken with a subset of intervention
participants at the completion of all study measures to explore participant
perceptions of the nurse-led lymphoma survivorship clinic (NLSC)
intervention, assessment measures and SCPTS. Feedback was also sought
from intervention participants’ GPs to determine the usefulness and utility of
the SCPTS to inform practice. As there was no published test–retest
reliability data for one of the chosen assessment measures (Short-Form
Survivor Unmet Needs Survey), this process was also undertaken as part of
this thesis.

Research Questions
A number of questions guided each of the four phases.

Phase One: Systematic/Integrative Literature Reviews
1. Models of survivorship care
a. What are the common attributes of survivorship models of care
developed generally for cancer patients and specifically for
haematology cancer patients?
b. What resources are required to support these models?
c. What are the potential benefits and shortfalls of these models?
d. What outcome measures have been used to evaluate these models
and what are the findings?
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2. Survivorship care plans and treatment summaries (SCPTS)
a. What are the common attributes of SCPTS developed for
haematological cancer patients?
b. What resources are required to develop SCPTS?
c. What are the potential benefits and limitations of SCPTS?
d. What outcome measures have been used to evaluate SCPTS and
what are the findings?
3. Needs assessment measures
a. What reliable and valid measurement tools are currently available
to measure the informational and practical needs of lymphoma
cancer survivors?
b. What are the implications of the findings from the review for
future research and clinical practice?

Phase Two: Intervention Development
1. What assessment instruments will be chosen to measure: survivorspecific informational, practical and emotional needs; depression, anxiety
and stress; mental adjustment; and patient empowerment?
2. What components are required for an SCPTS designed for lymphoma
survivors?
a. How will these be tested for content validity (apparent internal
consistency, clarity and reliability)?
3. What information and resources will be required to develop a tailored
resource pack, including health promotion strategies?

Phase Three: Pilot Pragmatic Randomised Controlled Trial (RCT)
1. Do participants assigned to the nurse-led lymphoma survivorship clinic
intervention demonstrate a reduction in perceived unmet informational,
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practical and emotional needs compared with those randomly assigned to
usual care?
2. Do participants assigned to the nurse-led lymphoma survivorship clinic
demonstrate a reduction in self-reported anxiety, depression and stress
and an increase in patient self-management behaviours compared with
participants randomly assigned to usual care?
3. Does the SF-SUNS demonstrate test–retest stability and reliability over
time?

Phase Four: Qualitative Interviews / General Practitioner Evaluation
1. What questions will best elicit participant perceptions of the assessment
measures, the nurse-led survivorship model of care and the SCPTS?
a. Who should assist with the interview schedule development and
who should undertake the interviews to reduce bias?
2. What questions and format will work best to elicit general practitioner
(GP) perceptions of the utility and usefulness of the SCPTS.
a. Who is best suited to provide advice and suggestions regarding
the development of an evaluation survey and cover letter that will
maximise response rates from GPs?
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Phase 1

Integrative / Systematic reviews

Models of survivorship

Survivorship care plans

Needs assessment tools

and treatment

to measure survivorship-

summaries

specific needs

care

Phase 2
Intervention Development
(literature reviews, key stakeholders, haematology
survivorship research advisory group)

Needs

Survivorship care plan &

assessment

treatment summary

schedule & GP

measures

template

evaluation

Resource pack

Phase 4

Phase 3

RCT

Qualitative interview

Qualitative

GP feedback

interviews

1Figure 1.1. Overall study design.

Components of the RCT
The main focus of this thesis has been the pragmatic RCT to test the nurseled model of lymphoma survivorship care intervention. This intervention
comprised three core components:
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1.

The administration of four self-reporting assessment measures over three
time periods
a. Baseline (Time 1), Three months' post-treatment completion
b. Three months' post-baseline (Time 2), Six months' posttreatment completion
c. Six months' post-baseline (Time 3), Nine months' posttreatment completion

2.

Provision of an individualised SCPTS consisting of
a. Diagnosis and treatment information
b. A tailored list of potential late effects with recommendations
for the GP to follow-up
c. Participant-derived concerns, health goals and proposed
actions
d. General health information, screening recommendations and
healthy lifestyle behaviour support

3.

Provision of tailored evidence-based education, information and
resources to address participant-reported needs, likely post-treatment
physical

and

emotional

concerns

and

maximising

participant

involvement in healthy lifestyle behaviours.

Overview of the Thesis
The very nature of a thesis by publication will involve some repetition of
information, necessary to ensure the readers of the published papers can
understand the wider context. As each paper was published from 2015 to
2018, the background and literature have been constantly updated; however,
the intent of the research remains unchanged. An introduction and summary
of content are given for each chapter.

12

CHAPTER 1. INTRODUCTION

Chapter Two is the literature review section of the thesis and comprises three
published papers. The integrative review of lymphoma models of
survivorship care was published in the internationally peer-reviewed journal
Supportive Care in Cancer. The integrative review of haematological cancer
survivorship care plans and treatment summaries was published in the
internationally peer-reviewed journal Oncology Nursing Forum. The final
paper in this chapter is a systematic review of needs assessment measures
used with lymphoma survivors and was published in the peer-reviewed
journal The Australian Journal of Cancer Nursing. Although some papers
included other haematology cancers to ensure a wide range of literature was
gathered, the primary focus has always been lymphoma. Included after each
paper is an updated literature review of current published research on the
three topics previously described.

Chapter Three describes the conceptual framework that guided the
development of the nurse-led lymphoma survivorship model of care.

Chapter Four describes the development of the essential elements of the
nurse-led lymphoma survivorship model of care: the advisory committee;
the unique survivorship care plan and treatment summary (SCPTS); the
assessment measures; and the resource pack. In addition, it provides further
details on the GP evaluations that were used in Phase Four. Where possible,
repetitive information contained in the methodology section (Chapter Five)
has been reduced in this chapter.

Chapter Five provides an account of the methodology of this thesis. This
consists of a protocol paper published in the prestigious and internationally
peer-reviewed journal British Medical Journal Open. It also includes the ethical
considerations of this study.
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Chapter Six is the results of the Phase Three pragmatic RCT, GP evaluations
and qualitative interviews undertaken in Phase Four and the test–retest
reliability analysis of one of the chosen assessment measures; the Short-Form
Survivor Unmet Needs Survey (SF-SUNS). This chapter provides a reporting
of the results of the pragmatic RCT and GP evaluations and is followed by
two published papers. Qualitative interviews were conducted with a subset
of intervention participants when they completed all aspects of the study.
These results have been published in the internationally peer-reviewed
journal European Journal of Oncology Nursing. Test–retest reliability of the SFSUNS was conducted during the pragmatic RCT, results of this analysis have
been published in the internationally peer-reviewed journal Asia-Pacific
Journal of Oncology Nursing.

Chapter Seven presents a discussion of Phase One literature reviews, Phase
Three pragmatic RCT and Phase Four GP evaluations and qualitative
interviews. Additionally, a summary of the test–retest analysis is presented.
This chapter includes the limitations and strengths of this thesis research.

Chapter Eight concludes the thesis and discusses the implications of the
study findings and makes recommendations relevant to nursing research
and practice, education and future research directions.

References throughout the thesis, including published papers, have been
combined into a final reference list. All published papers are included in the
appendix in their published form. Several supplementary elements of this
thesis are included in the appendix and are listed throughout the thesis.
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Glossary of Terms
The following terms have been used in the thesis and are defined here.

Active Treatment: Treatment that is used just after diagnosis until remission
of the cancer is achieved.

Assessment Measure: A questionnaire, scale or tool to assist in gathering
information to identify and evaluate a range of issues or functional ability of
the responder.

Autologous Transplant: A stem cell transplant using the patient’s own stem
cells that are given back as a “rescue” for high-dose, myeloablative
chemotherapy.

Cancer Nurse Coordinator: A registered nurse who is highly experienced
and knowledgeable. A specialist in cancer nursing, cancer care and cancer
treatments.

Chemotherapy: Chemical drug agents used to treat cancer.

De Novo: New diagnosis of a cancer that is not related to a previous cancer.

GP: General Practitioner.

HL: Hodgkin Lymphoma. One of two main types of lymphoma characterised
by the presence of Reed-Sternberg cells. Cancer cells originate in the
lymphatic system. Overall term given to several sub-types.
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Immunotherapy: Treatment of cancer using drugs that enhance, induce or
suppress an immune response in the person to fight cancer. They are thought
to work by slowing the growth and spread of cancer cells and by helping the
immune system to recognise and kill existing cancer cells.

Informational Needs: Information to assist in decision making and the
acquisition of skills to decrease fear, anxiety and misperception.

Late Effects: Absent or subclinical toxicities of treatment that can manifest
years later.

Long-Term Effects: Toxicities or issues that appear during treatment and
persist.

MOC: Models of Care.

Motivational Interviewing: A directive, patient-centred counselling style for
eliciting behaviour change, by assisting patients to explore and resolve
ambivalence.

Myeloablative: High-dose chemotherapy that kills cells in the bone marrow
spaces, including cancer cells and normal blood-forming cells. This treatment
will cause death if untreated by a stem cell transplant.

NHL: Non-Hodgkin Lymphoma. One of two main types of lymphoma, with
cancer cells originating in both lymphoid tissue and other organs. Overall
term given to several sub-types.

NLSC: Nurse-led Lymphoma Survivorship Clinic.
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PET: Positron emission tomography. An imagining scan that detects cancer
tumours. Routinely used to assess for disease status. HL patients with a clear
mid-treatment PET no longer have routine post-treatment scans.

PCP: Primary Care Provider.

Practical Needs: Direct interventions that support the survivor to complete a
task or meet a concern.

QoL: Quality of Life.

RCT: Randomised Controlled Trial.

SCPTS: Survivorship Care Plan and Treatment Summary. The care plan is a
personalised document that guides and coordinates follow-up care after
treatment has finished. It includes recommendations, information and
resources for surveillance of the diagnosed disease, screening for potential
long-term and late effects from treatment and health-promoting behaviours.
The treatment summary section is a comprehensive summary on the disease
and treatment and may include provider contact details.

Self-efficacy: a belief in your ability to achieve a task or succeed in a specific
situation.

Self-empowerment: a belief that you know what is best for yourself, and
therefore you can take control of your life through strength of mind, goal
setting and positive choices.
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Survivorship: The experience of living with, through and beyond a diagnosis
of cancer. Including the impact on family and friends.

Targeted Therapy: Used to treat cancer by blocking the growth of cancer
cells by interfering with specific target molecules.

Unmet Need: Concerns or issues where a lack of support or services is
perceived by a person, thereby making it difficult to receive the help they feel
they require.
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Chapter Two — Phase One

“You are not going to be left to your own devices when you are finished, there
will be someone to talk to. I think that would be good yeah” Male_HL
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2.0 Literature Reviews
Three manuscripts form this chapter. The literature reviews were an integral
aspect of Phase One and guided the design of the intervention to be tested in
the pragmatic randomised controlled trial used in this study.

The first integrative review was undertaken to examine the types of
survivorship models of care that are currently used in contemporary cancer
care in Australia and internationally as well as lymphoma-specific (if any)
models of care as reported in the published literature (Taylor, K., Chan, R.J.,
& Monterosso, L. (2015). Models of survivorship care provision in adult
patients with haematological cancer: An integrative literature review,
Supportive Care in Cancer, 23(5), 1447–1458). The complete PDF version is in
Appendix A.1.

An integrative review was also undertaken to assess the survivorship care
plans and treatment summaries (SCPTS) that are being used in lymphoma
patient cohorts (Taylor, K. & Monterosso, L. (2015). Survivorship care plans
and treatment summaries in adult patients with haematological cancer: An
integrative literature review, Oncology Nursing Forum, 42(3), 283–291). The
review provided an understanding of the types of SCPTS currently used
and/or tested including the barriers and facilitators to development and
delivery of such tools. This work facilitated the creation of a unique SCPTS
for this study. The complete PDF version is in Appendix A.2.

Lastly, a systematic literature review of the needs assessment measures that
have been used and tested for the assessment of unmet survivorship unmet
needs was undertaken (Taylor, K. & Monterosso, L. (2016). Systematic review
of the tools used to assess the informational and practical needs of acute
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leukaemia and lymphoma survivors, The Australian Journal of Cancer Nursing,
17(1), 6–12). This guided the selection of the Short-Form Survivor Unmet
Needs Survey (SF-SUNS) as the key survivorship-specific measure to assess
participants in the study. The complete PDF version is in Appendix A.3.
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2.1 Models of Survivorship Care
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Models of Survivorship Care Provision in Adult Patients with
Haematological Cancer: An Integrative Literature Review.

Abstract
Purpose: Increasing numbers of haematology cancer survivors warrants
identification of the most effective model of survivorship care to survivors
from a diverse range of haematological cancers with aggressive treatment
regimens. This review aimed to identify models of survivorship care to
support the needs of haematology cancer survivors.

Methods: An integrative literature review method utilised a search of
electronic databases (CINAHL, Medline, PsycInfo, PubMed, EMBASE,
PsycArticles, Cochrane Library) for eligible articles (up to July 2014). Articles
were included if they proposed or reported the use of a model of care for
haematology cancer survivors.

Results: Fourteen articles were included in this review. Eight articles
proposed and described models of care and six reported the use of a range of
survivorship models of care in haematology cancer survivors. No
randomised controlled trials or literature reviews were found to have been
undertaken specifically with this cohort of cancer survivors. There was
variation in the models described and who provided the survivorship care.

Conclusion: Due to the lack of studies evaluating the effectiveness of models
of care, it is difficult to determine the best model of care for haematology
cancer survivors. Many different models of care are being put into practice
before robust research is conducted. Therefore, well-designed high-quality
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pragmatic randomised controlled trials are required to inform clinical
practice.

Introduction
Internationally, survivorship care is recognised as a priority in the cancer
care continuum. This has been principally guided by the Institute of
Medicine (IOM) report in 2005, From Cancer Patient to Cancer Survivor: Lost in
Transition (Hewitt et al., 2005). By 2008, sixteen European countries had
defined national cancer plans, but to date very few have survivorship
services operating (McCabe, Faithfull, Makin, & Wengstrom, 2013). The
National Coalition for Cancer Survivorship (National Coalition for Cancer
Survivorship, 2014) defines survivorship as the experience of living with,
through and beyond a diagnosis of cancer and includes the impact on family,
friends and caregivers. It is recognised throughout the literature, based on
the IOM essential components of survivorship care, that survivorship care
should include the following components (Grant & Economou, 2008;
Landier, 2009):


Prevention; screening and interventions for recurrence, long-term and
late effects; early detection of new cancers;



Assessment, support, management and information provision of
physical, psychological, social and spiritual needs;



Monitoring, information, and promotion of healthy living behaviours and
disease prevention;



Coordination of care between providers to communicate overall health
needs.

Current conventional models of survivorship care, including routine followup, predominately focus on surveillance for recurrence and monitoring of
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physical side effects, rather than provision of supportive care, health
promotion, late effects monitoring and surveillance for new cancers (De
Leeuw & Larsson, 2013; Oeffinger & McCabe, 2006). With an increasing
awareness that communication between health care professionals and
patients is suboptimal and that information provided to patients and
primary care providers at treatment completion is often inadequate (DiciccoBloom & Cunningham, 2013; McCabe & Jacobs, 2012), there is a growing
movement to redesign how survivorship follow-up care is delivered.
Furthermore, cancer patients frequently experience multiple health problems
earlier than the general population (Panek-Hudson, 2013), suggesting a need
for early and ongoing, comprehensive approaches to management designed
to promote and support patient participation in maximising recovery.

Haematology cancer patients are underrepresented and understudied in
survivorship care (Swash, Hulbert-Williams, & Bramwell, 2014) despite
international figures indicating an increase in five year relative survival rates
(Sant et al., 2014). The most common haematological cancers are leukaemia,
lymphoma and multiple myeloma (MM) (National Cancer Institute, 2006).
Each of these has distinctive and complex treatment regimens that commonly
involve aggressive high dose chemotherapy agents, and/or targeted
therapies, radiotherapy and haematopoietic stem cell transplants (Carey et
al., 2012). Unfortunately, the consequence of largely aggressive treatment
includes long-term and late physical, practical and psychosocial effects
which

include:

fear

of

recurrence;

fertility;

relationship;

financial;

employment and insurance issues (Allart, Soubeyran, & Cousson-Gélie, 2013;
Arden-Close et al., 2011; Hall, Lynagh, Bryant, & Sanson-Fisher, 2013). A
qualitative study on specialist-led follow-up with haematology cancer
survivors reported a lack of preparation and support in finding information
and resources with poor continuity of care as patients transitioned into the
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survivorship phase (Parry, Morningstar, Kendall, & Coleman, 2010). These
patients therefore may require models of survivorship care with specific
components that differ from those designed for the more common cancers
(breast, prostate and colorectal).

Two systematic reviews (Howell et al., 2012; Sussman et al., 2012) and a
literature review (De Leeuw & Larsson, 2013) on survivorship models of care
have been recently published. Sussman et al. (2012) reviewed 12 randomised
controlled trials (RCTs) and four systematic reviews. De Leeuw and Larsson
(2013) reviewed 21 nurse-led follow-up studies and Howell et al. (2012)
evaluated 10 practice guidelines and nine RCTs. All primary outcomes in the
reviewed studies were related to recurrence detection and in some cases
health-related quality of life and/or patient satisfaction (De Leeuw & Larsson,
2013; Howell et al., 2012; Sussman et al., 2012). Importantly, all studies
included cancers with similar trajectories of care (breast, prostate, colon)
making generalisations to other complex cancers such as haematological
cancers difficult. Therefore, the haematology focus of this integrative
literature review will add to the limited body of knowledge currently
available in this cohort of survivors.

This integrative literature review undertook an analysis of the literature to
examine the following questions:
1. What are the common attributes of survivorship models of care
developed generally for cancer patients

and specifically for

haematology cancer patients?
a. What resources (human, financial, tools, care plans) are required to
support these models of care?
b. What are the potential benefits and shortfalls of these models of
care?
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c. What outcome measures have been used to evaluate these models
of care and what are the findings?

Method
The integrative literature review method was chosen as the theoretical
framework to guide this review. It is structured according to five stages:
problem formulation; literature search; data evaluation; data analysis and
presentation. This allows for an in-depth evaluation of the issues
encompassing the empirical, theoretical and clinical approaches within a
structured systematic methodology (Whittemore & Knafl, 2005).
Problem formulation
To date, the term ‘Model of Care’ (MOC) has not been well defined in
published literature. In this review, MOC, as defined by the Robert Wood
Johnson Foundation (Robert Wood Johnson Foundation, 2014), is a
conceptual outline of how to plan all current and future facility and clinical
services to guide and direct a patient’s experience within a health care
system. Essential elements of any MOC include: a clear identification of
health professionals responsible for planning and coordination of care; care
delivery setting (Sussman et al., 2012); promotion of health maintenance;
effective illness interventions; and establishing and evaluating expected
clinical outcomes (Gerber, Stout, Schmitz, & Stricker, 2012).

The medical specialist has traditionally led haematology cancer care followup, however other models of cancer survivorship follow-up are now
emerging (Weaver, Jessup, & Mayer, 2013). Therefore, the focus of this
integrative literature review was to identify models of care used by health
care providers to ensure quality survivorship follow-up for haematology
cancer survivors.
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Literature search
The primary search utilised the following electronic databases: Cumulative
Index to Nursing and Allied Health Literature (CINAHL); Medline; PsycInfo;
PubMed; EMBASE; PsycArticles and Cochrane Library from earliest records
to July 2014. Combinations of the following search terms were used: (model
of care or follow-up or nurse-led or shared care or primary care provider-led
or General Practitioner-led or oncology-led or end of treatment or post
treatment) and (survivorship or cancer survivor or survivorship care) and
(cancer or neoplasm or oncology) and (haematology or leukaemia or
lymphoma or multiple myeloma). A hand search of the reference lists from
full text articles was correspondingly employed. Searches were restricted to
the English language, humans and adults. Inclusion criteria used were:
clinician experiences of MOC for the post treatment phase of haematological
cancer; articles that reported on models of care; and articles that reported on
the structure of survivorship services. Exclusion criteria were: studies with
less than a 50% haematology cancer patient/haematologist cohort; studies
that reported MOC for patients who received curative surgery only (i.e. no
chemotherapy and/or radiotherapy treatment); studies reporting MOC from
child, adolescent or adult survivors of a childhood cancer; non-cancer MOC
studies; MOC studies that lacked provider of survivorship care information;
and opinion papers, letters, editorials, commentaries, conference abstracts,
conference proceedings or case studies.

Data evaluation stage
Abstract titles were reviewed by one author [KT] to assess eligibility. A
summary of the selection process (Moher, Liberati, Tetzlaff, Altman, & The
PRISMA Group, 2009) is provided in Figure 2.1.1. The initial search yielded
2907 abstracts. Following removal of duplicate articles and screening using
the exclusion and inclusion criteria, 61 full-text articles were retrieved. Of
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these, 14 articles met the inclusion criteria and were included in this review.
Methodological characteristics documented included: authors; publication
year; country; study design; model; provider; disease; years post treatment;
sample size and response rate; resources required; potential benefits;
potential deficits; outcome measures; results and level of evidence developed
by (Melynyk & Fineout-Overholt, 2011) shown in Table 2.1.1. Due to
variations in study population and methodologies used, meta-analysis was
not possible.

SCREENING

IDENTIFICATION

2907 abstracts identified:
CINAHL, EMBASE, Medline,
PsycInfo, PsycArticles,
Cochrane Library
January 1976 - June 2014

25 abstracts identified:
manual search of preliminary
literature

2910 abstracts after duplicates

2671 abstracts

removed

excluded

239 abstracts screened
using inclusion/ exclusion
criteria
47 articles excluded
No distinction between

ELIGIBILITY

treatment and survivors in
follow-up evaluated (n= 2)
61 full-text articles
assessed for eligibility

No model of care or follow-up
evaluated (n= 22)
Perception rather than

INCLUDED

experience of a survivorship
Studies included in
qualitative synthesis
N =14

MOC (n= 11)
Less than 50% haematological
cancer survivors (n=12)

2Figure 2.1.1. Flowchart of literature search results.
1
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Table 2.1.1 Levels of Evidence
Level

Evidence

I

Systematic review of all relevant randomised controlled trials

II

At least one well designed randomised controlled trial

III

Well-designed controlled trials without randomisation

IV

Well-designed cohort studies, case control studies, interrupted time
series with a control group, historically controlled studies, interrupted
time series without a control group or with case-series

V

Systematic reviews of descriptive and qualitative studies

VI

Single descriptive and qualitative studies

VII

Expert opinion from clinicians, authorities and/or reports of expert
committees or based on physiology

Results
Study characteristics
No systematic reviews of haematology cancer survivorship models of care
were found. In total, 14 articles were included in this review. Eight articles
described and proposed different models of survivorship care (Cooper, Loeb,
& Smith, 2010; Hahn & Ganz, 2011; Hewitt et al., 2005; Landier, 2009; Leigh,
2008; McCabe, Bhatia, et al., 2013; McCabe & Jacobs, 2012; Oeffinger &
McCabe, 2006) (Table 2.1.2). An additional six articles reported the use of a
range of models of care for haematology cancer survivors: two reported
nurse-led studies (Gates, Seymour, & Krishnasamy, 2012; John & Armes,
2013) and four referred to physician-led studies (Chubak et al., 2012; DiciccoBloom & Cunningham, 2013; Frew et al., 2010; Greenfield et al., 2009) (Table
2.1.3). The included articles reported views from Australia (n=1), United
States of America (USA) (n=10) and United Kingdom (UK) (n=3), shown in
Table 2.1.3. The eight articles that described and proposed various models of
survivorship care were categorised into three main settings: hospital-based;
primary care-based and shared care and included models, providers, and
characteristics. The results are shown in Table 2.1.2.
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These included articles used multiple terms to describe clinicians. For clarity,
the following terms have been used: primary care provider (PCP) to denote
community-based general practitioners (GP) or family physicians; specialist
to represent the main hospital consultant oncologist (medical, radiation,
surgical) or haematologist; and nurse which includes nurse specialist, nurse
practitioner (NP) or nurse coordinator.

Of the six studies that reported the use of specific models of survivorship
care, four were quantitative and two were qualitative studies. Studies
reflected moderate (IV) to low (VI) levels of evidence.

2Table 2.1.2 Existing or Proposed Models of Cancer Survivorship Care
Setting
Hospital

Model
Multi-

Provider
Oncologist, network

disciplinary

of consulting

survivorship

physicians, oncology

clinic

or haematology nurse

(Oeffinger &

practitioner (NP),

McCabe, 2006)

psychologist, social
worker

Model Characteristics
 Can be consultative or
ongoing


Multiple providers seen
at same visit



Complex and resource
intense



Co-morbid and treatment
related conditions can be
addressed



Can be extension of care,
embedded in treatment
team



Disease-specific specialist
defines follow-up plan



NP follow-up who
communicates with PCP
to initiate shared care



Large patient cohort
needed
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Consultative

Specialist



Ongoing (rarely

clinic (Cooper

Oncologist takes on

et al., 2010;

primary carer role)

Leigh, 2008)
Consultative

Specialist



clinic

One-time comprehensive
visit



(Oeffinger &
McCabe, 2006)

Treatment summary and
survivorship care plan



Review of
recommendations –
surveillance, screening,
health promotion

Survivorship

Specialist



follow-up

Separate from routine
care



clinic (Hewitt
et al., 2005;

Holistic assessment of
survivor



McCabe,
Bhatia, et al.,

End of treatment or on
maintenance therapy



2013)

Treatment summary,
survivorship care plan
and individualised
information provision



Can have telephone
follow-up

Late effects

Nurse and/or

clinic

specialist



Haematology /Oncology
treatment centres

[(McCabe &
Jacobs, 2012)
Nurse-led

Oncology nurse or NP



Comprehensive, long-

(Cooper et al.,

term follow-up to assess,

2010; Hewitt et

and provide primary care

al., 2005)

needs


ASCO surveillance
recommendations used



Clinic and/or telephone
follow-up

Primary

General

Nurse collaboration



Referral for services or
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Care

survivorship

with practice

clinic (Hahn &

specialist PCP (i.e.

Ganz, 2011;

breast care PCP)

refers to specialists

Landier, 2009)
PCP-led

PCP



Full transition to PCP

(McCabe &

after treatment

Jacobs, 2012)

completion


Can have communication
from specialist: late
effects management and
surveillance



Usually low risk for
recurrence or late effects

Shared

Shared care

Care

(Hewitt et al.,

Specialist & PCP

2005; Oeffinger



Oncologist for oncology
related issues



PCP for co-morbidities,

& McCabe,

other cancer screening

2006)

and prevention

Note. ASCO American Society of Clinical Oncology; NP Nurse practitioner; PCP
primary care physician

Data Analysis and Presentation
Cancer survivorship MOC
The first component of this integrative literature review was to identify
different models of survivorship care (Table 2.1.2). Characteristically,
hospital-based follow-up care is commonly specialist-led, with often no end
point (Cooper et al., 2010; Leigh, 2008). Survivors may acquire an impression
the specialist has become their primary carer, particularly if they have
assessed and treated co-morbid conditions during the treatment phase
(Oeffinger & McCabe, 2006). Multidisciplinary disease-specific clinics
(Landier, 2009; McCabe & Jacobs, 2012; Oeffinger & McCabe, 2006) and
survivorship clinics were most often a one-time consultation for an
assessment, plan of follow-up care provision and referrals to other health
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care providers (Hewitt et al., 2005; McCabe, Bhatia, et al., 2013). Clinics
within this framework frequently consulted on one aspect of post treatment
care, such as late effects (McCabe & Jacobs, 2012).

Nurse-led survivorship clinics, as described, were mostly hospital based and
delivered a number of interventions including: information; symptom
management; psychosocial support; allied health referrals and health
promotion strategies (Cooper et al., 2010). They can involve longer
consultations and more frequent patient contact (Cooper et al., 2010; De
Leeuw & Larsson, 2013). PCP-led models involved a complete transition of
all care from the hospital specialist to PCP (Hahn & Ganz, 2011; Landier,
2009; McCabe & Jacobs, 2012). This can be challenging for specialists who
decide to transition care, as the level of knowledge and experience amongst
PCPs can differ (Landier, 2009; McCabe, Bhatia, et al., 2013).

Shared care models involved more than two providers sharing care and
responsibility (Hewitt et al., 2005; McCabe & Jacobs, 2012). According to
Oeffinger and McCabe (2006) after treatment completion, the PCP assumes
responsibility for: maintenance of survivor health; management of any comorbid conditions; ongoing physical and psychosocial concerns; and health
promotion. The medical specialist provides a survivorship care plan and
treatment summary and ongoing consultation for recurrence or problematic
late effects if required. Both providers are to undertake monitoring, therefore
a clear delineation of responsibility for particular screening and surveillance
is important (Landier, 2009). Landier (2009) identified shared care as
appropriate for low risk and even some moderate risk patients, however
intensively treated patients (i.e. haematological cancers) require specialist
monitoring.
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Nurse-led
The two studies that evaluated nurse-led follow-up in lymphoma survivors
predominately targeted late effects and health promotion. Gates et al. (2012)
studied a nurse-led component of a haematology late effects survivorship
multidisciplinary team, whereas John and Armes (2013) reported on nurses
replacing specialist-led follow-up, independently delivering comprehensive
survivorship care. Both clinics assessed for supportive care needs and
concerns and delivered health promotion and information (Gates et al., 2012;
John & Armes, 2013). John and Armes (2013) provided an annual clinic with
nurse contact details, whereas Gates et al. (2012) delivered four consultations
over a six month period. Both studies measured different outcomes and
utilised different comparative groups, thereby making them difficult to
compare, especially as Gates et al. (2012) has only published preliminary
results. John and Armes (2013) prospective comparative study of 61 patients
concluded that patient satisfaction was equivalent in the nurse-led clinic
cohort compared with the medical-led clinic cohort and was in some cases
preferred. However, the number in each group was not reported and it is
possible patient satisfaction was related more to the decrease in wait times. It
would likewise be difficult to attribute lifestyle changes to the clinic as
patients were seen annually.

Physician-led
The included physician-led studies (n=4) presented comparisons of selfreported practices in survivorship follow-up (Dicicco-Bloom & Cunningham,
2013) and clinician perceptions of survivorship follow-up (Chubak et al.,
2012; Frew et al., 2010; Greenfield et al., 2009). A qualitative exploratory
study by Chubak et al. (2012) reported the views of clinicians and
administrators (n=40) from 10 integrated cancer centres. All respondents
reported shared care was being practised. This was based on the assumption
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that all survivors have a PCP, and despite respondents reporting a lack of
standard approaches to sharing care between clinicians. Support for
survivorship-specific care appeared lacking, with 22% (n=9) observing it
would not add to current care and may decrease care integration. The
authors concluded that interviewing respondents from sites without
survivorship care would give an unbiased account. However, there may
have been a lack of awareness related to the benefits of survivorship care.

Dicicco-Bloom and Cunningham (2013) qualitatively assessed the feasibility
of a shared care survivorship model with 21 primary care clinicians. The
overall perception was that primary carers are already involved in survivor
follow-up, despite poor information provision from specialists. They
perceived electronic medical records are often inaccessible. The authors
further concluded survivorship care plan reasearch is limited. PCPs felt
excluded once patients entered the hospital system, especially when followup extended well past treatment, to healthy patients with no recurrent
cancer. This was reflected in the study by Greenfield et al. (2009) who
reported the views of clinicians (n=475) regarding long-term follow-up and
found only 5% (n=14) of haematology cancer survivors are discharged after
two years, and only 42% (n=45 lymphoma) and 32% (n=10 leukaemia) are
discharged after five years. This finding may be explained by the complex
and ongoing late effect sequelae in haematology patients and their
expectation of long-term specialist follow-up. Although respondent numbers
were not reported, it was perceived that long-term specialist follow-up gave
survivors false reassurance and perpetuated the illness role. Whereas the
PCP-led model was perceived as normalising the survivors’ experience, with
a corresponding increase in co-morbid disease management. The authors
concluded by proposing a risk stratification process whereby low risk
survivors are transitioned early to PCP and high risk survivors stay within
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the hospital model or become part of a shared care model supported by
survivorship care plans.

Frew et al. (2010) studied survivor (n=626) and clinican (n=2302) views on
different models of care. Respondents could choose from a number of followup models, but were not asked if they would reject a particular model. What
was evident in the study by Frew et al. (2010) was specialist follow-up was
the most experienced by survivors (84% n=528) and clinicians (95% n=2167).
However specialists who had experienced non-specialist models of follow up
(60% n=819) preferred this model over all others including specialist-led
(87%).
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3Table 2.1.3 Methodological Characteristics of Models of Haematological Cancer Survivorship Care (n=6)
Author
Year

Study
Design

MOC

Disease

Provider

Years' PostTreatment

Country

2012
USA
VI

Potential
Benefits

Potential
Deficits

Outcome
Measures

Results

SCP—only 5
responders
identified the
use of Support
groups

Time and lack
of specialists to
follow-up
survivors

Clearer
evidence to
support
survivorship
care needed

Perspectives
on: survivor
needs; current
survivorship
practices;
barriers; areas
for future
research

Only 2/10 sites had
formal survivorship
programs (1 nurse-led,
1 physician assistantled)

Sample Size
(Response
Rate %)

Level of
Evidence
Chubak et al.

Resources
Required

Exploratory
study

Shared care

Semistructured
telephone
interviews

10 Cancer
Research
Network sites
Cancer types
not identified

6/10 sites
survivorspecific tools
not being used

40/48 (83%)
Administrators
/clinical
leaders/provid
ers in
oncology,
primary care

Responses for
survivorship care
needs: address fear
recurrence 35%;
information on longterm effects 40%;
nutritional and
exercise support 27%;
psychosocial support
62.5%
Overall uncertainty
about best models of
survivorship care

DiCicco-Bloom

In-depth

Shared care

21 Primary

Electronic

Primary care

No guidelines

Understand

Absence of systematic
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&
Cunningham
2013
USA
VI

interviews
on
information
sharing
to/from
specialist &
patients

care clinicians
(PCC) (11 PCP
& 10 NP)

medical
records access
SCP

Unknown
patient types
or
survivorship
period

perspective
Information
sharing
ensures
effective care
transitions

or consensus
for many
cancers on
screening,
surveillance,
late effects (LE)

nature of
interactions
between
primary care,
specialist &
patient

information sharing
among PCP, patient,
specialist
Some patients continue
to see PCC during
treatment
Reliance on patients to
provide clinical
information from
specialists (not always
reliable for complex
conditions/treatment)
Academic hospital
settings were worst in
communication to PCC
SCP effect on patient
outcomes—limited
evidence

Frew et al.
2010
UK
IV

Comparison
survey on
models of
follow-up

Models
presented for
perception &
experience:
hospital-based;
telephone;
non-specialist;
group; patient
managed; no

Cancer
diagnosis or
treatment not
disclosed
Range to over
10 years
626 (21%)
survivors/carer

Nil described

Non-specialist
models tend to
provide more
psychological
support

Survey did not
ask for
survivor
diagnosis &
treatment
which may
alter model
preference
Survey did not

Perceptions of
reasons for
follow-up;
levels of
preference for
different
follow-up
models; effect
of individual
experience on

Reasons for follow-up:
monitoring for early
complications;
detecting recurrence;
detecting LE,
providing information
& support (70%)
Preference for model of
follow-up experienced:
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follow-up

940 (32%) PCP

ask if any
models would
be rejected so
potential
deficits not
identified

804 specialists
including
haematology
558
nurses/allied
health (47%)

follow-up
model
preference

86% survivors
preferred hospitalbased follow-up,
which was experienced
most (84%)
Clinicians had
experience of more
models of follow-up
Specialists endorsed
non-specialist or
patient managed
follow-up (87%)
PCP endorsed
hospital-based and
patient managed
follow-up (83%)

Gates et al.
2012
Australia
IV

Quasiexperimental
comparison
healthy
cohort versus
Hodgkin
lymphoma
(HL)
survivors

Late effects
MDT
haematology
transplant
physician,
radiation
oncology,
cardiology,
endocrinology,
primary care
liaison,
psychology,

HL
5 years
30 HL + 30
healthy
participants
(91%)

Education
package

Health
promotion

Screening tools

Psychosocial
issues
identified &
resources and
support given

(Late Effects
Supportive
Care Needs
Screening Tool;
The General
Health Index;
The Health
Promoting

Importance of
surveillance
Survivor sees
all relevant

SCP not given
until 2nd visit
(at 4 months)

Primary
outcome:
health
promotion
intervention
from nurse to
improve HL
survivors
knowledge
and motivation
to adopt health
promoting

No final published
results from this study
Anecdotal analysis
shows appreciation of:
SCP; screening
assessment

40

LE social
worker, LE
CNC)

Lifestyle
Profile II)

2009
UK
IV

E-survey
comparison
of clinician
views on
long-term
follow-up

PCP-led

behaviours
Secondary
outcomes:
improved
perception of
health status;
reduced LE
unmet needs;
reduced LE
worry

SCP copy to
survivor/PCP

Nurse-led
clinic for
health
promotion: 2
visits + 2
phone calls
Greenfield et
al.

providers on
same day

18–45-year-old
breast,
lymphoma,
leukaemia, or
germ cell
survivors
>2 years
421 cancer
clinicians (36%
haematologist,
33%
oncologist,
18% surgeon,
10% nurse, 2%
other)
54 PCP

Communicatio
n
Specialist
nurse support
(91% most
important
resource)
Risk
stratification—
low risk to
PCPs, high risk
hospital
follow-up
SCP & TS

Specialists can
focus on acute
care
Lower costs
PCP: existing
relationship
with survivor;
accessible;
convenient;
knowledge of
local support;
expertise in
chronic health

Potential loss
of outcome
data, LE
information to
specialists
PCP: Lack
expertise in
survivor-ship
issues,
increases
survivor
anxiety, time
issues
No tumour
specific followup guidelines

Compare longterm followup: reasons for
follow-up;
advantage/disa
dvantage of
PCP-led
follow-up;
current
practice;
resources and
support
required

Specialists rated
clinical reasons for
follow-up higher
Nurses and PCP rated
both clinical &
supportive reasons
higher
Reasons for follow-up:
PCP rated recurrence
(96%)
Specialists rated LE
(76%) recurrence (71%)
Haematologist use of
follow-up protocol for
leukaemia and
lymphoma 19%
Discharge to PCP: 5%
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at 2 years
42–32% by 5 years
John & Armes
2013
UK
IV

Prospective
comparison
specialist-led
versus nurseled

Survivorship
follow-up
clinic
Nurse-led
(replaces
specialist
follow-up)

Lymphoma

2 CNS

3 years

Information
prescription

50 notes
audited (25 per
group)
120 survivors
(60 per group)
assessed wait
time
61 (82%)
survivors
assessed
patient
satisfaction

Longer
consultations
Written
information
provision
Holistic needs
assessment
Monitoring for
late effects
Health
promotion
Post-treatment
contact

Annual clinic
visit Preferred
clinic not
assessed

Documentatio
n
Wait time
Patient
satisfaction

Documentation
improved—50% of
psychological & sexual
issues still not
recorded
Wait times reduced
from average 65 mins
(specialist) to 10 mins
(Nurse)
Nurse-led was equal to
specialist-led clinic and
preferred in some
areas
Nursing telephone
workload increased

(unclear split
medical-led
versus nurseled)
Note. CNC Cancer Nurse Consultant; CNS Cancer Nurse Specialist; HL Hodgkin Lymphoma; LE Late effects; MDT multi-disciplinary team; MM multiple
myeloma; NHL Non-Hodgkin Lymphoma; NP Nurse practitioner; PCP primary care provider; SCP survivorship care plan; TS treatment summary
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Discussion
Deciding upon a model of survivorship follow-up care for haematology
cancer survivors is difficult due to the considerable variability between the
types of haematological cancers, range of treatment regimens and long-term
and late effects that impact the survivorship phase of the cancer continuum
(Hall, Lynagh, et al., 2013). For haematology cancer survivors, different
models have been proposed and utilised. However, we are unable to
determine the best or the most appropriate model. This finding is consistent
with those of Campbell et al. (2011), reporting that no model was identified
as better than any others. The reasons for these findings are that most of the
articles were not evaluative in nature, and do not allow comparison. Patients
who have only received a single model of care would not be able to comment
on potential benefits of other models of care, therefore further research in
understanding survivors’ perspectives of follow-up care is required.

The transition of survivor care to the PCP requires PCP willingness. A study
involving PCP views reported the willingness to accept exclusive care for
lymphoma patients was three years after treatment completion (Del Giudice,
Grunfeld, Harvey, Piliotis, & Verma, 2009). This may be due to the complex
nature and length of the treatment regimens (Allart et al., 2013) and a lack of
tumour specific follow-up protocols used by haematologists (Greenfield et
al., 2009). With a lack of guidance and comprehensive information
communicated from the haematologist (Dicicco-Bloom & Cunningham, 2013;
Greenfield et al., 2009), PCPs may be reluctant to accept exclusive care of
what they perceive as complex and ‘high risk’ patients (Del Giudice et al.,
2009). Shared care maybe more satisfatory to haematologists, survivors and
PCPs as it encompasses the strengths and expertise of providers from more
than one discipline. As a study of follow-up care providers has reported, a
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high proportion of survivors are followed up by multiple providers
(Forsythe et al., 2014). Therefore, it is important that good coordination and
communication is in place to reduce the possibility of either incomplete or
duplication of services between multiple providers. Cooper et al. (2010)
proposed that patients’ transition into survivorship phase and out to primary
care through specialist nurses so that monitoring for recurrence, psychosocial
needs and health promotion are addressed and communicated to survivors
and health care providers. This too has implications with John and Armes
(2013) demonstrating that increased nurse workload occurred with patients
utilising telephone contact between the scheduled clinic visits.

Establishing survivorship care provision will require careful planning and
robust prospective evaluations. It is important to note that coordinated
survivorship care interventions are complex interventions (Medical Research
Council, 2000) and can be resource intensive, requiring robust evaluations
using patient and system outcomes. This integrative review identified the
three models of care: physician-led, nurse-led and shared care models.
Ultimately, high quality pragmatic RCTs are required to test the effectiveness
of these models. There is an urgent need for health research funders to
understand the need for good survivorship cancer care and fund the
development and evaluation of the effects of various models of survivorship
care.

To the best of our knowledge, this review is the first that examines the
characteristics, resources required and effectiveness of survivorship care
models specifically for patients with haematological cancer. A number of
limitations of this review are acknowledged. The search revealed only a
relatively small number of articles that met the inclusion criteria.
Furthermore, the variation of study methodology, range of measures,
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populations and follow-up approaches made it difficult to compare models
of care and enabled only tentative conclusions (Gates et al., 2012; John &
Armes, 2013). Additionally, short-term follow-up or the timing of
interventions may have been insufficient to report whether different models
have impacted survivorship care. Finally, an inherent bias in interpretation
might be due to the evaluator.

Conclusion
There is a paucity of effectiveness research related to haematology cancer
survivors and specifically models of survivorship care in this cohort. Shared
care models have been suggested as an alternative to exclusive specialist
care. For shared care to work effectively ongoing communication channels
need to be established and maintained. Nurse-led models have been
proposed as another feasible model, where a specialist nurse intervenes
directly and acts as the conduit between patient, hospital-based treatment
team and PCP. However, more research is needed to define how these
models should be best configured and evaluated for their effectiveness. For
future

development,

a

haematology-specific

survivor-based

needs

assessment tool, individualised treatment summary and survivorship care
plan would be integral. These would assist in guiding survivor-centred
screening, health promotion and identification of needs to be monitored and
managed. This approach may address many of the barriers that have been
postulated.

Future research will need to account for increasing cancer incidence and
survival rates, making extensive specialist follow-up care more difficult to
maintain for new patients and survivors. To provide quality survivorship
care, new and innovative models of haematology survivorship follow-up are
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required that address the need for long-term follow-up that accounts for
potential late treatment effects, risks of secondary cancers, development of
treatment related co-morbid conditions and psychosocial well-being. This
review revealed a lack of high quality evidence suggesting the effectiveness
of any single model of care. A well-designed pragmatic randomised
controlled trial, assessing patient and system outcomes including costs, is
required to inform clinical practice.
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Literature Review Update
The same search criteria, terms and databases were reviewed to ascertain
recent developments or research in lymphoma models of survivorship care
in the published literature. The search period was 2014 to January 2018. In
this period, no new models of haematology or lymphoma-specific
survivorship care were proposed or tested.

Results revealed 10 abstracts worthy of further assessment. Five articles
either did not include lymphoma cohorts (Downs-Holmes, Dracon,
Svarovsky, & Sustin, 2014; Hebdon, Abrahamson, McComb, & Sands, 2014;
Jefford et al., 2016; Ye, Cheung, Goddard, Horvat, & Olson, 2015) or used a
lymphoma cohort of less than 50% (Sharp et al., 2014). One article reported
the perception of quality care rather than a model of survivorship care
(Tzelepis et al., 2015). Of the remaining articles reviewed, three studies were
related to follow-up care that was already occurring with survivors (Christen
et al., 2016; Franco et al., 2017; Matheson et al., 2016), and the fourth article
reported a study of

nurses opinions

regarding

survivorship care

(Langbecker, Ekberg, Yates, Chan, & Chan, 2016). Although these articles
would not have met the original inclusion criteria, they have been described
below as they continue to inform current follow-up practices which may not
be meeting the needs of lymphoma survivors.

Two articles reported studies of survivors who had been diagnosed with
cancer, including lymphoma, when they were aged between 16–39 years
(Christen et al., 2016; Matheson et al., 2016). Christen et al. (2016) reported
the preferences for support from survivors who were more than five years'
post-diagnosis and showed that 92 (57%) were still receiving follow-up with
a medical focus. There was a clear preference for oncology specialist follow-
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up. Conceivably this could be due to a lack of exposure to other models of
survivorship care and the need for late effects monitoring. A study of HL
survivors (n=10), two and seven months' post-treatment (Matheson et al.,
2016) described the loss of security when treatment completed. Survivors
wanted better preparation and information for the future regarding recovery,
such as mitigating the effects of fatigue; body image; fertility; sexuality;
employment; socialising; and how to assess for lymphoma recurrence. No
model of survivorship care was proposed; however, the authors suggested
informal peer support and use of patient navigators as a worthwhile support
mechanism when treatment completes.

Two qualitative studies examined specialist-led discussions (Franco et al.,
2017) and haematology cancer nurses’ opinions on survivorship care
(Langbecker et al., 2016). The specialist-led qualitative study recorded 21
discussions led by doctors who were transitioning their lymphoma patients
into the survivorship phase (n=40 patient visits recorded) (Franco et al.,
2017). The study revealed a lack of consistency in discussion content or
format. Data revealed that patients were seeking normalisation of their
current health problems and trying to understand their general health in the
future. Doctors did not provide reassurance or predictions of long-term
outcomes. Patients were encouraged by their doctors to seek routine followup with other health care providers once specialist follow-up ceased after
five years. Health promotion discussions were haphazard, with few specific
recommendations, assistance or referrals. Social issues and emotional health
and well-being were not widely discussed. The authors indicated that if
discussions on the important areas of health promotion and psychosocial
issues had occurred, it might have decreased fear of recurrence, distress and
uncertainty. Likewise, the authors suggested these types of discussions may
have acknowledged and supported patients who have experienced a major
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life event which could have ongoing impacts on personal relationships,
finances and employment (Franco et al., 2017). The study of haematology
cancer nurses’ opinions (n=136) of survivorship care (Langbecker et al., 2016)
revealed two main themes; the ongoing focus on active treatment, and which
health professional should be responsible for providing survivorship care.
The authors indicated nurses were interested in developing models of
survivorship care; however, there were many challenges to overcome before
this type of survivorship care could be utilised.

These articles support the continuing need to explore survivorship models of
care that are patient-centred, structured and address concerns of perceived
importance to the survivor when treatment is completed.
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2.2 Survivorship Care Plans and Treatment
Summaries
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Survivorship Care Plans and Treatment Summaries in Adult
Patients with Hematological Cancer: An Integrative Literature
Review.

Abstract
Problem Identification: Survivorship care plans [SCPs] and treatment
summaries [TS] have been recommended by the Institute of Medicine as
facilitators to deliver holistic survivorship follow-up care. An integrative
literature review was undertaken to identify current SCPs and TS to meet
haematological cancer survivors needs.

Literature Search: A search of relevant electronic databases for eligible
articles was executed. Included articles described SCP and/or TS use with
haematological cancer survivors or haematologists.

Data Evaluation: Four articles that reported on experience, dissemination or
components of SCPs and/or TS were included. Haematology-specific
literature was limited and no randomized control trials or literature reviews
were found for the haematological cancer survivor cohort.

Synthesis: Content analysis was used to summarize the findings.

Conclusions: This review revealed a lack of high quality evidence evaluating
the effectiveness of SCPs and/or TS on haematological survivorship followup care. Nurses have established expertise in health promotion, information,
support and resource provision, and therefore can develop and disseminate
SCPs and TS to facilitate communication between the survivor, specialist and
primary care.
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Implications for Practice or Research: Well-designed randomized control
trials on SCPs and TS are required, especially for cancers not well
represented in the literature.

Introduction
Survivorship, as defined by the National Coalition for Cancer Survivorship
(2014), is the experience of living with, through and beyond a diagnosis of
cancer including the impact on family, friends and caregivers. Survivorship
care is recognized as a priority in the cancer care continuum and, has largely
been driven by the Institute of Medicine [IOM] report in 2005, From Cancer
Patient to Cancer Survivor: Lost in Transition (Hewitt et al., 2005). A key
recommendation of this report was provision of a survivorship care plan and
treatment summary (SCPTS) for all survivors (Palmer et al., 2014). Following
the report many countries around the world developed and initiated national
cancer initiatives (McCabe, Faithfull, et al., 2013). Utilising IOM essential
elements,

SCPTS,

survivorship

care

should

include

the

following

components (Grant & Economou, 2008; Landier, 2009; Rechis et al., 2013):


Prevention; screening and intervention for recurrence, long-term and late
effects; early detection of new cancers or second malignancies (including
recommended surveillance guidelines such as colonoscopy, skin checks,
mammogram, pap smear); and co-morbidities;



Psychosocial

well-being

assessment,

support,

management

and

information provision for physical, psychological, social and spiritual
needs;


Monitoring, information, and promotion of healthy living behaviours and
disease prevention including: diet and exercise recommendations;
tobacco cessation; decreasing alcohol consumption; sun protection; and
healthy weight management; and
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Coordination of care between providers to communicate overall health
needs.

Currently, routine follow-up focuses largely on surveillance for recurrence
and monitoring physical side effects; thus, neglecting supportive care, health
promotion, late effects monitoring and surveillance for new cancers (De
Leeuw

&

Larsson,

2013). There

is an increasing

awareness that

communication between health care professionals, including primary care
providers [PCPs] and patients is suboptimal, and that important information
is

often not

provided

at

treatment

completion

(Dicicco-Bloom &

Cunningham, 2013; McCabe & Jacobs, 2012). Furthermore it is reported that
cancer patients frequently experience multiple health problems earlier than
the general population (Panek-Hudson, 2013). This suggests a need for
comprehensive early and ongoing approaches to management that should
take advantage of ‘teachable moments’ at the end of active treatment to
promote and support patient participation in maximising recovery by the
adoption of healthy lifestyle behaviours (Alfano et al., 2012; Grant &
Economou, 2008; Hewitt et al., 2005; Panek-Hudson, 2013).

The provision of SCPTS have been seen as important elements of
communication with survivors and the numerous multi-disciplinary health
care providers. What appears as an obvious solution to ensuring optimal
follow-up and recommendation adherence is hampered by the complexity of
cancer types and treatment. Especially evident within haematological cancers
which are made up of diverse blood, immune and bone marrow diseases that
make standardisation of inclusions very difficult (Rechis et al., 2013).
Furthermore, in this survivor cohort there is an absence of clear guidelines
for follow-up care (Earle, 2007; Phillips & Currow, 2010; Rechis et al., 2013).
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The most common haematological cancers are leukaemia, lymphoma and
multiple myeloma [MM] (National Cancer Institute, 2006). Each cancer type
has distinctive and complex treatment regimens that commonly involve high
dose chemotherapy agents, and/or targeted therapies, radiotherapy and
hematopoietic stem cell transplants (Carey et al., 2012), often at different
institutions. Unfortunately, the outcome of these largely aggressive
treatments is a number of long-term and late physical, practical and
psychosocial effects which commonly include: fear of recurrence; fatigue;
nutrition; exercise; fertility; relationship; financial; employment; and
insurance issues (Allart et al., 2013; Hall, Lynagh, et al., 2013). These patients
therefore require SCPTS that reflect disease-specific differences rather than
those designed for the more common cancers (breast, prostate and colorectal)
who follow similar patterns of survivorship and for whom SCPTS templates
are widely available.

Haematological cancer patients are understudied and underrepresented in
survivorship care (Swash et al., 2014) despite increasing five-year relative
survival rates internationally (Sant et al., 2014). Consequently, the
haematology focus of this integrative review will add to the limited body of
knowledge currently available in this cohort of survivors.

This integrative review undertook an analysis of the literature to examine the
following questions:
1. What are the common attributes of SCPs and TS developed for
haematological cancer patients?
a. What resources (human, templates) are required to develop
these SCPs and TS?
b. What are the potential benefits and limitations of these SCPs
and TS?
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c. What outcome measures have been used to evaluate these SCPs
and TS and what are the findings?

Method
The integrative review method was chosen as the theoretical framework to
guide this literature review as it allows for an in-depth evaluation of the
issues encompassing the empirical, theoretical and clinical approaches within
a structured systematic methodology (Whittemore & Knafl, 2005). The
method is structured according to five stages: problem formulation; literature
search; data evaluation; data analysis and presentation (Whittemore & Knafl,
2005).

Problem formulation
In this review, a SCP is defined as a personalised document that guides and
coordinates follow-up care, including recommended surveillance, screening,
and health promoting behaviours, in addition to providing information,
education and resources for management of potential long-term and late
effects of cancer treatment (Hausman et al., 2011; Salz et al., 2014). Within
cancer survivorship, TS specifically refer to comprehensively summarised
information on disease, procedures and treatments received for a particular
cancer (Hausman et al., 2011; Jabson & Bowen, 2013). The aim of these tools
is to provide written communication from the treatment team to survivor,
and current and future health care providers with clear delineation of
responsibility of care (Earle, 2006; McCabe, Bhatia, et al., 2013). A number of
components have been proposed for inclusion in SCPTS based on
recommendations from the IOM (Hewitt et al., 2005). An overview of
relevant components for haematological cancer survivors have been listed in
Box 2.2.1 and have been adapted from the published literature (Ganz et al.,
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2008; Hewitt et al., 2005; McCabe, Bhatia, et al., 2013; Palmer et al., 2014; Salz
et al., 2014).

There is consensus that responsibility for the creation and dissemination of
these tools rests with the treating team (Earle, 2007; Hausman et al., 2011;
Hewitt, Bamundo, Day, & Harvey, 2007; McCabe, Faithfull, et al., 2013; Salz
et al., 2014; Stricker et al., 2011). However, it has been identified that
development of such individualised tools are time consuming, especially if
treatment occurs across multiple sites and there is a lack of integration or
absence of electronic records (Earle, 2007; McCabe, Bhatia, et al., 2013; Parry,
Kent, Forsythe, Alfano, & Rowland, 2013; Rechis et al., 2013; Salz et al., 2014).
Accordingly, nurses have been suggested as the logical choice to create and
deliver SCPTS, not only to “free up” specialists time but also because of their
well-established role in providing information to patients that is holistic and
individualised (Jackson et al., 2013; Marbach & Griffie, 2011).
4Box 2.2.1 Components for Haematological Survivorship Care Plan and
Treatment Summary
Survivorship Care Plan


Follow-up schedule including all relevant health care providers responsibility



Recovery timeframes for treatment toxicities



Health care providers responsible for (including provision of referral/tests):
o

monitoring of long-term effects and onset of potential late effects

o

monitoring and screening for recurrence and second cancers

o

recommended cancer screenings (e.g. mammogram, pap smear, skin
checks, colonoscopy)

o


co-morbid conditions

Monitoring for potential physical, psychological, social issues and referrals for:
o

fear of recurrence

o

anxiety / depression

o

relationship issues (marital, parenting, family and friends)

o

fertility and sexual functioning

o

employment, financial assistance, insurance, legal aid
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o




counselling

Promotion of healthy lifestyle behaviours
o

smoking cessation

o

alcohol reduction

o

healthy dietary modifications, weight reduction

o

physical activity

Resource list and where to find information on:
o

support groups

o

other allied health providers

o

specific disease and treatment information

Treatment Summary


Diagnosis, tests performed, results



Disease characteristics, site, stage / classification



Date of treatment initiation and completion



Chemotherapy / targeted therapy drugs and cycles: amount, alterations
(reduction / escalation)



Type of Surgery (if applicable)



Radiotherapy: site, dosage, timeframe



Clinical trials



Blood product support



Transplant: Allogeneic / Autologous



Maintenance treatments and impact on health



Adverse reactions or complications



Contact information for each modality



Coordinator of continuing care contact information



Psychosocial, nutritional, and other supportive services used

Templates can reduce the time required to complete SCPTS, providing
information is readily accessible. The American Society of Clinical Oncology
[ASCO] and NursingCenter Prescription for Living provide three page
downloadable templates (McCabe, Partridge, Grunfeld, & Hudson, 2013).
Internet-based SCP tools such as the Journey Forward™ Survivorship Care
Plan Builder and LIVESTRONG™ Care Plan (Hausman et al., 2011) deliver a
comprehensive summary and detailed long-term follow-up plan of care once
pertinent information is provided. However their utility is limited by the
length (14 pages) of the tool (McCabe, Partridge, et al., 2013). For survivors
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and health care professionals outside the USA, educational and supportive
care resources may not be applicable. Hill-Kayser et al. (2013) studied use
and satisfaction of the LIVESTRONG Care Plan and found responding
survivors rated the provision and amount of information as good to excellent
(93% n=276). Interestingly it was reported that 65% (n=186) of responding
survivors had not been given information contained in the SCP by health
care providers after treatment completion. Furthermore, psychosocial
concerns or risks were often not addressed, thereby necessitating later
delivery after a health care professional had performed a follow-up needs
assessment (Belansky & Mahon, 2012). Ganz et al. (2008) and Stricker et al.
(2011) proposed a dedicated survivorship visit is ideal to assess needs and
deliver SCPTS, however, they did not stipulate when that visit should take
place.

The majority of studies on SCPTS are largely descriptive or exploratory and
have not established evidence that use of SCPTS improve survivor outcomes
(Grant & Economou, 2008; McCabe, Faithfull, et al., 2013). A randomised
control trial of breast cancer patients by Grunfeld et al. (2011) compared SCP
provision to PCPs with usual care (no SCP), and showed no difference in
patient-reported outcomes between the two groups. This study has been
criticised (Jefford, Schofield, & Emery, 2012; Stricker, Jacobs, & Palmer, 2012)
as control PCPs received a comprehensive discharge letter that may have
contained recommendations for follow-up. Since both groups may have
received similar information albeit in different formats, results should be
viewed with caution due to potential contamination of the control group.
Since published literature in haematological cancer survivorship is rare the
focus of this integrative review was to identify SCPTS used with
haematological cancer survivors to facilitate development of tools that can be
used with this unique survivor cohort.
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Literature search
The primary search utilised the following electronic databases: Cumulative
Index to Nursing and Allied Health Literature [CINAHL]; Medline; PsycInfo;
PubMed; EMBASE; PsycArticles and the Cochrane Library from January
2000 to July 2014. Combinations of the following search terms were used:
(survivorship care plan or treatment summary or follow-up care plan or post
treatment plan or written follow-up instructions) AND (survivorship or
cancer survivor) AND (cancer or neoplasm or oncology) AND (haematology
or leukaemia or lymphoma or multiple myeloma). A hand search of
reference lists from full texts was also employed. Searches were restricted to
the English language, humans and adults. Inclusion criteria were: studies
that reported on SCP and TS use in post treatment phase of haematological
cancer survivorship; and studies that reported usage perceptions of SCPTS
experienced by health care providers and/or survivors. Exclusion criteria
were: studies with less than a 25% haematological cancer patient cohort or
haematologist viewpoint; studies reporting SCPTS from child, adolescent,
adult survivors of a childhood cancer or non-cancer populations; and
opinion papers, letters, editorials, commentaries, conference abstracts,
conference proceedings or case studies.

Data evaluation stage
Abstract titles were reviewed by one author [KT] to assess eligibility. A
summary of the selection process (Moher et al., 2009) is provided in Figure
2.2.1. The initial search yielded 697 abstracts. Duplicate articles were
removed and abstracts were screened against the inclusion and exclusion
criteria. Abstracts that did not provide cancer or provider type were sought
for further screening. Twenty full-text articles were retrieved; of these four
articles

were

reviewed.

Documented

methodological

characteristics

included: authors and study information; intervention; sample characteristics
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including participant details, response rate and years' post treatment;
outcome measures; results; limitations and comments and level of evidence
as developed by (Melynyk & Fineout-Overholt, 2011). Due to variations in
study population and methodologies used, meta-analysis was not possible.
Results are shown in Table 2.2.1.

The haematology component in the majority of studies was low. No
systematic reviews on studies related to SCPTS were identified. The four
included studies were all from the USA. They assessed both survivor and
clinician views on the experience of receiving or disseminating SCPTS.
Included articles used various terms to describe treating clinicians. For clarity
in this integrative review, the term specialist will refer to the following
treating consultants: haematologist, medical or radiation oncologist. The
research studies all used quantitative approaches and reflected a low level
(IV) of quantitative evidence. Reviewed studies were related to the
survivorship phase of the cancer trajectory.
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3Figure 2.2.1. Flowchart of literature search results.

5Table 2.2.1 Levels of Evidence
Level

Evidence

I

Systematic review of all relevant randomised control trials

II

At least one well designed randomised control trial

III

Well-designed controlled trials without randomisation

IV

Well-designed cohort studies, case control studies, interrupted time
series with a control group, historically controlled studies, interrupted
time series without a control group or with case series

V

Systematic reviews of descriptive and qualitative studies

VI

Single descriptive and qualitative studies

VII

Expert opinion from clinicians, authorities and/or reports of expert
committees or based on physiology

(Melynyk & Fineout-Overholt, 2011)
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Data Analysis and Presentation

Characteristics of reviewed articles are detailed in Table 2.2.2.
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6Table 2.2.2 Methodological Characteristics of Haematological Cancer Survivorship Care Plans and Treatment Summaries (n=4)
Author
Curcio et al
2012
USA

Friedman
et al
2010
USA

Study
Design
Pre/posttest
questionnaire

Mailed
questionnaire

Intervention
Survivorship
protocol with
SCPTS
developed by
specialist and
NP (40–75
minutes to
complete)
Delivered by NP
using ASCOgeneric template
SCP and rating
of the most
important
informational
needs

Sample
Characteristics
30 survivors
convenience sample
included:
breast (53%); NHL
(26%); lung (10%);
gastrointestinal
(10%)
<2 years' posttreatment
10/24 (41%) PCP
8/10 (80%) staff
67/164 (41%) NHL
survivors
9 months–12.6 years'
post-treatment
22/76 (29%)
physicians involved
in survivorship care

Outcome Measures

Results

Improved disease
knowledge
Decreased anxiety
Satisfaction
Fidelity to NCCN
follow-up guidelines
Cost-benefit analysis

Increased knowledge: disease,
treatment, follow-up, signs of
recurrence, LE
Decreased anxiety
High satisfaction in survivors
(76%) and staff (100%)
PCP satisfied (100%)
Consistent fidelity to NCCN
guidelines

Informational SCP
needs of survivors /
physicians
Congruence between
survivors /
physicians

Survivor needs: recurrence
screening, LE, treatment,
overall health monitoring,
nutrition, exercise, insurance,
finances
Physician needs: treatment
complications
Higher concordance on
medical issues compared to
psychosocial issues

Limitations and
Comments
Low anxiety
scores at baseline
Small samples
No cost-benefit
analysis
SCPTS to
survivor/PCP

Level of
Evidence
IV

Small samples
Same questions
for
survivors/physicia
ns
Disease specific
cohort

IV
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Merport et
al
2012
USA

Mailed
questionnaire

SCPTS
developed /
delivered by
specialist
TS inclusions
reported:
diagnosis; stage;
treatment; start
dates; treatment
fields; drugs

108/369 (29%)
specialists
[Haematologist
(32%)]
400/3568 (11%) PCP
Cancers reported:
breast (44%); prostate
(36%); colorectal
(35%); lung (31%);
haematology (20%)

SCP and TS use and
obstacles among
specialists
SCP and TS receipt
and informational
preferences among
PCPs

Use: 56% prepare TS
14% prepare SCP (sent to
PCP/patient)
Obstacles: 47% no training;
46% no template; 40% no
reimbursement
Receipt of TS 54%
Information preferences: 95%
treatment summary; 89%
follow-up schedule; 89%
recommendations; 84%
potential side effects; 67%
treatment-related health risks

Sabatino et
al
2013
USA

2010
National
Health
Interview
Survey
[NHIS] data

Survivor
reported receipt
of TS or written
follow-up plan

1345 (60.8%)
survivors including:
breast (20%); prostate
(14%); cervix/uterus
(13%); melanoma
(11%); colorectal
(8%); other (31%)
[including
haematology]
<4 years and >4 years
post treatment

Receipt of TS and/or
follow-up
instructions
Recent surveillance
for recurrence, other
cancer screening

Survivors <4 years received:
38% TS
58% written follow-up
29.4% both
33.1% neither
More treatment modalities—
lower TS provision
Higher income and clinical
trial participation—higher
written instruction provision

Low response
rates
Self-reported
practices
Responder bias
(potential over
estimation of use)
Reported lack of
routine use of
TS/SCP

IV

Haematology
IV
sample % not
specified
Self-reported data
may not reflect
actual documents
received
Separate reporting
of survivors
diagnosed after
IOM report
(<4 years)
Note. ASCO-American Society of Clinical Oncology; IOM-Institute of Medicine; LE-late effects; NCCN-National Comprehensive Cancer Network; NHL-nonHodgkin lymphoma; NP-nurse practitioner
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The study by Sabatino et al. (2013) reported a subset of survivors (n=407)
who were within four years of diagnosis, a timeframe that corresponded to
the IOM report calling for all survivors to receive SCPTS. Survivors were
asked if they had ever received a SCP and /or TS. The authors found that 38%
(n=155) of survivors acknowledged receipt of a treatment summary and 58%
(n=236) written follow-up instructions or plan. The authors reported that
written follow-up instructions were received more often in those recipients
who were part of a clinical trial (85% n=346) and demographically were
reported as having a higher income (67% n=274). Hematopoietic stem cell
transplant survivors were included, however numbers were not reported.

Curcio, Lambe, Schneider, and Khan (2012) studied both survivors and
clinicians. Haematological cancer survivors accounted for 26% (n=8) of the
overall survivor cohort studied (n=30). Survivors were highly satisfied with
the provision of SCPTS and reported an increase in knowledge. Anxiety
levels decreased, although levels were not high at baseline, and may have
decreased naturally with time. Equally survivor satisfaction may have been
related to the survivorship visit and follow-up telephone call rather than SCP
provision. PCPs were reported as being satisfied (100% n=10) with SCPTS.
The authors reported PCPs appreciated the content, which aided
communication and were useful tools to provide clarification of the
survivor’s follow-up plan.

Friedman, Coan, Smith, Herndon II, and Abernethy (2010) studied nonHodgkin lymphoma survivors (n=67) and physicians (n=22) involved in
survivorship care. The informational needs on the SCP were reported as
being congruent between the PCP and survivor. Interestingly all respondents
rated medical content more important than psychosocial issues, perhaps
reflecting survivor expectations in the current model of survivorship follow-
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up. Furthermore, survivors ranked the plan to monitor overall health the
sixth most important element of the SCP compared to physicians who
ranked it thirteenth. This led the authors to conclude that survivors’ view
follow-up as part of general health maintenance, whereas physicians
separate cancer survivorship care and non-cancer related care.

Merport, Lemon, Nyambose, and Prout (2012) evaluated clinician (n=108) use
and PCP (n=400) receipt of SCPTS. Fifty-four percent (n=216) of PCPs
received a TS. However, the study reported that only 42% (n=46) of
specialists (including haematologists) prepared a TS. SCP preparation by
specialists was low at 14% (n=15), nonetheless the authors reported all SCP
were sent to survivors and PCPs. Barriers identified in this study included:
no template was provided; no training was given to health care professionals
on how to develop SCPTS; and specialists perceived no financial
reimbursement was given for their time in developing and delivering SCPTS.
Therefore, a lack of support from treating clinicians may mean development
and dissemination remains low, with the possibility SCP remains medically
focused.

All these studies showed a lack of routine use of SCP TS even though
survivors and PCPs valued the tools and the direction for survivorship
follow-up they provided.

Discussion
Published haematology research regarding SCPTS is limited. Currently no
randomised control trials or literature reviews exist for this understudied
cohort of cancer survivors. This is despite the current belief that SCPTS are
beneficial in complex and rare cancer survivor groups such as haematology
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(Mor Shalom, Hahn, Casillas, & Ganz, 2011) where health problems may take
many years to develop (Sabatino et al., 2013). With the increased risk of
psychosocial, physical and economic long-term and late effects from disease
and cancer therapy, patients often experience difficulties accessing post
treatment follow-up which may potentially lead to poorer overall health
outcomes (Friedman et al., 2010).

Within the literature that reported the development and dissemination of the
SCPTS (Curcio et al., 2012; Merport et al., 2012) there was a lack of
information regarding resources used by the specialist to develop the SCPTS
(Merport et al., 2012). Similarly, information on how generic ASCO templates
were tailored by the specialist and nurse practitioner for the different cancer
survivors was not provided (Curcio et al., 2012). Details on any evidencedbased guidelines for follow-up care used in SCP (Merport et al., 2012), and
the clinical expertise of the health professionals creating SCPTS was equally
lacking.

Standardised templates linked to electronic health records that would
directly populate TS have been proposed to provide health providers with
diagnosis and treatment information (Merport et al., 2012; Salz et al., 2014),
particularly relevant when survivors have had treatment across a number of
sites (Merport et al., 2012). Sabatino et al. (2013) similarly found low TS and
SCP delivery when survivors had more than one treatment modality.
Furthermore, the long duration of treatment that occurs in some
haematological cancer regimens can make it difficult to find and summarise
dose modifications and issues that have occurred over the entire treatment
phase. It is clear that haematology-specific cancer SCPTS templates and
guidelines are necessary as generic cancer templates cannot convey all the
appropriate information required, adding to the complexity of this issue
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(Friedman et al., 2010). As recommended by Curcio et al. (2012) and Sabatino
et al. (2013) provision of SCPTS soon after treatment completion is required
to assess the need for information and resources.

Friedman et al. (2010) argued that providing extra information to survivors
could overload and dilute the impact of the most important information that
needs to be conveyed. This view is supported by Cox and Faithfull (2013)
who

reported

clinicians

consider

late

effects

information

impacts

psychological adjustment and increases the amount of late effects through
autosuggestion. However, these authors reflect the perception of clinicians
rather than patients and as Hill-Kayser et al. (2013) argue this paternalistic
approach is no longer acceptable. Providing tailored SCPTS to cancer
survivors, empowers individuals to learn about their disease and treatment
and assume responsibility for future surveillance and disease management,
facilitating engagement in a future healthy lifestyle (Jackson et al., 2013). This
is particularly vital for younger survivors given the expectation of a longer
survivorship period (Jabson & Bowen, 2013).

Multidisciplinary collaboration has been suggested (Mor Shalom et al., 2011)
as a strategy for developing SCPTS. Interdisciplinary education needs to
acknowledge the value of each provider’s contribution within the team.
Recommendations that clearly detail provider responsibility can ensure
survivors are not over or under tested and adhere to recommendations that
are evidenced or consensus based (Curcio et al., 2012).

Nurses can be a key component in implementing care plans, and providing
comprehensive

information,

education

and

resources,

especially

in

preventative health and screening as reported by Curcio et al. (2012). Mor
Shalom et al. (2011) revealed nurse practitioner-developed SCP may not be
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read by PCPs, and indeed 100% PCPs (n=15) reported they would not act
upon expensive testing recommendations. Therefore, specialists need to
reinforce the importance of nurses as an essential element in survivorship
care planning (Hewitt et al., 2007).

It is important that SCPTS be developed in conjunction with a robust model
of haematological survivorship follow-up care that will address the issues
and barriers related to implementation. Many professional organisations are
calling for SCP development for accreditation, but there is risk that cancer
programs that develop SCP to meet professional requirements may be
reluctant to make the organisational changes necessary to actually deliver the
SCP to survivors and PCPs (Birken, Mayer, & Weiner, 2013). Institutions
and/or specialists who perceive a lack of financial reimbursement and
support for the additional time required to prepare and deliver SCPTS
maybe be disinclined to support widespread implementation (Earle, 2007;
McCabe, Partridge, et al., 2013; Salz et al., 2014).

A number of limitations of this review are acknowledged. The search
revealed a small number of articles meeting inclusion criteria. All studies
reviewed had low sample numbers and/or response rates, especially for
those studies which explored PCP experiences of SCPTS. Haematological
survivor and haematologist

numbers were limited, decreasing the

applicability to haematological cancer survivors. The reliance on selfreported practices in all the studies and a lack of comparison groups restricts
the conclusions that can be drawn. Study participants may have had more
experience with and/or a bias towards or against SCPTS implementation.
This lack of standardisation makes it difficult to compare and draw
conclusions regarding the benefits for survivors with the dissemination of
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these tools. Finally, an inherent bias in interpretation might be due to the
evaluator.

Conclusion and Implications for Nursing
This integrative review identified published literature on SCPTS and their
applicability to haematological cancer survivors. Treatment advances in
haematological cancer means patients are living longer (Sant et al., 2014),
however the extended recovery trajectory involves a heavier symptom
burden and post treatment complications due to the aggressive nature of
both the haematological disease and the treatment required. Therefore, these
haematological cancers are unlike the other cancers that are currently used as
benchmarks such as breast or prostate (Parry et al., 2010).

Nurses can influence and guide the development of relevant survivorship
care recommendations, thereby facilitating a paradigm shift to encompass all
aspects of the cancer trajectory. Nurses with advanced research skills (e.g.
PhD prepared) would be well placed to take the lead in adopting and
translating current follow-up guidelines for haematological cancer patients
into evidenced-based and disease-specific templates. Nurses are in a position
to provide and disseminate SCPTS comprising individualised and relevant
resources, information and education to ensure the needs of haematological
cancer survivors are met. Correspondingly nurses need to support and
empower survivors to take control of and ultimately self-manage their
ongoing needs.

This review revealed a lack of high quality evidence related to
haematological cancer survivor care. Addressing specific and ongoing
concerns of these patients, along with the dissemination of this information
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to survivors and clinicians, especially in primary care is important. As
survival

rates

continue

to

increase,

the

successful

integration

of

haematological survivorship care into the cancer continuum is vital.

Future Research
Further research will need to account for the inclusion of each component of
the SCP, the survivor’s desire for this knowledge and information, as well as
the best way to develop and deliver haematological cancer specific SCPTS.
Research is required on the types of models of care most suitable for
delivering SCPTS to haematological cancer survivors, including their
perspectives on follow-up provision. Nurse-led haematology survivorship
clinics that facilitate shared care between the treating team and primary care
may be the most appropriate model to deliver SCPTS to achieve the best
outcomes for patients transitioning into the survivorship period and require
further evidence-based research. Methods that will optimise communication
and clarity with provider responsibility, thereby decreasing over or under
use of surveillance and screening tests are fundamental aspects of this
research. Finally, research in how best to decrease the amount of time needed
to prepare SCPTS, and the ideal time to effectively deliver SCPTS is
necessary. Well-designed pragmatic randomised controlled trials are
required to inform clinical practice. As the amount of outcome-based
research increases so too will our understanding of providing optimal
survivorship care.
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Literature Review Update
The same search criteria, terms and databases were reviewed to ascertain
recent developments or research in lymphoma survivorship care plans and
treatment summaries in the published literature. The search period was 2014
to January 2018. Results found 17 abstracts worthy of further assessment.

Assessment of the articles revealed no new articles that meet the inclusion
criteria of the original integrative review (Behrend, 2014; Brennan, Gormally,
Butow, Boyle, & Spillane, 2014; Frick et al., 2017; Jabson, 2015, 2015;
Klemanski et al., 2016; Kvale et al., 2016; Maly et al., 2017; Mayer, 2014;
Mayer, Birken, Check, & Chen, 2015; Mayer, Green, et al., 2015; Palos et al.,
2014; Playdon et al., 2016; Rosenberg et al., 2016; van de Poll-Franse,
Nicolaije, & Ezendam, 2017). The majority of articles included breast cancer
cohorts and, therefore, predominantly female participants, which may not
accurately reflect the perceptions and use of SCPTS by lymphoma survivors
or men. Two articles of interest that did not meet the inclusion criteria have
been described (Brant et al., 2016; Mayer et al., 2016). Both articles relate to
SCP use and primary care, a specific area of interest examined in this thesis.

The study by Brant et al. (2016), reporting satisfaction with an SCP, evaluated
breast (n=52, 78%) and lymphoma (n=15, 22%) survivors, carers (n=39) and
n=23 primary care providers (PCP). Results from the lymphoma cohort
revealed higher quality of life (QoL) scores compared with breast cancer
survivors, and that PCPs of lymphoma survivors were highly satisfied with
the SCP. The authors suggested that an SCP may contribute to improved
patient confidence in PCPs who provide survivorship care. Conversely the
study of a breast cancer cohort (which may not be applicable to lymphoma
survivors) randomised 34 females into two groups; SCP only group, where
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an SCP was delivered by an oncology nurse practitioner (NP) and an SCP
plus PCP group, where participants received an SCP from the NP and
attended a six-week follow-up visit with their PCP. Both groups reported
improved confidence in survivorship information; however the SCP only
group were identified as having increased worry compared with the group
who were able to discuss the SCP with their PCP at the six-week follow-up
visit (Mayer et al., 2016).
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2.3 Needs Assessment Measures
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Systematic

Review

of

the

Tools

Used

to

Assess

the

Informational and Practical Needs of Acute Leukaemia and
Lymphoma Survivors.

Abstract
Purpose: To identify validated measurement tools to assess the informational
and practical concerns of leukaemia and lymphoma survivors. Cancer nurses
have the potential to lead the way in providing quality post-treatment
survivorship care.

Method: This systematic review utilised a search of electronic databases for
eligible articles published to March 2014. Included articles described a tool to
assess informational and/or practical concerns of leukaemia and/or
lymphoma survivors.

Results: Seven full text articles were identified that described cancer-specific
tools used to assess informational and/or practical needs of this survivor
cohort. There was variation in the use of cancer survivor-specific tools and
generic cancer tools.

Conclusions:

No haematology-specific

needs assessment

tools

were

identified. Therefore, only tentative conclusions on the best tool for this
cohort can be made. Further research is required to develop reliable and
validated tools that will support the selection of the most appropriate tool for
leukaemia and lymphoma survivors.
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Introduction
Leukaemia and lymphoma are the most common blood and bone marrow
cancers (National Cancer Institute, 2006). Effective treatments are largely
aggressive and cause a number of long-term and late physical, practical and
psychosocial effects, which significantly impact lifestyle in the survivorship
phase (Arden-Close et al., 2011). Survivorship is defined as the experience of
living with, through and beyond a diagnosis of cancer (National Coalition for
Cancer Survivorship, 2014). As with other cancers the haematology cancer
health professional role has extended to include provision of patient care in
the survivorship phase. This important step forward has been driven largely
by the 2005 Institute of Medicine (IOM) report From Cancer Patient to Cancer
Survivor: Lost in Transition (Hewitt et al., 2005), considered the seminal paper
for cancer survivorship. The report recommended survivorship care as a
priority in the cancer trajectory with a number of specific issues relevant to
the survivorship phase. These issues can be categorised according to the
seven domains of Fitch (2008) supportive care framework; physical,
informational, emotional, psychological, social, spiritual and practical
concerns. The framework can be used across the cancer continuum including
haematology survivorship care (Hall, Campbell, et al., 2013). Whilst
survivorship care is developing for other cancers, haematology cancers
remain understudied in survivorship literature (Swash et al., 2014) despite
increasing five-year relative survival rates internationally (Hall, Lynagh, et
al., 2013; Rowland & Bellizzi, 2008; Sant et al., 2014).

The purpose of this review was to source tools that could be used to assess
two domains from the supportive care framework: informational and
practical concerns. These were chosen as a result of our findings from a
qualitative study undertaken with leukaemia and lymphoma patients that
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revealed a number of unmet needs, predominately informational and
practical (Monterosso et al., 2015), thought to relate in part to the extensive
nature of the treatment and the uncertainty around long term remission and
potential late effects.

The terms ‘informational needs’ and ‘practical needs’ are rarely considered
or defined as separate entities in the literature. For clarity and consistency
Fitch’s definitions (Fitch, 2008) of needs have been used. Informational needs
are defined as information to assist in decision-making and acquiring of
skills to decrease fear, anxiety and misperception (Fitch, 2008). Fear of
recurrence is often reported as an informational need for this cohort (Koch,
Jansen, Brenner, & Arndt, 2013). Two recent systematic reviews on this topic
reported tools used to measure fear of recurrence; tools to measure other
informational needs were not reported (Koch et al., 2013; Thewes et al., 2012).
Practical needs are defined as direct interventions or help that support the
survivor to complete a task or meet a concern (Fitch, 2008). Insurance and
employment issues are often cited as unmet needs for leukaemia and
lymphoma survivors (Chen et al., 2012). Other common informational and
practical needs reported in haematology survivorship literature include late
effects, fatigue, nutrition, exercise, fertility and sexual concerns, relationship
issues, financial issues, personal care and accessing support services (Allart
et al., 2013; Arden-Close et al., 2011; Beckjord, Arora, Bellizzi, Hamilton, &
Rowland, 2011; Behringer et al., 2013; Gates et al., 2015; Hall, Lynagh, et al.,
2013; Hawkins et al., 2008).

Gates et al. (Gates et al., 2015) argued that haematology cancer nurses have
an important role in this changing dynamic, especially in developing
sustainable, nurse-led survivorship care. If nurses are to take on a greater
role in survivorship care they require accurate, reliable and validated tools to
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assess patients entering the post-treatment phase (Muzzatti & Annunziata,
2013). Hawkins et al. (2008) proposed that tools designed for patients to selfidentify perceived needs are required to support survivorship care. These
tools could then guide the development of appropriate models of care,
resources and tailored support that are patient-centred rather than based on
the perceptions of health professionals (Fitch, 2008; McDowell et al., 2010).
The timing of patient needs assessments is equally important. Research
showing interventions and assessments undertaken in the early survivorship
phase (up to two years post-diagnosis) can lead to fewer unmet needs
moving into the extended survivorship phase (over five years)(Aziz, 2007;
McDowell et al., 2010).

There is a dearth of published literature that has critically evaluated tools
used to measure the perceived unmet needs of leukaemia and lymphoma
survivors (Arden-Close, Pacey, & Eiser, 2010; Muzzatti & Annunziata, 2013).
Tools specifically developed for these patients in the treatment phase such as
the Functional Assessment of Cancer Therapy: Lymphoma or Leukaemia
(FACT-LYM, FACT-Leu) have also been in the survivor population (Cella et
al., 2012; Hlubocky, Webster, Cashy, Beaumont, & Cella, 2013). Hence, it is
possible survivor-specific needs may not be captured.

Given that each cancer patient’s journey is unique it is important to measure
individual needs and match practical support to meet these needs. Therefore,
the leukaemia and lymphoma-specific focus of this paper will add to the
limited body of knowledge currently available in this survivor cohort.
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The following questions guided this systematic review:
1. What reliable and valid measurement tools are currently available to
measure the informational and practical needs of acute leukaemia and
lymphoma cancer survivors?
2. What are the implications of the findings from this review for future
research and clinical practice?

Method
A systematic review methodology was chosen to guide this review. To guide
literature searches and analysis of articles, a study protocol was devised. As
the use of needs assessment tools dictates a quantitative study method,
qualitative studies and the qualitative component of quantitative studies
were excluded. Mixed methods research was included with only the
quantitative element evaluated.

Literature search
The primary search utilised the following electronic databases: Cumulative
Index to Nursing and Allied Health Literature (CINAHL), Medline,
PsychInfo, PubMed, EMBASE, PsychArticles, and the Cochrane Library from
earliest records to March 2014. Search terms related to leukaemia and
lymphoma cancers, assessment, survivorship and needs. A hand search of
the reference lists from full text articles was also employed. Searches were
restricted to English and adult acute leukaemia or lymphoma survivors.
Inclusion and exclusion criteria are shown in Table 2.3.1. Studies with only
multiple myeloma participants were excluded as these patients are living
with cancer (Osborne et al., 2012). Likewise, studies with only allogeneic
transplant participants were excluded as they have ongoing conditions such
as Graft-versus-Host-Disease.
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7Table 2.3.1 Inclusion and Exclusion Criteria
Inclusion Criteria


Use of a cancer survivor-specific or generic cancer tool or instrument



Validity and reliability of tool tested with leukaemia and/or lymphoma
cancer survivors



Informational and/or practical needs reported



Adult leukaemia and lymphoma cancer survivors only

Exclusion Criteria


Tools used in the treatment or diagnostic phase



Tools used with relapse or secondary leukaemia or lymphoma cancer
survivors only



Studies reporting survivors of a childhood leukaemia or lymphoma cancer



Studies related to caregivers, or comparative studies between caregivers and
survivors



Studies with less than 50% leukaemia or lymphoma cancer survivor cohort



Opinion papers, letters, editorials, commentaries, conference proceedings, or
case studies

Quality appraisal and data extraction
Abstract titles were reviewed by author (KT) to assess eligibility. The
instrument/tool(s) used in eligible full text articles were then appraised (KT
and LM) to determine whether they measured informational and/or practical
needs of the leukaemia or lymphoma survivor. A summary of the selection
process using the PRISMA 2009 Flow Diagram (Moher et al., 2009) is
provided in Figure 2.3.1.
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IDENTIFICATION

5234 abstracts identified:
CINAHL, EMBASE, Medline,
PsycInfo, PsycArticles,
Cochrane Library

98 abstracts identified: manual

January 1970 - M arch 2014

search of preliminary literature

5285 abstracts after duplicates

5016 abstracts

removed

excluded

SCREENING

25 articles excluded
269 abstracts screened

Abstracts only (n= 3)

using inclusion/ exclusion
criteria

Haematology patients
comprised < 50% study
population or cohort not

ELIGIBILITY

identified specifically (n=8)
Treatment or clinical trial related
32 full-text articles
assessed for eligibility

(n= 2)
Focus not relevant (i.e. distress,
age, late effects, transplant,
spirituality, adaption, tool only

INCLUDED

comparisons (n= 9)
Studies included in
qualitative synthesis
N =7

Literature review did not target
informational / practical needs
(n= 3)

4Figure 2.3.1. Flowchart of literature search results.

The

methodological

characteristics

documented

included:

authors;

publication year; study design; comparison group; outcome measures;
disease; sample size and response rate; survivorship period; cancer-specific
and non-cancer specific tools; reported unmet informational and practical
needs; results and study quality (Fowkes & Fulton, 1991) shown in Table
2.3.2. Due to variations in study population, methodologies and tools used,
meta-analysis was not possible. Study quality was assessed using Fowkes
and Fulton (1991) guidelines and checklist for critically appraising
quantitative research. Assessment of the methodological quality of studies

81

CHAPTER 2. PHASE I

utilised a classification system of poor (under 40% of quality items), good
(40–70% of quality items) or very good (over 70% of quality items) as
reported by Hall, Lynagh, et al. (2013). In addition, the validity of each tool
was assessed according to: how the tool covered the informational and/or
practical needs of the participants; correlation with other generic cancer or
survivor-specific tools; and whether results confirmed study outcomes. Tool
reliability was determined by internal consistency of the items and whether
test–retest reliability had been performed. Generalisability of the tool to
leukaemia or lymphoma survivors was gauged from the study results, along
with the clinical usefulness of the tool for these survivors.
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8Table 2.3.2 Methodological Characteristics of Selected Articles (n=9)
Authors
Year
Country

Study Design
Comparison Group
Outcomes Measured

Disease
Sample Size
(Response
Rate %)
Survivorship
Period

Tools
Cancer Survivorspecific
Non-cancer
Tools/Investigator
Questions

Unmet
Information/Pr
actical Needs
Reported

Results

Study
Quality

Arden-Close
et al
2011
UK

Cross sectional
Administered
questionnaires
Gender comparison
Health related quality
of life, late effects and
perceived vulnerability;
satisfaction with care;
expectations and
satisfaction of clinic
visit

Lymphoma
n=115 (79.9%)
>5 yrs

Only questions
related to
discussion of
topics, late
effects

No gender difference in late
effects or perceived vulnerability
Men: more late effects, worse
health related quality of life,
wanted to discuss more topics
(women discussed the topics)
Shorter wait time=more topics
discussed
Health related quality of life
dependent on whether survivors’
follow-up expectations are met

Good

Friedman et
al
2010
USA

Cross sectional
Mailed questionnaire
Comparison of
survivors and

Non-Hodgkin
lymphoma
n=67 (41%)
9 months–12.6

QoL-CS (Quality of
Life Cancer
Survivors)
Yes
SF-12v2 (Medical
Outcomes Study
Health Survey Short
Form 12 version 2)
Princess Margaret
Hospital Satisfaction
with Doctor
Questionnaire
18 late effects & 10
general issues at
consultation
Investigator
questionnaire

Informational
needs to be
included in
survivorship

Survivorship care plan tailored
for particular survivors
Survivor: survivorship care plan
inclusions: screening for

Poor
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Hall et al
2013
Australia
Canada

Hjermstad et
al
2003
Norway

physicians
Informational
survivorship care plan
needs of survivors and
physicians
Congruence between
survivors / physicians

years
Physicians
involved in
survivorship
care
n=22 (29%)

care plan

Cross sectional
Cross cultural
Mailed questionnaires
Comparison of
Australian and
Canadian haematology
survivors
Percentage of survivors
reporting unmet needs;
domain scores; 10 most
prevalent high unmet
needs
Prospective cohort at 4
time points
Administered
questionnaires
Comparison of
autologous lymphoma

Leukaemia,
lymphoma,
multiple
myeloma
Australia:
n=268 (37%)
>3 years
Canada: n=169
(45%)
1–5 years

SUNS (Survivors’
Unmet Needs
Survey)
Yes

Informational
needs: cancer
recurrence and
spread
Work &
financial needs

Leukaemia,
lymphoma
n=123 (94%)
<1 year posttransplant

CARES-SF (CAncer
Rehabilitation
Evaluation System
Short Form)
No
EORTC QLQ-C30

Financial,
insurance,
weight gain,
transport, fear
of recurrence,
employment,

recurrence/late effects; treatment
summary; monitor overall
health/nutrition/exercise;
insurance
Survivor/Physician concordance
higher on medical issues
compared to psychosocial issues
No differences reported between
survivorship length
Similar levels of unmet needs
Fatigue highest concern across
both cohorts
Multiple areas of need found in;
females, younger age, expense
due to cancer, vocational
education level, seeing Dr re
treatment or concerns
Work & financial needs higher for
Australian survivors

Few patients requested help with
any items
CARES-SF useful for assessing
sexual, marital, medical
interaction to address specific
issues at follow-up

Good

Good
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Lobb et al
2009
Australia

Parry et al
2012
USA

with allogeneic
leukaemia transplant
patients
Rehabilitation needs
and health related
quality of life; physical
function measures of
CARES-SF compared to
EORTC QLQ-C30
Cross sectional
Mailed questionnaire
No comparison group
Assessment of unmet
informational and
emotional needs after
treatment

Mixed methods
Cross sectional
Mailed questionnaire
No comparison group
Health service and
psychosocial needs of
adult leukaemia and

(European
Organization for
Research and
Treatment Quality of
Life Core
questionnaire)
No

fatigue

High correlation with physical
function between the two scales

Leukaemia,
lymphoma,
multiple
myeloma
n=66 (50%)
6 weeks–1 year
post-treatment

CaSUN (Cancer
Survivors Unmet
Needs Survey)
Yes

Concerns: fear
of recurrence;
care
coordination;
information on
services

Lymphoma,
leukaemia
n=477 (45%)
< 4 years

Houts et al Service
Need Inventory,
refined by Kornlith
et al.
14 items

Practical needs:
child care;
financial

Care coordination after treatment
important, significant for
unmarried or working patients
Fear of recurrence, emotional &
relationship needs greater in
younger patients
Top endorsed needs: managing
health with medical team;
communication between doctors;
best medical care
Unmet need highest in: sexual
issues; handling medical and
living expenses; emotional
difficulties; employment; health
insurance
Women more likely to report
unmet child care needs
Relationships were observed

Good

Poor
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lymphoma survivors
Zebrack
2000
USA

Mixed methods
Cross sectional
Mailed questionnaires /
semi structured
interviews
No comparison group
Experience of quality of
life in long term
survivors at various life
stages

Leukaemia,
lymphoma
n=53 (50%)
10 years

QoL-CS (Quality of
Life Cancer
Survivors)
Yes
27 in depth
interviews

Fear of
recurrence,
fatigue,
employment,
support,
financial, family

among service needs,
overlapping areas of unmet need
Fatigue, pain, fear of recurrence—
ongoing issues
Family distress and finances
continue to impact survivors
Financial issues worse in older
survivors
Relapse not related to quality of
life
Income rated significantly to
quality of life
Positive associations with ability
to cope after cancer

Good
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Data Analysis
The initial search yielded a large number of abstracts (n=5234). Following
removal of duplicate articles and abstract screening using exclusion and
inclusion criteria, 32 full text articles were sought and further appraised. Of
these, seven articles were reviewed and referred to one or more relevant
tools (Arden-Close et al., 2011; Friedman et al., 2010; Hall, Campbell, et al.,
2013; Hjermstad et al., 2003; Lobb et al., 2009; Parry, Lomax, Morningstar, &
Fairclough, 2012; Zebrack, 2000). No tool had been specifically developed for
exclusive use with leukaemia or lymphoma survivors. Two studies reported
researcher-developed questionnaires (Arden-Close et al., 2011; Friedman et
al., 2010).

The seven included articles reporting haematological cancer survivor cohort
studies from Australia (n=2), Canada (n=1), the United States of America
(USA) (n=3), Norway (n=1) and United Kingdom (UK) (n=1). The periods of
survivorship ranged from six weeks post-treatment through to 12 years after
diagnosis (Arden-Close et al., 2011; Friedman et al., 2010; Hall, Campbell, et
al., 2013; Hjermstad et al., 2003; Lobb et al., 2009; Parry et al., 2012; Zebrack,
2000). Of the reviewed studies, four utilised comparative groups related to
unmet needs among different: treatment types (Hjermstad et al., 2003);
countries (Hall, Campbell, et al., 2013); gender (Arden-Close et al., 2011); and
survivors and physicians (Friedman et al., 2010). Outcome measures varied
across all studies, although the majority related to unmet needs after
treatment completion (Table 2.3.2). The assessment of methodological quality
(Fowkes & Fulton, 1991) revealed most studies (n=5) were ‘good’; two were
classified as ‘poor’. Two studies (Parry et al., 2012; Zebrack, 2000) utilised
mixed method designs, six studies (Arden-Close et al., 2011; Friedman et al.,
2010; Hall, Campbell, et al., 2013; Lobb et al., 2009; Parry et al., 2012; Zebrack,
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2000) were cross sectional and one (Hjermstad et al., 2003) was prospective.
Methodological quality varied with sample sizes ranging from 22 to 477
participants and response rates varying from between 29% and 94%.

Results
Five tools were identified and could be dichotomised as either those
designed for cancer survivors (survivor-specific) or those developed for
cancer patients undergoing treatment and used with a cancer survivor cohort
(generic cancer tools). Utilising the definitions of informational and practical
needs as previously described ensured consistency with the data extracted
from the articles. Comparisons of the five main assessment tools identified in
this review are shown in Table 2.3.3.
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9Table 2.3.3 Comparison of Assessment Tools
Tool

Cancer
Survivorspecific

Content

Scale
Scoring

Information
Needs

Practical
Needs

CARES-SF (CAncer
Rehabilitation Evaluation
System Short Form)
CaSUN (Cancer Survivors
Unmet Needs Survey)

No

5 point
Lower scores =
fewer problems
5 point
Higher scores =
greater needs

No

Yes

Yes

Yes

EORTC QLQ-C30 (European
Organization for Research
and Treatment Quality of
Life Core questionnaire)

No

59 items—degree problem applies
5 summary scales: physical; psychosocial;
sexual; marital; medical interaction
35 supportive care needs items, 6 positive
outcome items, 1 open ended item
5 needs domains: existential survivorship;
comprehensive cancer care; information;
quality of life; relationships
5 functioning scales: physical; role;
emotional; social; cognitive
3 symptom scales: pain; fatigue; nausea &
vomiting
6 items: dyspnoea; sleep; appetite; diarrhoea;
constipation; financial impact

No

Yes

QoL-CS (Quality of Life
Cancer Survivors)

Yes

8 point
Function: higher
scores = better
function
Symptom: higher
scores = more
problems
10 point
Higher scores =
best QoL

No

Yes

SUNS (Survivors’ Unmet
Needs Survey)

Yes

5 point
Higher scores =
greater need

Yes

Yes

Yes

4 domains: physical well-being (8 items),
psychological well-being (18 items), social
well-being (8 items), spiritual/existential
well-being (7 items)
5 domains: informational needs (8 items),
financial concerns (11 items), access &
continuity of care (22 items), relationships (15
items), emotional health (33 items)
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The generic cancer tools: CAncer Rehabilitation Evaluation System Short
Form (CARES-SF); and European Organization for Research and Treatment
Quality of Life Core questionnaire (EORTC QLQ-C30) were not survivorspecific and no data in relation to previous use in any haematology survivor
cohorts was described (Hjermstad et al., 2003). Reliability scores and validity
information was variable in the detail reported. Similarly, the three cancer
survivor-specific tools: Cancer Survivors Unmet Needs Survey (CaSUN);
Quality of Life Cancer Survivors (QoL-CS); and Survivors’ Unmet Needs
Survey (SUNS) provided variable reliability and validity data (Arden-Close
et al., 2011; Hall, Campbell, et al., 2013; Lobb et al., 2009; Zebrack, 2000).

All studies documented tool domains and scoring scales. Only two tools
addressed both informational and practical needs (CaSUN, SUNS) (Hall,
Campbell, et al., 2013; Lobb et al., 2009). The SUNS is the only tool developed
using a mixed cohort that included haematological cancer survivors (Hall,
Campbell, et al., 2013). All reviewed articles reported the clinical usefulness
of the tools to the haematological cohort studied.

The majority of studies (n=5) assessed the informational needs of survivors
(Table 2.3.2). Of the survivor-specific tools used to assess informational
needs, the CaSUN (Lobb et al., 2009) includes an explicit information domain
with response items such as: “I need up to date information”; “I need
understandable information”. It is assumed that follow-up is required for
those patients who score highly for such items. The SUNS tool similarly
includes an informational domain with questions targeted to “Finding
information …” or “Dealing with fears … or feelings…”(Hall, Campbell, et
al., 2013). In general, a high score allows the assessor to identify areas of
need. However, neither tool explicitly asks if the survivor would like help
with their issue or concern.
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Arden-Close et al. (2011) measured gender-related informational needs using
the cancer survivor-specific tool QoL-CS. Although this article made genderspecific recommendations, it did not provide insight into what assessment
tools best identify gender differences. Friedman et al. (2010) developed a
questionnaire that focused on information that should be included in
survivorship care plans such as: specific information about cancer
recurrence; nutrition and exercise; screening plan; information for family
members. This questionnaire both identified needs and enquired whether
respondents wanted information. On the other hand, the CARES-SF
(Hjermstad et al., 2003) does enquire if patients would like assistance with
their

concerns.

However,

it

does

not

explicitly

identify

survivor

informational needs. In contrast, Parry et al. (2012) used a non-validated
survey that identified informational and practical needs of haematology
survivors examining if participants received the help they required.

The definition of `practical need’ differed between authors, making
identification of suitable tools somewhat difficult. The QoL-CS tool (ArdenClose et al., 2011; Zebrack, 2000) examined practical concerns including:
employment; sexuality; financial burden and fatigue. Unlike the other cancer
survivor-specific tools, a higher score indicated a better quality of life
outcome. It was unclear if the tool recommended users to follow-up concerns
that generated low scores. Similarly, the EORTC QLQ-C30 assessed the
practical need of financial concerns but focused on more treatment related
concerns that are unlikely in the survivorship phase (Hjermstad et al., 2003).
Needs relating to fatigue management, fertility, sexuality, nutrition, exercise,
insurance, finances and employment were explored by the majority of tools
or investigator-derived questionnaires to varying degrees. The late effects of
treatment were reported as both an informational need and a practical area
where a plan for screening should occur (Arden-Close et al., 2011; Friedman

91

CHAPTER 2. PHASE I

et al., 2010). Likewise, fear of recurrence issues were similarly reported
(Friedman et al., 2010; Hall, Campbell, et al., 2013; Hjermstad et al., 2003;
Lobb et al., 2009; Zebrack, 2000).

Although a variety of tools were used, there was consensus regarding the
most prevalent leukaemia and lymphoma survivor informational and
practical needs. The commonly reported informational needs were: treatment
late effects; cancer recurrence including fear of recurrence; care coordination;
and information on available resources (Friedman et al., 2010; Hall,
Campbell, et al., 2013; Hjermstad et al., 2003; Lobb et al., 2009; Zebrack, 2000).
The most consistently identified practical needs were: fatigue management;
employment; financial; insurance; family; and sexuality (Hall, Campbell, et
al., 2013; Hjermstad et al., 2003; Lobb et al., 2009; Parry et al., 2012; Zebrack,
2000). Arden-Close et al. (2011) addressed potential differences in gender and
found men wanted more information however were often unable to receive
this from the medical consultation. Women, on the other hand, were able to
discuss the topics they wanted. Other studies found women had higher
unmet needs related to family issues (Hall, Campbell, et al., 2013; Lobb et al.,
2009; Parry et al., 2012); similarly younger survivors had higher unmet
informational and practical needs (Hall, Campbell, et al., 2013; Lobb et al.,
2009). Conversely disease and treatment type did not identify those with
greater unmet needs.

Discussion
Providing information across the cancer continuum is one of the most
important aspects of care, yet it is a frequently reported unmet need
especially in the survivorship phase (Husson et al., 2013). Leukaemia and
lymphoma patients differ from other cancer patients in the considerable
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variability between their cancer types and the range of treatments affecting
many aspects of their lives (Hall, Lynagh, et al., 2013). With improving
survival rates, those diagnosed younger (18–45 years) can now expect to live
longer, raising additional concerns and unmet needs (Arden-Close et al.,
2011). Information provision must be individualised and tailored to specific
patients’ needs (Husson et al., 2013; Parry et al., 2012). As highlighted by
Friedman et al. (2010) survivorship care plans need to account for differing
informational and practical needs of survivors, primary care providers and
haematologists.

Generic cancer tools include items related to diagnosis and treatment issues,
which are not necessarily specific to the survivorship phase. This review has
shown that survivor-specific tools can be used to assess unmet needs of
leukaemia and lymphoma participants in the survivorship phase. Therefore,
tools specific to the survivorship phase would be more appropriate to assess
for unmet needs and concerns in this cohort.

Arden-Close et al. (2011) and Aziz (2007) have argued that survivors should
be afforded the opportunity to obtain support and access resources earlier in
the survivorship continuum. They assert survivors need information about
immediate and long-term impacts of the cancer, together with practical needs
related to fatigue, exercise, nutrition, fertility, sexuality, insurance, finances,
employment and late effects. Leukaemia and lymphoma survivors may also
want resources to address healthy lifestyle choices (Arden-Close et al., 2011;
Boyes, Girgis, D’Este, & Zucca, 2012) or support to deal with the
psychosocial aspects such as relationships, anxiety and fear of recurrence,
reported in many studies as the highest unmet needs (Hall, Campbell, et al.,
2013; Hjermstad et al., 2003; Lobb et al., 2009).
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We acknowledge a number of limitations. There was variation in tools used
across a wide range of survivors from the early survivorship phases (under
two years) (Hall, Campbell, et al., 2013; Hjermstad et al., 2003; Lobb et al.,
2009; Parry et al., 2012) through to 12 years post diagnosis (Friedman et al.,
2010; Zebrack, 2000). This made comparative generalisations of informational
and practical needs difficult and enabled only tentative conclusions. Our
findings are limited to comparing those areas surveyed with the assessment
tools. As such, the review could not determine a broader range of supportive
care needs for all haematological cancer survivors. Further, the relatively low
response rate reported for some studies reduces the likelihood of the sample
being representative of leukaemia and/or lymphoma survivor populations,
and sampling bias could result in distorted conclusions. Extracting the
psychometric properties of the tools was hampered by a lack of detailed data
to support validity and reliability (Hall, Campbell, et al., 2013; Hjermstad et
al., 2003; Lobb et al., 2009). Finally, an inherent bias in interpretation might
be considered.

Notwithstanding the limitations, this review identified a consensus on the
most prevalent informational and practical needs of leukaemia and
lymphoma survivors. This important finding can assist haematology cancer
nurses when making decisions regarding the most appropriate tools to use
and may assist in the development of haematology cancer survivor-specific
tools that measure: perceived informational and practical needs; the extent to
which needs are being met; and the survivors’ need for support across all
supportive care domains. In this way nurses are ideally positioned to
provide individualised information and resources to these survivors and
further this area of research.
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Conclusion
There is a paucity of studies related to leukaemia and lymphoma survivors
and specific validated tools that can be used to identify and measure the
informational and practical needs of this cohort. While cancer survivorspecific needs assessment tools do exist and have been used with more
common cancer groups, further research is required to determine their
relevance and applicability to leukaemia and lymphoma survivors to ensure
specific concerns are heard and addressed via appropriate support and
information. Equally, generating psychometric data will ensure valid and
reliable tools are utilised. As the only tool developed that included a
haematology cohort, the use of the SUNS tool in further leukaemia and
lymphoma survivor populations will allow a greater body of knowledge to
be developed.
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Literature Review Update
The same search criteria, terms and databases were reviewed to ascertain
recent developments and published research on needs assessment measures
used with lymphoma survivors. The search period was 2014 to January 2018.
Results found 30 abstracts worthy of further assessment, however no articles
met the original inclusion criteria.

Of these, six articles did not include lymphoma survivor cohorts (Burg et al.,
2015; Czerw, Marek, & Deptała, 2015; de Jong, Tamminga, de Boer, & FringsDresen, 2016; Faller et al., 2016; Smith, Klassen, Coa, & Hannum, 2016) or the
lymphoma survivor cohort was less than 50% (Klassen et al., 2017).

Seventeen articles did not discuss needs assessment measures and reported
health care provider perceptions (Coa et al., 2015; Daniel, Emmons, Fasciano,
Fuemmeler, & Demark-Wahnefried, 2015; Karvinen, Bruner, & Truant, 2015;
Spector et al., 2015) or measured only one informational or practical need,
such as fear of recurrence (van de Wal et al., 2016), distress (Hall et al., 2016;
Magyari et al., 2017; Mojs et al., 2017; Oerlemans et al., 2014; Raphael, Frey, &
Gott, 2017), fatigue (Daniels et al., 2014; de Lima et al., 2017; Kreissl et al.,
2016; Linendoll et al., 2016), cognition impairment (Krolak et al., 2017;
Zimmer et al., 2015) or employment (Arboe et al., 2017). Five articles assessed
the impact of cancer on the survivor rather than their practical and
informational unmet needs (Bryant et al., 2015; Drost et al., 2016; Jones et al.,
2015; Sarker et al., 2017; Smith, Samsa, Ganz, & Zimmerman, 2014).

Two articles included information from studies that had been identified and
reviewed in the systematic review article of this thesis (Hall, D'Este, Tzelepis,
Lynagh, & Sanson-Fisher, 2014; Jiao et al., 2017). Hall, D'Este, et al. (2014)
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undertook a sub-analysis of the participants who had indicated high or very
high unmet needs in the SUNS. Jiao et al. (2017) undertook a rapid review of
needs assessment measures for post-treatment survivors. The authors
identified six studies that described five needs assessment measures. Two
measures were specific to survivors of a childhood cancer, and the three
other measures had been used in studies previously examined in this review.

Chapter Summary
Published literature related to models of post-treatment follow-up cancer
care and cancer survivorship care was reviewed and discussed in the
published model of cancer survivorship care review and updated review.
There was a lack of robust evidence to guide development of evidence-based
survivorship models of care including recommendations for the health
professional best placed to lead and/or deliver this care. Therefore, as the
researcher is a nurse, it was important to develop and test the viability of a
nurse-led survivorship model of care.

Similarly, the second integrative literature review revealed a lack of evidence
in the published literature regarding the use of SCPTS with lymphoma
survivors, and the methods and frameworks that could be used to develop
and deliver these tools. Further, there was a lack of personalisation of the
SCPTS to the patient. Consequently, this prompted the researcher to develop
and test a unique lymphoma-specific SCPTS for this study, the detail of
which is outlined in Chapter Four.

There is still a need for strong research that tests the appropriateness of
currently validated cancer survivorship-specific measures that will best
assess unmet needs in lymphoma survivor cohorts. The final systematic
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literature review assessed validated needs assessment measures that had
been developed and/or tested with lymphoma survivors. This work resulted
in the Short-Form Survivor Unmet Needs Survey (SF-SUNS) being chosen as
the most appropriate measure for this study. Further details are outlined in
Chapter Four.

In summary, at the completion of these reviews, clear gaps were evident in
some areas: the most suitable model of care for lymphoma survivors; the
most appropriate SCPTS to use with this cohort; and the best measures to
capture lymphoma survivorship-specific unmet needs. The outcomes from
these reviews supported the need for high-quality research such as the
pragmatic randomised controlled trial used for this thesis. The following
chapter outlines the conceptual framework that guided this thesis.
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Chapter Three — Conceptual Framework

“Being able to put my thoughts and feelings into words, being able to just say it
out loud to someone was quite therapeutic and then discussing some solutions
was really really helpful” Female_HL
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3.0 Conceptual Framework
The purpose of this chapter is to outline the conceptual framework that
guided the development and/or pilot testing of essential elements of the
nurse-led lymphoma survivorship model of care. These included the unique
survivorship care plan and treatment summary, choice of assessment
measures and development of a resource pack. These essential elements will
be further detailed in Chapter Four. Included in the discussion of the
conceptual framework is a description of motivational interviewing, a
technique that was used with participants randomised to the intervention of
the pragmatic RCT.

Conceptual Framework
This study is guided by Bandura’s theory of self-efficacy; defined as one’s
ability to succeed in a specific situation or achieve a specified skill, such as
making a difficult decision or, within the context of this study,
communicating with a health care professional (Bandura, 1977). Within the
area of health, self-efficacy is identified as an affirmative personal resource
that can contribute to managing one’s health generally and how an
individual manages a crisis (Schumacher, Sauerland, Silling, Berdel, &
Stelljes, 2014). In this instance a lymphoma diagnosis, treatment and life
thereafter. An individual’s sense of self-efficacy can have a major influence
on how challenges, tasks and goals are approached (Bandura, 1977). This is
the principal concept underpinning self-management education, which
teaches patients to identify their problems and provides skills in decision
making and developing an appropriate action plan (Bodenheimer, Lorig,
Holman, & Grumbach, 2002; Philip, Merluzzi, Zhang, & Heitzmann, 2013).
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Empowering patients to become responsible for the management of their
health and well-being can contribute to the influence and control patients
(self-efficacy) ultimately have over their health. Positive effects of
empowerment in patients who are managing the consequences of a cancer
diagnosis and treatment can lead to improved quality of life and survival
through improved health outcomes including physical and emotional wellbeing (Bodenheimer et al., 2002; Foster et al., 2015; Kuijpers, Groen, &
Aaronson, 2013). It has been reported that encouraging self-efficacy and
assisting patients to become self-empowered may help lymphoma survivors
adjust to the challenges of their lives during and after treatment and assist in
the resumption of “normal” life activities (Schumacher et al., 2014).

Notwithstanding the positive influences of individual or self-empowerment
and self-efficacy, previous life experiences held by the patient can impact
upon how he/she will cope and function from diagnosis, throughout
treatment and in the post-treatment phase of life (Richardson, 2002).
Perceived self-efficacy has a direct influence on the choices that individuals
make and how they cope once they have initiated a course of action
(Bandura, 1977). Self-efficacy, as mentioned previously, is task-specific and
therefore an individual can learn in a specific setting, regardless of previous
failure in other contexts. Similarly, motivation can be influenced by selfefficacy. Individuals with high self-efficacy are more likely to actively persist
and complete a task. Individuals with low self-efficacy may sometimes be
motivated to learn more about a subject or situation they are unfamiliar with.
However it may also lead to a state of learned helplessness and lack of
motivation (Bandura, 1977). Consequences of inadequate support may
include lower levels of self-management, reduced utilisation of appropriate
support services and worsening health (Foster et al., 2015; Hoffman, Lent, &
Raque-Bogdan, 2013). It is therefore imperative that a patient’s life
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experiences be explored and considered when developing a model of
survivorship care in order to provide an appropriate level of support that is
tailored to the individual.

Working with individuals (i.e. cancer survivors in the context of this study)
to develop a personalised patient action plan (i.e. survivorship care plan) that
includes tailored healthy lifestyle resources will likely result in a reduction in
the perceived need for support from the health care system by patients
(Bodenheimer et al., 2002; Foster & Fenlon, 2011). Maintaining patients’
motivation to enact healthy lifestyle changes and “follow through” is
important particularly for those individuals who may have lower levels of
empowerment and/or self-efficacy (Foster et al., 2015), since it is known that
people who give up a task before completion will retain their self-debilitating
and/or limiting expectations (Bandura, 1977).

In keeping with the concepts underpinning self-empowerment and selfefficacy, it was recognised that a nurse-led model of survivorship care
developed specifically for this study needed to incorporate self-reported
assessment measures to accurately identify an individual survivor’s ability to
self-manage his/her health and well-being (Philip et al., 2013). Further, it was
anticipated there would be variations across domains measured (i.e.
survivorship needs; depression, anxiety and stress; mental adjustment to
cancer; self-empowerment). Patient self-assessment can facilitate targeted
support that will allow lymphoma survivors to improve self-efficacy and
management of the effects of a lymphoma diagnosis and treatment (Foster et
al., 2015). The conceptual framework guiding this study’s nurse-led
lymphoma survivorship model of care is outlined in Figure 3.1.1.
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Motivational interviewing was explored as a credible technique to use in the
nurse-led lymphoma survivorship model of care. This form of interviewing
is defined as a directive, patient-centred counselling style for prompting
behaviour change by facilitating patients to explore and resolve uncertainty
(Litt, 2006). The researcher was guided by the four principles of motivational
interviewing when developing the study intervention: resisting the urge to
fix participant problems; gaining understanding of the participant’s
motivations; listening with empathy; and empowering the participant to
have hope for the future and be positive they could make changes if desired
(Rollnick, Miller, & Butler, 2008).

To assist intervention participants with the process of making changes to
unhealthy lifestyle behaviours such as cigarette smoking and excessive
alcohol consumption, the researcher customised a motivational chart based
on work by Rollnick et al. (2008) to provide to these participants (Appendix
J.2 ). During a motivational interview, questions can be posed to the
interviewee as he/she works with the researcher through the process of
change to help guide thoughts and motivations. Questions such as: ‘why do
you want to make a change?’; ‘what important benefits do you anticipate will
come from the change?’; ‘how will you make the change?’; ‘what are you
already doing towards making the change?

Once a motivational chart has been completed, the role of the interviewer is
to summarise the benefits and barriers posed by the interviewee and reflect
all the positive change behaviours the interviewee has committed to
undertake. Interviewees who are not ready to make changes at the first
nurse-led lymphoma survivorship clinic (NLSC) appointment will be
encouraged to address these issues at subsequent NLSC appointments. The
success of this approach requires interviewees to feel in control of these
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changes since permanent behaviour changes can only be made by
individuals who are motivated (Rollnick et al., 2008). Bandura’s theory of
self-efficacy (Bandura, 1977) is also a principal concept in self-management
education, which teaches patients to identify their problems and provides
skills in decision making and developing an appropriate action plan
(Bodenheimer et al., 2002). Empowering patients to become more responsible
for the management of their health and well-being can contribute to the
influence and control patients have over their health which has the
advantage of improving quality of life (Bodenheimer et al., 2002; Kuijpers et
al., 2013). It is anticipated that increasing a patient’s empowerment and
providing healthy lifestyle resources will result in a reduction in the
perceived need for support from the health care system by patients
(Bodenheimer et al., 2002).
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5Figure 3.1.1. Conceptual diagram of the nurse-led lymphoma survivorship model of care
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Chapter Summary
In summary, the nurse-led model of survivorship care utilised a conceptual
model based on self-efficacy and the development of a self-management plan
with actions to assist lymphoma survivors to recover their health and wellbeing and to engage in healthy lifestyle behaviours.

Development of a survivor-centred SCPTS, the identification of assessment
measures that would allow survivors to self-report issues and concerns and
the assembly of appropriate and targeted resources facilitated lymphoma
survivors to transition into the survivorship phase with support. An
important element of the conceptual framework of this model of care was to
understand the life experiences and factors that were important to the
individual before they were diagnosed with lymphoma and how these
experiences and factors may have influenced their motivation for selfefficacy and empowerment.

The following chapter of this thesis details the development of the essential
elements of the survivorship model of care which were used in the pragmatic
RCT.
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Chapter Four — Phase Two

“Because you do feel a bit sometimes like you are just treated like a number.
Having things individualised helped a lot” Female_NHL
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4.0 Intervention Development
The purpose of this chapter is to describe in detail the processes related to the
development of a nurse-led lymphoma survivorship model of care. While the
following information has been presented using separate headings for
clarity, it does not necessarily reflect that development occurred linearly.
Development of some components occurred concurrently where necessary.
The rationale for concurrent development was to progress the proposed
research as expeditiously as possible to meet candidacy and Human
Research Ethics Committee (HREC) submission requirements promptly since
the estimated time frames required for approval were somewhat lengthy.

This chapter begins with a brief section that describes the haematology
survivorship research advisory committee that was initiated to guide the
nurse-led lymphoma survivorship model of care. The model of care
comprised the following essential components: development of a lymphoma
survivorship care plan and treatment summary (SCPTS); assessment
measures; and development of a resource pack. These components are
described briefly in Chapter Five of this thesis, with more detail given in this
chapter to provide clarity on development. Likewise, the final section of the
chapter provides detail on the development of the GP evaluation (Phase
Four), which is briefly discussed in Chapter Five.

Haematology Survivorship Research Advisory Committee
(HSRAC)
This committee was convened in 2014, at the beginning of the research
process and comprised academic and clinical health professionals (doctors,
nurses and psychologists), a community support group executive and two

108

CHAPTER 4. PHASE II

consumers who met monthly at the study site for the duration of the study.
The committee was guided by Terms of Reference, with the primary aim to
provide insight, feedback and guidance on the development of the
intervention

components

for

the

pragmatic

RCT,

including

inclusion/exclusion criteria, timeframes and recruitment strategies. The
opinions of all members were valued, especially those of the consumers who
had a unique insight into lymphoma post-treatment follow-up at the study
site.

Survivorship Care Plan and Treatment Summary
The unique lymphoma-specific survivorship care plan and treatment
summary (SCPTS ) developed for this RCT is described in Chapter Five, in
the form of a published protocol article (Taylor, Joske, Bulsara, Bulsara, &
Monterosso, 2016). However, detail is provided in this chapter regarding
how the SCPTS was created.

At the completion of the integrative review on SCPTS, no Australian or
international SCPTS were perceived as appropriate for use in the study
centre. Therefore, an SCPTS was developed that was more patient-centred
and unique to this study cohort. The first full draft comprised two pages of
diagnosis and treatment information including chemotherapy drug names
and information on administration, dosing, protocol changes and potential
long-term and late effects which included recommended follow-up by the
GP. This was followed by a page that allowed lymphoma survivors an
opportunity to document their health concerns and health goals. Two further
pages listed general health screening and healthy lifestyle behaviour
information. This draft was presented to the SCGH Haematology
Department for review prior to content validation. The draft SCPTS was sent
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to health professionals including GPs and consumers to ascertain apparent
internal consistency, clarity and reliability. Appendix F.2 contains the
validation document that was sent with the SCPTS. All reviewers received
the same document to review.

Each item was assessed for:


Content clarity—whether each item was clearly defined (Yes/No)



Apparent internal consistency
o a) whether each item belonged in the SCPTS (Yes/No)
o b) the general fit with other items (Yes/No)



Content validity—level of relevance of each item
o 4-point Likert-type rating scale (1=not relevant to 4=highly
relevant).

The content validity index (CVI) (Polit & Beck, 2006) score was generated for
each item. “Yes” scores (content, clarity and apparent internal consistency)
and scores of 3 or 4 (content validity) were added. The intent of the
evaluation was to remove low scoring items and to assess for agreement of
greater than 80% per item. A comments section was provided for each item
to gain further feedback.

Six consumers completed an evaluation. Results indicated consumers were
unsure what late effects meant or what was meant by extra-nodal disease.
There was however, overwhelming consensus on the clarity (CVI: .98), the
apparent internal consistency (CVI: 100) and relevancy (CVI: .95) of the
items. Consumer comments related to the meaning of late effects and made
suggestions on the wording of elements of the SCPTS, i.e. ‘could it say main
aims, not goals?’. Two consumers felt the general lifestyle information
should already be known to patients.
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Six clinicians completed the evaluation; these included haematology nurses
(n=4) and GPs (n=2). Consensus was achieved on clarity (CVI: .99). Apparent
internal consistency was slightly lower (CVI: .91), this result was evident
from GPs who did not find all the treatment summary information was
required, although the result of whether each item generally belonged within
the SCPTS was high (CVI of .99). Relevancy of items generated a low result
(CVI: .84). This was again attributed to the GPs who indicated all the detailed
drug information and disease information was not relevant. Comments
reflected that a long treatment summary with information thought more
relevant to the haematologist should be removed. One GP commented that it
would be inappropriate to ask a patient what their main health concerns
would be, this should be specified by the doctor.

One of the evaluated GPs sent the document to other GPs (n=6) for comment.
Feedback was emailed to the researcher; however, no evaluation forms were
completed. It was unclear what information had been provided on the intent
of the SCPTS. All feedback was considered, however not all comments were
relevant. Suggestions for inclusion on the SCPTS that were not deemed
relevant by the HSRAC were: listing all past medical history; all allergies and
adverse reactions not related to treatment; travel immunisation schedules;
information on sexually transmitted diseases;

contraception advice;

stratification of recurrence risk; male and female versions; and doctorderived concerns not patient-derived. Comments that were relevant
included: reducing the treatment summary section and removing the
chemotherapy drug lists; giving the general health information to the
survivor only (GPs indicated they know this information); and moving the
potential late effects section to after the treatment summary section.
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A section for haematologists to sign the TS and late effects section was added
as research had indicated nurse-led SCPTS might not be valued by GPs (Mor
Shalom et al., 2011). Once consensus was reached from HSRAC on changes
to the treatment section and the wording of a few items, the final document
was a TS (half a page in length) and SCP (one and a half pages in length),
with the general health information in a two-page document for survivors
(Appendix F.1). The final SCPTS was reviewed and approved by the
haematologists at the study site for provision to patients recruited to the trial.

A search of the literature was undertaken for potential late effects that can
affect lymphoma survivors. Two documents in chart form were created for
NHL and HL late effects, including recommendations for follow-up. These
documents were circulated to the SCGH haematologists and radiation
oncologists for review and comment. Once approved, they were used when
completing potential late effect information on the SCPTS.

Measures
At the completion of the needs assessment systematic review (Taylor &
Monterosso, 2016) and in consultation with the HSRAC, four assessment
measures were chosen for the pragmatic RCT. These measures were required
to ascertain: survivor-specific informational, practical and emotional needs;
anxiety, depression and stress; mental adjustment to cancer; and patient
empowerment. Copies of the assessment measures are located in Appendix
E.2 to E.5.

The needs assessment systematic review (Chapter 2.3) identified the
importance of a survivor-specific measure that had been developed with a
cohort of survivors including lymphoma survivors. The measure chosen was
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the Short-Form Survivor Unmet Needs Survey (SF-SUNS)(Campbell et al., 2014).
Further information on this measure is found throughout the thesis and
particularly in Chapter 6.3.

The prevalence of the symptoms of distress are often overlooked in
survivorship research (Holland et al., 2010). Therefore, it was imperative that
a measure be found that would allow participants an opportunity to selfreport items that encompass distress such as depression, anxiety and stress.
Thus, the Depression Anxiety Stress Scale (DASS21)(Antony, Bieling, Cox,
Enns, & Swinson, 1998; Lovibond & Lovibond, 1995) was chosen for this
study. Distress has been defined as a multifactorial disagreeable emotional
experience that may interfere with the ability to cope effectively with cancer,
and can be psychological, social and/or spiritual in nature (Holland et al.,
2010). To improve the identification and management of distress, screening
in survivors is essential as many aspects of distress, such as fear of cancer
recurrence, uncertainty about the future, loss of health, anger and
preoccupation with thoughts around cancer may continue after treatment
completion (McCarter et al., 2018). Patient outcomes are improved when
distress screening is implemented and interventions provided (Mitchell,
2013), however many research studies that report a lack of benefit with
screening are more likely due to a lack of appropriate follow-up for those
identified with distress (Meijer et al., 2013). During this study, as items of
distress were identified, the appropriate support and resources were offered
to the intervention group participants during the study period. For those in
the control group, support was offered after they had completed all elements
of the study.

Leading on from the selection of the DASS21 to measure components of
distress, an assessment measure that has items that are similarly related to
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aspects of distress and coping was considered appropriate to gauge a wider
view on patient-reported concerns and issues in this area. Therefore the Mini
Mental Adjustment to Cancer Scale (Mini-MAC) (Watson, Law, & dos Santos,
1994) was selected.

The fourth measure chosen was the Patient Empowerment Scale (PES) (Bulsara
& Styles, 2013) as it was important to measure the self-reported level of a
patient’s coping ability and self-efficacy in managing their illness and
making decisions about support strategies. Empowerment can be seen as a
proactive strategy in acknowledging what an individual feels they can
control, and equally importantly, what lies outside of their control (Bulsara &
Styles, 2013). This was meaningful for the study as the SCPTS involved
participant-derived aspects. Consequently, it was important to assess the
level of a participant’s empowerment, especially when they would be
encouraged to seek out support and information for themselves as required.

Assessment measures would be posted to those randomised to the control
group after baseline; therefore, a letter was created to remind them about the
study and to encourage them to complete and return the assessment
measures. (Appendix G).

Resource Pack
A resource pack was developed after consideration of the evidence (reported
haematology survivor unmet needs and concerns) from the integrative
reviews undertaken in Phase One. The information assembled for
dissemination to the intervention group participants needed to address
anticipated

participant-identified

unmet

needs,

likely

post-treatment

physical and emotional concerns, and to encourage optimal participant
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involvement in healthy lifestyle behaviours. Information currently in use by
established cancer support sources such as the Cancer Council Australia and
the various state-based Cancer Council websites were assessed. Standardised
Australian Government information (as referenced below) was likewise
obtained. Where information was insufficient or not targeted to the
lymphoma cohort, the researcher adapted the information using a variety of
credible cancer sources including Australian, North American and United
Kingdom oncology websites.

All participants were offered the following booklets and information sheets:


Living Well After Cancer (Bell & Fagan, 2015)



Exercise for People Living with Cancer (Bruce, 2016)



New insurance policies (Cancer Council Western Australia, 2016)



Australian Guide to Healthy Eating (Australian Government, 2015)



Coping with fear of recurrence (American Society of Clinical
Oncology, 2015)



Coping with cancer fatigue (Cancer Council Victoria, 2015)



Coping with memory and concentration impairment (developed by
the researcher)



Cancer survivor exercise program (Edith Cowan University, 2015)



Cancer Council WA “Life Now” information and dates (Cancer
Council Western Australia, 2015–2017)
o A programme of supportive care activities such as exercise,
yoga, meditation for any person who has or had cancer

Targeted information was offered based on responses to the baseline
measures or requested from the participant at the first NLSC appointment.
This could include the following booklets and/or information sheets:


“Cancer and Your Finances” (Bruce, 2015)
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“Sexuality, Intimacy and Cancer” (Bruce, 2016)



Rekindle study information, University of Sydney, Australia
o This was a study to test an online resource to promote sexual
well-being for patients and partners. Once recruitment closed
in 2016 this information was no longer offered.



Cancer Council Pro Bono programs (legal, financial and workplace
advisory) (Cancer Council Australia, 2015)



Information on insurance and countries with reciprocal health care
agreements with Australia (developed by the researcher)



Quit smoking (Cancer Council, 2016)



Motivational chart (developed by the researcher)



Mental Health Plan information (Australian Government, 2015)



Canteen (CanTeen, 2015)
o A support group to help young people (12–25 years) cope with
cancer in their family, or their own cancer



Centrelink (Australian Government, 2015)
o An Australian Government department delivering social and
health payments and services.

A checklist was created of resources and information given to the
intervention participants throughout the study period (Appendix J.1).

General Practitioner (GP) Evaluation
The completed SCPTS was given to all intervention participants and sent to
GPs. Participants were encouraged to share this document with future health
professionals and discuss with their GP during the trial. It was important
therefore to gain an understanding of the thoughts and perceptions of GPs
who received the SCPTS. This was to gauge the use and usefulness of the
document.
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An evaluation based on the proposed SCPTS was developed. Advice on the
document was sought from the GP on the HSRAC to make the evaluation
targeted and succinct and to ensure that the cover letters to accompany the
evaluation and SCPTS similarly were clear and concise. The final evaluation
was one and a half pages in length and was checked by a GP researcher from
the University of Melbourne, not involved in the research. His comments
indicated the size and content was appropriate to gain the information
required.

The evaluation collected a small amount of demographic information: years
working as a GP; gender; and if the intervention participant had been seen in
the last six months. The first section of the evaluation comprised ‘yes/no/not
applicable’ questions related to the SCPTS, receipt and discussions (7 items).
The next section rated elements of the SCPTS and used a Likert-type scale:
1=very poor; 2=poor; 3=adequate; 4=good; 5=very good (4 items). Five open
questions followed and ascertained if: further information was required;
information did not belong on the SCPTS; any general comments; further
haematology education required; and the preferred format for education.
The final evaluation form is found in Appendix H.

The GP cover letters were each one page in length. The introductory cover
letter was attached to the initial posting of the SCPTS after the intervention
participant had completed the first NLSC intervention appointment. The
content gave a brief overview of their patient’s involvement in the RCT and
the intent of the SCPTS. Any urgent clinic concerns were directed to the
haematology department at the study site (SCGH). As previously described
GP input had indicated a listing of chemotherapy drug names was not
required, therefore a link to EviQ (an Australian evidence-based cancer
treatment protocols and information website for health professionals) with
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username and password were included if GPs wanted to look drug
information up for themselves. The subsequent cover letter was attached
with the evaluation and a further copy of the SCPTS to remind the GP their
patient had participated in an RCT and to ask if they would complete an
evaluation. Both cover letters are found in Appendix H.

Chapter Summary
In summary, a number of important elements were developed that guided
the thesis and the components that would be tested in the pragmatic RCT. A
unique lymphoma-specific SCPTS was developed. However, it was
important to ensure the content validity of the SCPTS items prior to use in
the pragmatic RCT. Likewise, it was important the haematologists were
confident that evidence-based late effects information and recommendations
were going to be given to their patients. In addition, this chapter discussed
the assessment measures chosen and the resource pack that was developed.
Furthermore, the creation of an evaluation of the SCPTS by GPs has been
detailed in this chapter as only condensed detail was provided in Chapter
Five, methodology and Chapter Six, pragmatic RCT results.

The following methodology chapter of this thesis is in the format of the
protocol journal article that was published in the British Medical Journal Open,
and which provides a complete overview of the pragmatic RCT.
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Chapter Five — Methodology

“A bit more confidence to go ahead in the future” Female_HL
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5.0 Protocol and Methods
The protocol and methods used to conduct Phase Three and Four of this
thesis are represented by the manuscript published in the British Journal of
Medicine Open access in 2016. This manuscript has been reproduced here, and
the complete PDF version is in Appendix A.4. A detailed discussion was
limited by the journal word count requirement. Therefore, further details are
in Chapter Four.
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Protocol for Care After Lymphoma (CALy) Trial: A Phase II
Pilot Randomised Controlled Trial of a Lymphoma Nurse-led
Model of Survivorship Care.

Abstract
Introduction: Lymphoma is the sixth most common cancer diagnosed in
Australia and internationally. Due to the aggressive nature of the disease and
intensity of treatment, survivors face long-term effects that impact on quality
of life. Current models of follow-up post-treatment fail to address these
complex issues. Given that 74% of lymphoma cancer patients now survive
five years beyond diagnosis and treatment, it is important to address this gap
in care.

Aim: To determine self-reported informational and practical needs, anxiety,
depression, stress, coping and empowerment at baseline, three and six
months.

Methods and Analysis: A pilot randomised controlled trial will test the effect
of a nurse-led lymphoma survivorship clinic compared with usual posttreatment care at a large tertiary cancer centre in Western Australia. The
intervention will comprise three face-to-face appointments with delivery of
tailored resources, a survivorship care plan and treatment summary (SCPTS).
The SCPTS will be given to the participant and general practitioner.
Intervention participants will be interviewed at completion to explore the
perceived value of the intervention components and preferred dose.
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An evaluation developed for GPs will assess receipt and use of SCPTS. The
primary intent of analysis will be to address the feasibility of a larger trial
and requisite effect and sample size.

Ethics and Dissemination: Ethics approval has been granted by the
University of Notre Dame Australia and Sir Charles Gairdner Hospital in
Western Australia. Peer-reviewed publications and conference presentations
will report the results of this phase II trial.

Trial Registration:

Australian New Zealand Clinical Trial Registry

ANZCTRN12615000530527.

Introduction
Lymphoma is a general term for over 20 blood cancers that originate from T
and B cells in the lymphatic system (American Cancer Society, 2014), where
lymphocytes undergo a malignant change and multiply uncontrollably.
Lymphomas, when combined, represent the sixth most commonly diagnosed
cancer worldwide (Surveillance Epidemiology and End Results (SEER),
2014), with Hodgkin (HL) and non-Hodgkin lymphoma (NHL) the two main
forms. Hodgkin lymphoma represents 11.5% of all lymphomas and is the
third most common cancer in the adolescent and young adult population
(American Cancer Society, 2014). With the exception of Hodgkin lymphoma,
incidence increases with age, thus non-Hodgkin lymphoma is predominantly
a cancer of the older population (over 65 years) (American Cancer Society,
2014; Quaresma, Coleman, & Rachet, 2015).

The incidence of lymphoma in Australia is increasing, with a projected
diagnosis of 5680 cases in 2015. This will equate to 4.5% of all cancer cases
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(Australian Institute of Health and Welfare, 2014). In Australia, the overall
survival rate has improved and approximately 74% of people diagnosed with
lymphoma are reported as being alive at 5 years compared with 49% in the
1980s (Australian Institute of Health and Welfare, 2014). Despite these
encouraging results (Sant et al., 2014), this group of cancers remain understudied and subsequently under-represented in survivorship care (Swash et
al., 2014).

Lymphoma treatment regimens commonly involve aggressive high dose
chemotherapy

and/or

targeted

therapy

agents,

radiotherapy

and

haematopoietic stem cell transplants (Carey et al., 2012). Such treatments
result in distressing long-term and late physical, practical and psychosocial
effects, which can produce ongoing unmet needs. These needs relate to
physical and psychosocial impacts such as: fear of recurrence; fatigue; poor
nutrition; exercise; fertility; relationship; financial; employment; and
insurance issues (Taylor et al., 2015). Furthermore, these patients commonly
experience related health problems earlier than the general population
(Panek-Hudson, 2013) and are at risk of specific late effects. Cardiovascular
disease is particularly pertinent in this cohort due to chemotherapy
combinations and cumulative dosing (Aleman et al., 2007; Ng et al., 2011) as
well as mediastinal radiotherapy (Travis et al., 2012; van LeeuwenSegarceanu et al., 2011). Patient health and lifestyle behaviours, for example
smoking, likewise have an effect on disease development (Ng et al., 2011).
Lymphoma patients have an increased relative risk of second cancers, higher
when diagnosed at a younger age (Grinyer, 2010; Hemminki et al., 2008) and
further elevated when treatment includes radiotherapy (Ng et al., 2011;
Travis et al., 2012). The potential for the development of bone marrow
disease is greater in the first decade, however unlike second cancer risk, this
decreases and then plateaus in the second decade (Ng et al., 2011). Patients
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who require a haematopoietic stem cell transplant have additional transplant
related late effects risks (Bishop et al., 2010; Choi et al., 2008). Although
patients may be unable to modify some late effect risks, awareness of
relevant

potential

late

effects

may

ensure

timely

follow-up

for

symptomology (Ng et al., 2011).

The traditional model of haematological cancer care follow-up has largely
been haematologist-led within the acute hospital setting (Taylor et al, 2015).
Information at treatment completion is often inadequate (Dicicco-Bloom &
Cunningham, 2013; McCabe & Jacobs, 2012), with a lack of clear guidelines
for the ongoing management of survivors (Phillips & Currow, 2010). This has
led to an emerging focus on redesigning survivorship follow-up care and
delivery.
Lobb et al. (2009) demonstrated patient-reported needs amongst Western
Australian haematological cancer survivors (n=66) not addressed during
routine follow-up post-treatment completion and thereby classified as unmet
needs. Almost two thirds of respondents (59%) would have found it helpful
to talk with a health professional at treatment completion. A recent
qualitative study conducted by the authors with lymphoma and leukaemia
cancer survivors (n=19) in Western Australia (Monterosso et al., 2015) found
unmet needs relating to information, practical support, coping strategies and
transitioning from active treatment into the survivorship phase. Findings
suggested that tailored, end of treatment interventions should form a key
component of survivorship care. Participants suggested a cancer coordinator
nurse as an important element to initiate and transition patients into the
survivorship phase.

Nurse-led models of care have demonstrated potentially satisfactory
outcomes (Gates et al., 2015; Howell et al., 2012; John & Armes, 2013) and are
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proposed as an acceptable pathway to transition into the survivorship phase
(Cooper et al., 2010). A dedicated nurse-led survivorship clinic to administer
patient-centred survivor-specific needs assessments is an important aspect of
survivorship care to address patient concerns and empowering survivors to
manage their own health and ongoing symptoms (Fitch, 2008; Ganz et al.,
2008; McDowell et al., 2010; Stricker et al., 2011).

Empowering patients enables them to become more responsible for the
management of their own health and well-being and can contribute to the
influence and control patients have over their own health which has the
advantage of improving quality of life (Bodenheimer et al., 2002; Kuijpers et
al., 2013). Bandura’s theory of self-efficacy (Bandura, 1977), the principal
concept in self-management education, teaches patients to identify their
problems and provides skills in decision making and developing an
appropriate action plan (Bodenheimer et al., 2002). It is anticipated that
increasing empowerment and providing healthy lifestyle resources will
result in a reduction in the patient perceived need for support from the
health care system (Bodenheimer et al., 2002).

Survivorship care plans (SCPs) and treatment summaries (TS) have been
recommended as facilitators to deliver holistic survivorship follow-up care
by: the Institute of Medicine (Palmer et al., 2014); the American Society of
Clinical Oncology (McCabe, Bhatia, et al., 2013); the UK National Cancer
Survivorship Initiative (MacMillan Cancer Support & NHS Improvement,
2010); and the proposed Clinical Oncology Society of Australia survivorship
guidelines (Clinical Oncology Society of Australia, 2014). A personalised SCP
would guide follow-up care by including recommendations, information and
resources for surveillance, screening of potential long-term and late effects,
and health promoting behaviours (Taylor & Monterosso, 2015). The TS
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would comprehensively summarise information on diagnosis and treatments
(Hausman et al., 2011; Jabson & Bowen, 2013). Cancer nurses have
established expertise in the areas of health promotion, information, support
and resource provision (Jackson et al., 2013), and therefore can develop and
disseminate SCPs and TS to facilitate communication between the survivor,
specialist and primary care.

Aim
The aim of the Care After Lymphoma (CALy) study is to develop and
empirically test an evidence-based nurse-led lymphoma survivorship clinic
to transition participants into the survivorship phase, using a pilot
randomised controlled trial (RCT) design. This phase II trial of an
intervention is aimed at reducing the immediate and long-term physical and
psychosocial consequences of haematological cancer treatment and to enable
the participant to return to normal functioning sooner. The nurse-led
lymphoma survivorship clinic has three core components: 1) needs
assessments to determine individual informational or practical issues or
concerns; 2) provision of a tailored SCPTS to enhance communication
between the participant and all other health professionals with whom the
patient has contact post-treatment; and 3) provision of individualised
evidence-based education, information and resources to address patientreported needs, likely post-treatment physical and emotional concerns and
maximising participant involvement in healthy lifestyle behaviours. The
aims are aligned with the Australian national research priority for
preventative healthcare to reduce comorbid diseases in cancer survivors.

The Medical Research Council framework for the development and
evaluation of complex interventions has guided the development of this trial
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(Campbell et al., 2007; Medical Research Council, 2000). The evaluation of a
model for nurse-led evidence-based survivorship care will provide level II
baseline data to: endorse the suitability of outcome measures; establish
acceptability of the intervention and randomisation; provide recruitment and
attrition rates; support hypothesis development; and calculate sample sizes
for future phase III multisite randomised controlled trials. In addition, it will
add psychometric information on the Short-Form Survivor Unmet Needs
Survey (SF-SUNS) and will provide data on a test–retest analysis.

Research Questions
The following research questions guide this pilot RCT:
1. Do participants assigned to the nurse-led lymphoma survivorship
clinic demonstrate a reduction in perceived unmet informational and
practical needs compared with those randomly assigned to usual
care?
2. Do participants assigned to the nurse-led lymphoma survivorship
clinic demonstrate a reduction in self-reported anxiety, depression
and stress and an increase in patient self-management behaviours
compared with participants randomly assigned to usual care?
3. What is the perceived efficacy and value of the nurse-led lymphoma
survivorship clinic from the perspective of a subset of survivors in the
intervention group?
4. To what extent does the provision of a SCPTS to GPs improve the
communication between the treating hospital, GP and the participant?
5. Does the Short-Form Survivor Unmet Needs Survey (SF-SUNS)
demonstrate stability and reliability over time?
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Methods
Design
The evidence to support the development of this phase II CALy trial
comprised a qualitative study using a focus group methodology with
lymphoma, leukaemia and multiple myeloma survivors (Monterosso et al.,
2015). The evidence also encompassed three systematic reviews regarding:
models of haematological survivorship care; survivorship care plans and
treatment summaries in haematological cancer patients; and tools used to
assess the informational and practical needs of acute leukaemia and
lymphoma survivors (Taylor et al., 2015; Taylor & Monterosso, 2015; Taylor
& Monterosso, 2016). Information gained from this preliminary work guided
the intervention components to be developed and the operationalisation of
the feasibility and acceptability of a nurse-led RCT.

The randomised controlled trial framework has been developed using the
Consolidated Standards of Reporting Trials (CONSORT) statement and
checklist (Moher et al., 2010; Schulz, Altman, & Moher, 2010). Outcomes will
be measured using validated needs assessment instruments. Reporting will
include: inclusion and exclusion criteria; missing data; drop out; and early
closure of the trial if required (Figure 5.1.1). The survivorship cancer nurse
coordinator (CNC) is a specialist cancer nurse with an extensive haematology
nursing background and formal counselling qualifications, including
motivational interview techniques.
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6Figure 5.1.1. Trial flow chart.
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Population and setting
A convenience sample of lymphoma cancer patients from a specialised
haematology department in a comprehensive cancer centre of a large acute
tertiary hospital in Perth, Western Australia, will be used. Follow-up by a
haematologist occurs every three months for the first 12 months. The nurseled survivorship clinic intervention will be an additional care activity to the
medical haematology follow-up and will involve three appointments over six
months. It will commence at three months post-treatment completion and
cease at nine months post-treatment.

Inclusion criteria
1. Pathologically confirmed new diagnosis of Hodgkin or non-Hodgkin
lymphoma.
2. Completed

first-line

curative-intent

chemotherapy

or

second-line

curative-intent autologous stem cell transplant within the previous three
months.
3. No evidence of lymphoma disease on mid-treatment interim PET scan or
post-treatment PET scan where these are performed.
4. Able to understand and read English.
5. Over 18 years of age.

Exclusion criteria
1. Diagnosis

of

other

haematological

malignancy

or

an incurable

lymphoma.
2. Did not undergo chemotherapy.
3. Further treatment and follow-up at another hospital.
4. Intellectually impaired or experiencing an acute mental health condition
that precludes the ability to provide informed consent.
5. Comorbid condition requiring monthly visits with GP.
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To measure selection bias, minimal data will be completed on eligible
participants who decline to participate. Reasons for refusal will be recorded
to gain valuable information for future research.

Recruitment
Identification of eligible participants will be undertaken by haematology
clinicians who will provide details to the survivorship cancer nurse
coordinator. Ongoing education of clinicians (haematologists and nurses)
regarding all aspects of the study, its progress and recruitment will facilitate
cooperation and support. Eligible participants will be met after treatment
completion by the CNC who will discuss the study and provide a Participant
Information and Consent Form (PICF). Consenting participants randomised
to the intervention group (n=30) will be offered the opportunity to consent to
a qualitative interview at completion of all time points. Approximately one
third of participants (n=10) will be required for this phase. Participant’s
names and contact details will be entered onto a master-coding sheet and
assigned a numerical identifier code after randomisation.

Survivorship Care Plan (SCP) and Treatment Summary (TS)
An extensive review of the literature (Taylor & Monterosso, 2015) and
available survivorship care plans and treatment summaries was undertaken.
Many institutions in Australia are utilising USA based templates that are
large (up to 20 pages), not tailored to the individual and provide resources
that are not contextualised to the Australian healthcare setting. Therefore, we
developed a lymphoma SCPTS in collaboration with a haematology
consultant, GP and other multidisciplinary team members (e.g. consumers,
psychologist, cancer nurses, and academic cancer researchers). This has been
created as a word document template to be filled in by the nurse. The
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perspectives of lymphoma survivors (n=6) and clinicians (including GPs)
(n=6) were sought to determine the relevance of the proposed SCPTS items.
Each item was assessed for content and apparent internal consistency
(whether items should be included and the general fit with other items)
using either yes or no responses to the items. Content validity utilised a
rating scale (1=not relevant to 4=highly relevant). The content validity index
(CVI) (Polit & Beck, 2006) was generated for each item by adding the number
of “yes” scores (content, clarity and apparent internal consistency) and scores
of 3 or 4 (content validity). The mean CVI consumer results were as follows:
clarity 0.98; apparent internal consistency 100; content validity 0.95.
Consumers demonstrated complete agreement of 1.0 for internal consistency
items. The mean CVI clinician results were as follows: clarity 0.99; apparent
internal consistency 0.95; content validity 0.84. Feedback in the comments
section of the evaluation interestingly indicated GPs did not value or require
a large treatment summary document. Consensus of the research team was
reached for the TS (half a page in length) and SCP (one and a half pages in
length).

The TS is completed using existing medical record information such as:
diagnosis; treatment; complications; and use of allied health providers. The
first section of the SCP includes a table for the inclusion of individualised
potential late effects. This table comprises: the late effect; information for the
GP about tests or follow-up required and when; and the symptomology the
participant needs to be aware of, with encouragement to follow these up
with the GP. Prior to recruitment a comprehensive list of potential late effects
and follow-up required was developed for each lymphoma type using
available published literature and guidelines (KT). This list was circulated,
discussed and amended by the haematologists who were aware these would
be used to guide their population of the table. Tailored individualised
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potential late effects will be documented based on treatments administered,
participant’s demographics and health characteristics. Once the TS and this
aspect of the SCP are completed it will be emailed to the haematologist for
final approval. Once amendments (if any) are made the haematologist signs
the TS. The second page of the SCP is patient-centred and populated by the
nurse in consultation with the participant. Participants will be asked to
identify three main concerns, health goals and proposed actions to achieve
these goals.

Sample size
The calculation of a sample size is not required for pilot RCTs as effect size is
not yet known. Rather the purpose of the pilot is to determine variability in
measures from which effect sizes can be calculated. Approximately 75
patients are seen per year at the study setting; however, this figure is
inclusive of new and existing patients. Therefore, a consecutive sample of 60
participants will be recruited and randomised 1:1 to either control or
intervention group (30 participants are expected in each group). It is
necessary

to

establish

test–retest

reliability

for

the

SF-SUNS

by

demonstrating a minimum intraclass correlation (ICC) of 0.8. Therefore, a
sample size of 39 (rounded up to 40 participants) administered on two
consecutive occasions no more than five days apart (baseline and 5 days
later) is required to achieve 80% power to detect this ICC of 0.8 (Walter,
Eliasziw, & Donner, 1998).

Patient-reported outcome measures
A review of the literature (Taylor & Monterosso, 2016) has resulted in four
assessment instruments being selected to measure the outcomes proposed:
Short-Form Survivor Unmet Needs Survey (SF-SUNS); Depression Anxiety Stress
Scale (DASS21); Mini Mental Adjustment to Cancer Scale (Mini-MAC); and
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Patient Empowerment Scale (PES). These instruments have demonstrated
reliability and validity with haematological cancer survivors as shown in
Table 5.1.1.

10Table 5.1.1 Outcomes Assessment Instruments
Instrument

Use

Items and
Factors

Internal
Consistency

Additional
Issues

Short-Form
Survivor
Unmet
Needs
Survey (SFSUNS)
(Campbell et
al., 2014)

Developed
for cancer
survivors to
assess unmet
needs. Assess
the gap
between
patient selfreported
concerns and
the level of
support they
require

30 items—0
(no unmet
need) to 4
(very high
unmet need)

Cronbach’s
alpha scores
for all domains
were ≥ 0.85

Test–retest
reliability not
established

Depression
Anxiety
Stress Scale
(DASS-21)
(Lovibond &
Lovibond,
1995)

Measures
multiple
dimensions
of
depression,
anxiety and
stress

Three 7 item
scales—0
(did not
apply to me
at all) to 3
(applied to
me very
much, or
most of the
time)

Four factors:
information
(3 items);
financial
concerns (8
items); access
and
continuity of
Discriminates care (6
between
items);
survivors at
relationships
different
and
stages postemotional
treatment
health (13
completion
items)

ICC across all
domains high
i.e. ≥0.9
indicating SFSUNS reliably
measured the
level of unmet
need

Cronbach’s
alpha
subscales
scores were:
0.94
depression;
0.87 anxiety;
and 0.91 for
stress (Antony
et al., 1998)

Will be
undertaken
during this
study

Used to support
SUNS
psychometric
properties in
haematology
cancer survivors

5 severity
ratings:
normal; mild;
moderate;
severe; and
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extremely
severe
Mini Mental
Adjustment
to Cancer
Scale (MiniMAC)
(Boyes,
Girgis,
D'Este, &
Zucca, 2011)

Measures
cancerspecific
coping
strategies

29-item—5
cancerspecific
coping
strategies:
helplessnesshopelessness
(8 items);
anxious
preoccupatio
n (8 items);
fighting spirit
(4 items);
cognitive
avoidance (4
items); and
fatalism (5
items).

Reliability
using
Cronbach’s
alpha
coefficients for
each subscale
ranged from
0.62–0.88

Used with small
sample of
haematology
cancer survivors

A high degree
of reliability
has been
established
using the
Rasch
Extended
Model with
the Person
Separation
Index of 0.926

Used in
haematology /
oncology
patients

Scale—1
(Definitely
does not
apply to me)
to 4
(definitely
applies to
me)
Patient
Empowerme
nt Scale (PES)
(Bulsara &
Styles, 2013)

Measures
15-item 4level of
point Likertpatient’s
type scale
coping ability
and selfefficacy in
terms of
managing
their illness
and making
decisions
about
support
strategies

Note: Cronbach’s alpha is considered a measure of scale reliability and a high score
indicates good internal consistency reliability of the test.
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Baseline data collection
Baseline data collection from consenting participants will occur three months
after treatment completion. All participants will self-report demographic
information and complete the four assessment instruments. In addition, they
will receive a second SF-SUNS instrument to complete no later than five days
after the baseline testing. These will be returned via a reply-paid envelope to
allow the researchers to undertake test–retest reliability testing. Medical
demographic information obtained will include: type of haematological
cancer; stage of disease; type of treatment received (chemotherapy,
immunotherapy, radiotherapy); date of diagnosis; time since diagnosis;
treatment complications or dose modifications; and comorbidities. Personal
demographic information collected will include: sex; age; marital status; age
of children (if any); postcode; occupation; income level; education level;
health behaviours such as smoking, alcohol consumption and weight.

Randomisation
After baseline assessment participants will be randomised to either the
current standard of care or intervention group. Computer generated random
numbers using a four-digit sequence have been generated and linked to
group allocation by an independent statistician. An independent member of
the research team, to ensure confidentiality and offset bias in randomisation,
has sealed a hard copy of each individual number and group in an opaque
envelope. The envelopes are consecutively numbered and will be distributed
to consenting participants in this order. Control group participants will be
made aware that another researcher will follow-up non-questionnaire return
with a telephone call to the participant after two weeks.
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Control group
Control group participants will receive follow-up care as per haematologists’
usual practice. At three and six months after baseline, the same four
assessment instruments will be sent to the participant and they will selfreport any issues or unmet supportive care needs. An addressed reply-paid
envelope will be provided to return assessments. Participants who score high
unmet needs will be encouraged to discuss these with their haematologist at
their usual follow-up appointment.

Intervention group
Following baseline data collection, intervention group participants will have
an appointment at the nurse-led lymphoma survivorship clinic. The first
page of the SCPTS will be populated prior to this appointment. At the first
nurse-led lymphoma survivorship clinic, any concerns the participant has
regarding the end of treatment will be discussed and normalised. The nurse
will discuss the TS and potential late effects. The second page of the SCP will
be completed by the nurse using an electronic template in collaboration with
the participant. At this time the importance of follow-up recommendations
will be emphasised. The SCP will then be printed, signed and dated by the
participant and the nurse. The completed SCPTS will then be copied, with
the original given to the participant, a copy placed in the participant’s
medical records, and a copy sent to their GP. Motivational interviewing
techniques will be employed for healthy lifestyle behaviours and to assess for
readiness to make behavioural change. Participants will be encouraged to
identify and explore behaviours they would like to modify using a chart that
enables them to list likes and dislikes of specific behaviours and potential
impacts of perceived behavioural change. By listening to concerns,
highlighting conflicts arising from behaviour and documenting on the chart
will potentially enable participants to assume control of decision making

137

CHAPTER 5. METHODOLOGY

related to behavioural change. Participants will be encouraged to set realistic
timeframes and identify habits and beliefs that may possibly be hindering
change. Tailored evidenced-based information and advice in a resource pack
will then be issued. It is anticipated that a consultation of 60 minutes will be
required in a private clinic room.

A further two appointments will be made at three and six months after
baseline, where the same four assessment instruments will be completed by
the participant and they will self-report any issues or unmet supportive care
needs. These will be discussed and the appropriate resources support and
information provided. Participants will be encouraged to discuss their health
concerns, goals and progress with any action they may have taken.
Participants will be asked if they have seen their GP in the last three months
and if they took the SCPTS and discussed any of the late effects screening
recommendations, their participant-identified concerns or goals. This will aid
the transition to GP follow-up where the benefits of shared care will be
explained. A checklist for each participant of the resources provided will be
kept.

Data Analysis
Quantitative data will be analysed using univariate and multivariate
statistical techniques with SPSS data analysis software. Descriptive statistics
will be used to analyse the demographic variables collected. Responses to the
SF-SUNS, DASS21, Mini-MAC and PES will be scored according to the
algorithms in the instrument manuals. Measures from all instruments will be
checked for normal variance within the two groups. Within each group,
paired t-test comparisons will be made between baseline measurements and
at each time point: baseline; three months; six months. Differences between
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intervention and control groups will then be assessed at each time point.
Test–retest reliability using ICC will be undertaken on the SF-SUNS
instrument. The minimum ICC value required for this scale is 0.8.
Participants who drop out or are lost to follow up or need to be excluded
after commencement will be accounted for by intention to treat analyses.
Confidence intervals will reflect the contrast between groups to show
treatment effect. Missing data, incomplete answers and non-response will be
recorded.

Qualitative interviews
Supplementary in-depth semi-structured interviews will occur with
approximately 10 consenting participants when they have completed all
intervention components (after six months). This number will allow for
saturation of themes (Crouch & McKenzie, 2006; Onwuegbuzie & Leech,
2007; Sandelowski, 1995). Telephone interviews will be digitally recorded
and undertaken by an independent researcher to ensure participants are
given the opportunity to freely express both positive and negative
perceptions of their experience. The use of a qualitative approach will
provide depth of information regarding the personal impact of the nurse-led
lymphoma survivorship clinic on the participant. The interviews will also
highlight any issues or challenges for this group that could be better
addressed in the future.
Interviews will be transcribed verbatim and thematic analysis used to
determine themes and patterns within the text (Grbich, 1998; Patton, 2014;
Smith, 2007). QSR NVivo qualitative analysis data management software will
be used to manage interview data.
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GP evaluations
A non-validated evaluation will be sent to GPs who have received the
SCPTS. This was developed in consultation with a GP and will ascertain if
GPs made use of the SCPTS and to elicit perceptions of the value and
effectiveness of this document in facilitating communication between the
treating hospital and GP, and GP and participant. This will guide future
refinement of the SCPTS. Analysis will utilise descriptive statistics and
distribution analysis techniques. Open-ended questions will utilise content
analysis techniques. GPs will be called by the researcher after two weeks for
non-return of the questionnaire to remind them to fill in and return the
evaluation in the reply-paid envelope.

Discussion
A significant culture change is required for providers to recognise
survivorship care as a standard component of quality cancer care that
involves all health professionals, participants and families. The gap in
knowledge contributes to a current model of survivorship care that is
fragmented, with inadequate service provision at treatment completion,
leading to unmet needs along the survivorship continuum (De Leeuw &
Larsson, 2013). The cancer specialist is not necessarily required for routine
screening and follow-up. However, the involvement of other health
professionals, including primary care, necessitates the need for an awareness
of the treatment delivered and the long-term and late effect risks (Taylor &
Monterosso, 2015).

This study will address the lack of robust empirical evidence in haematology
survivorship care. A nurse-led model of care would assist patients
transitioning from the end of treatment to the survivorship phase.
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Furthermore, the provision of an individualised SCPTS is a means to
empower individuals with knowledge about their disease and treatment and
to assume responsibility for future surveillance and disease management. It
will likewise take advantage of ‘teachable moments’ at the end of active
treatment to support and promote patient participation in healthy lifestyle
behaviours (Taylor et al., 2015). This is particularly vital for younger
survivors, given the expectation of a longer survivorship period (Jabson &
Bowen, 2013).

The intervention has been timed to occur in the early survivorship phase.
This has been supported by preliminary focus group work including
lymphoma cancer survivors who indicated they often felt abandoned at
treatment completion (Monterosso et al., 2015). This timing also concords
with McDowell et al. (2010) who found assessments and interventions
undertaken in the early survivorship phase (up to two years post diagnosis)
led to fewer unmet needs moving into the extended survivorship phase (over
five years).

The CALy trial will examine the impact and effectiveness of the nurse-led
lymphoma survivorship clinic intervention through an assessment of the
important clinical outcomes: unmet informational and practical needs;
depression, anxiety and stress; coping; and self-empowerment as measured
by the instruments chosen. It is therefore designed to improve the
identification of unmet needs. Testing of such an intervention by a
randomised controlled trial has not been published in lymphoma
survivorship studies to date. Consequently, it will make a significant
contribution to the planning and delivery of survivorship care. Likewise, it
represents a substantial and original contribution to knowledge and support
for haematology survivorship care as few studies aim to improve the
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psychosocial and supportive care of this cohort. If the intervention achieves
its intended outcomes, it may potentially lead to the development of nurseled haematology survivorship clinics across the tertiary health sector in
Western Australia that could ultimately be expanded to all cancer survivors.

Ethics
Ethics approval has been gained from the relevant hospital (2015-020) and
university (015007F) Human Research Ethics Committees (HRECs). The trial
is registered at the Australian and New Zealand Clinical Trials Registry
(ACTRN 1261500530527) and the Western Australia Cancer Clinical Trials
Registry. The trial is open to patient recruitment. It is not expected
participants will be exposed to any undue risks or harm by participation.
Participant information will remain confidential and de-identified where
appropriate. Economic harm will be minimised by providing appointments
when the participant is already attending the hospital. Exploring concerns
may be distressing and if this occurs, participants will be referred to the
appropriate counselling services as per usual clinical practice. Collected data
will be securely stored at the university for 15 years after study completion
and will only be accessible with written permission from the researcher and
relevant university and hospital sites.
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Chapter Summary
In summary, this published article outlines the development of the nurse-led
lymphoma survivorship model of care and the components that were
required to undertake a high-quality phase II pilot pragmatic RCT. These
include:


Development and review of a unique tailored survivorship care plan and
treatment summary (SCPTS)



Selection of four assessment measures



Motivational interviewing chart



Development of a resource pack



Three structured appointments in the nurse-led lymphoma survivorship
intervention



Creation of a General Practitioner (GP) evaluation of the SCPTS



Development of the interview schedule

Where detail is limited, further information is in Chapter Four of this thesis.

The following chapter of this thesis reports in the first section on the results
that were obtained from the pragmatic RCT and the GP evaluations. The
following two sections are the results of the qualitative interviews and the
test–retest reliability analysis of the SF-SUNS. These are presented in the
format of journal articles that were published in the European Journal of
Oncology Nursing and the Asia-Pacific Journal of Oncology Nursing respectively.
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Chapter Six — Results

“I got the chance to talk over my concerns and I think that is very important.”
Female_HL
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6.0 Results of Phase Three and Phase Four
Four sections form this chapter. The first two sections describe the statistical
techniques applied to the data followed by results for the pragmatic
randomised controlled trial (RCT) and general practitioner (GP) evaluation
surveys. The third section of this chapter presents the sixth and final
published paper that reports the results from the qualitative semi-structured
interviews undertaken with a subset of intervention participants after their
completion of the study. Interviews were conducted by an independent
researcher to minimise potential bias and allow participants an opportunity
to speak freely about their perceptions and experiences. This published
manuscript has been reproduced in this chapter (Taylor, K., Monterosso, L.,
& Bulsara, C. (2018). Qualitative results from a phase II pilot randomised
controlled trial of a lymphoma nurse-led model of survivorship care,
European Journal of Oncology Nursing, 35, 9–14). The complete PDF version is
in Appendix A.5.

The final section comprises the fifth published journal article that reports the
test–retest reliability of the SF-SUNS, the survivorship-specific needs
assessment measure selected for this research. This testing was undertaken
as published test–retest reliability data was not yet available when the study
protocol was developed. This manuscript has been reproduced in this
chapter (Taylor, K., Bulsara, M., & Monterosso, L. (2018). Test–retest
reliability of the Short-Form Survivor Unmet Needs Survey, Asia-Pacific
Journal of Oncology Nursing, 5(2), 165–171). The complete PDF version is in
Appendix A.6.
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6.1 Results of the Pragmatic Pilot
Randomised Controlled Trial
Statistical Techniques
Quantitative data were analysed using IBM SPSS version 25 (IBM Corp,
2017). Demographic variables were described using mean, standard
deviation, median and range where applicable. The degree of sample
generalisation between groups (control and intervention) was ascertained
and reported using a Pearson Chi-square test, except when cell counts were
below five in which case a Fisher’s Exact test result was reported. Subjective
data such as lifestyle factors was not tested. Responses to the SF-SUNS,
DASS21, Mini-MAC and PES used Likert-type scales and were scored
according to the algorithms provided in the relevant instrument manuals.
Analysis was by intention to treat, unanswered items on questionnaires were
recorded. Statistical significance was set at 0.05 (2-tailed) unless otherwise
stated.

Non-parametric tests were used where measures were not normally
distributed as determined by the Shapiro Wilk test. The Kruskal–Wallis test
was used to compare total scale and domain scores of each instrument at
each time point across age, gender, and lymphoma type. Within each group,
paired t-test (or non-parametric alternative Wilcoxon Paired Rank Sum test)
comparisons on the total scale and domain scores of each instrument were
made between Time 1 (baseline) and Time 2 (3 months) and Time 1 and Time
3 (6 months). Independent t-tests (or non-parametric Mann–Whitney U test)
were used to assess the differences on the total scale and domain scores and
each item between the two groups at each time point. The Friedman test was
used to measure the intervention participants across the three time points on
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the total scale and domain scores of each instrument.

Linear Mixed Modelling (LMM) with Bonferroni post-hoc comparisons were
used to examine change over the study timeframe between the control and
intervention groups. LMM is suitable for data where: multiple measures are
repeatedly taken from the same individuals; data is not necessarily normally
distributed; and permits missing data points (missing at random) (West,
Welch, & Galecki, 2015). Therefore, LMM provides flexibility of modelling
data means along with the variances and covariances (IBM Corp, 2017). Each
assessment measure, including the domains within each measure, were
treated as a separate dependent variable model. Covariates were treated as
fixed effects and included group (control versus intervention), time (1, 2 and
3), with cofounders of age, gender and lymphoma type. Individuals were
treated as a random effect. Group x time and gender x time interactions were
examined for each model and were included in the final reported model only
if statistically significant. Place of residence was not modelled due to the low
numbers from regional or rural areas. Final model residuals were assessed
for normality to check the assumption for the LMM was met. All models
were assessed to meet this assumption with only some slight deviation in the
tails for some models.

Spearman’s Rho correlation coefficient analysis was used to describe the
relationship between the SF-SUNS and each of the other measures; PES,
DASS21, Mini-MAC. Combined scores from the two groups were used at
each time point to describe the strength and direction of the correlation. The
strength of the correlation coefficient was determined using the following
values: small r=.10 to .29; medium r=.30 to .49; large r=.50 to 1.0 (Cohen,
1988).
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The CONSORT (Consolidated Standards of Reporting Trials) diagram
(Moher et al., 2010) depicting the flow of participants through this trial is
presented in Figure 6.1.1. Missing data were minimal and estimated not to
exceed 1–1.5% of the total data volume. Recruitment commenced in July 2015
and was completed in January 2017. All participants had completed the
study by October 2017.

Quantitative analysis tables demonstrating the depth of analysis undertaken
in this thesis are found in Appendix L for the following:


Reliability of assessment measures (Table 1)



Wilcoxon Singed Rank Sum test (Table 2)



Linear mixed models, non-significant results of the SF-SUNS (Table 3)
and Mini-MAC (Table 4).



Paired t-tests (Table 5)



Independent t-tests (Table 5)



Kruskal–Wallis tests (Tables 6–8)
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Assessed for eligibility (n= 88)
Excluded (n= 28)
Not meeting inclusion criteria
(n= 5)
Declined to participate (n= 21)
Other reasons (n=2)

Enrolment

Randomised (n= 60)

Allocation
Allocated to intervention (n= 30)
Received allocated intervention
(n= 30)

Allocated to control (usual care)
(n= 30)

Follow-Up
Discontinued intervention (relapsed
after Time 2) (n= 1)

Lost to follow-up (uncontactable /
did not return assessment
measures) (n= 1)

Analysis
Analysed (n= 30)
Excluded from analysis at Time 3
(n= 1)

Analysed (n= 30)
Excluded from analysis after
baseline (n= 1)

7Figure 6.1.1. CONSORT flow diagram for pragmatic RCT.

Results
Demographic data
Of 88 eligible patients (Figure 6.1.1), 60 consented to participate in the trial
(68%). The 28 patients who were excluded had comparable demographic
characteristics (obtained from their medical records) with those of
participants; there were more males (n=16, 58%) than females (n=12, 42%)
with a similar age range (24–82 years, M=63 years, SD=14). Like the
participants, the majority of non-participants were in a relationship, had
NHL, and were within the first eight months since diagnosis. Reasons for
exclusion included:


Not meeting inclusion criteria due to relapse of disease (n=5)
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Declined to participate (n=21)
o Extra time required at the hospital (n=8)
o Travel to the hospital for regional patients (n=2)
o Feeling overwhelmed by treatment experience or wanting
to move on and forget they had lymphoma (n=9)
o Not interested with no other reason given (n=2)



Other reasons (n=2)
o Died after assessment for eligibility

Demographic and disease characteristics of study participants are shown in
Table 6.1.1 for both control and intervention groups. More males (73%) than
females (27%) were randomised to the intervention group indicating a
statistically significant degree of generalisation which was not seen in the
control group. Likewise, lymphoma type was disproportionate, with an
increased number of HL cases in the intervention group (40%) compared
with recognised worldwide trends in lymphoma distribution which were
mirrored in the control group; NHL (80%), HL (20%) (Howlader et al., 2016).
There were a greater number of participants within the first eight months of
diagnosis, an expected result when recruiting participants after treatment
completion. A statistically significant degree of sample generalisation in
marital status was found; however, this difference was not significant when
participants were grouped into ‘in a relationship’ or ‘not in a relationship’.
There were more metropolitan residents in the study, although similar
representation of residence was found in both groups.

Three age group categories were chosen to reflect the adolescent and young
adult age range (18–29 years), those with more likelihood of working and
having children living at home (30–59 years) and those less likely to be
working or have dependent children (>60 years).
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11Table 6.1.1 Demographic Characteristics for RCT Participants (n=60)

Characteristics

Intervention
n=30

Control
n=30

N (%)

N (%)

Gender
Male
Female

22 (73)

12 (40)

8 (27)

18 (60)

Age group (years)
18–29

8 (27)

5 (16)

30–59

12 (40)

14 (47)

60–86

10 (33)

11(37)

Lymphoma diagnosis
Non-Hodgkin

18 (60)

24 (80)

Hodgkin

12 (40)

6 (20)

Time since diagnosis
5–8 months

20 (67)

18 (60)

>9 months

10 (33)

12 (40)

Marital status
Single

9 (30)

5 (16)

17 (57)

20 (67)

4 (13)

2 (7)

0 (0)

3 (10)

12 (40)

9 (30)

Adult children

9 (30)

13 (43)

No children

9 (30)

8 (27)

Married/defacto
Divorced/separated
Widowed

Group Difference
Pearson
ChiSquare

P Value

6.79

.018

0.89

.712

2.86

.158

0.29

.789

5.14*

.273

1.56

.498

1.09

.435

Children^
<25 (living at home)

Highest level of education
Secondary school or less

7 (23)

11 (37)

Trade/vocational college

9 (30)

9 (30)

14 (47)

10 (33)

University
Employment status#
Working

15 (50)

12 (40)

Not working

15 (50)

18 (60)

retired

7 (23)

9 (30)

no return to work date

5 (16)

5 (16)
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looking for work

2 (7)

4 (13)

sick pension

1 (3)

0 (0)

Income level
$0–$30,000

13 (43)

15 (50)

$30,001–$70,000

7 (23)

6 (20)

$70,001–100,000

4 (13)

5 (16)

2 (7)

1 (3)

4 (13)

1 (3)

0 (0)

2 (7)

$100,001–$130,000
>$130,000
chose not to answer
Residence
Metropolitan

24 (80)

26 (87)

6 (20)

4 (13)

Current smoker

4 (13)

3 (10)

Quit <12 months

2 (7)

2 (7)

Quit >12 months

5 (16)

5 (16)

19 (63)

20 (67)

17 (57)

19 (63)

Occasional <1 drink/week

9 (30)

10 (33)

2–3 drinks/week

6 (20)

3 (10)

4–5 drinks/week

1 (3)

0 (0)

6–7 drinks/week

0 (0)

3 (10)

Binge drinking weekends

1 (3)

0 (0)

2–3 drinks/night

0 (0)

3 (10)

13 (43)

11 (37)

1 (3)

0 (0)

5 (16)

6 (20)

Regional

4.10*

.586

0.48*

.731

Lifestyle factors^
Smoking

Never smoked
Alcohol consumption
Current

Never
Weight
Underweight (<50 kg)
Overweight (>95 kg)

Note. Bolded p value indicates statistical significance p<.05; *Fisher’s Exact test result
reported; #Two main groups examined— ‘Working’ or ‘Not working’; ^Subjective
data not analysed
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Assessment measures
All participants completed all items on the SF-SUNS, DASS21 and MiniMAC. The PES gave participants the option of leaving a question blank;
however, most participants completed all items across the three time points.
The question most frequently left blank was “complementary therapies help
me cope with my illness” (n=12, 48%). There were more missing items from
the control group (19 vs 6 items). Across both groups, there were five missing
items at Time 1, 12 items at Time 2 and eight items at Time 3.

Cronbach’s alpha results supported scale reliability in all measures across the
three time points. Cronbach’s alphas in the present study ranged from:


SF-SUNS = .70 to .96



DASS21 = .79 to .94



Mini-MAC = .58 to .90



PES = .75 to .79

Unmet needs (as measured by the SF-SUNS) and patient empowerment (as
measured by the PES) demonstrated a medium to strong, negative
correlation between the two variables at: Time 1, r=–.51, n=60, p=<.001; Time
2, r=–.35, n=59, p=<.001; and Time 3, r=–.56, n=58, p=<.001. High levels of
empowerment were associated with lower levels of unmet needs. The
relationship between SF-SUNS and psychological distress (as measured by
the DASS21) revealed a strong, positive correlation between the two
variables at: Time 1, r=.75, n=60, p=<.001; Time 2, r=.80, n=59, p=<.001; and
Time 3, r=.77, n=58, p=<.001. Low levels of psychological distress were
associated with lower levels of unmet needs. Likewise, the relationship
between the SF-SUNS and mental adjustment to cancer (as measured by the
Mini-MAC) indicated a strong, positive correlation between the two
variables at: Time 1, r=.58, n=60, p=<.001; Time 2, r=.71, n=59, p=<.001; and
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Time 3, r=.67, n=58, p=<.001. Lower levels of unmet needs were associated
with better mental adjustment to the cancer diagnosis.

Fidelity
Control group
No participant randomised to the control group received the SCPTS or the
resource pack during the study. Four participants (13%) required at least one
phone call at Time 2 for non-return of measures, resulting in three (75%)
returned. At Time 3, 10 participants (33%) required at least one phone call for
non-return of measures. Seven participants (70%) posted back the measures
within a month and two (20%) brought the completed measures to their
haematologist appointment. Twenty-nine participants completed Time 2 and
Time 3 measurements.

Intervention group
All intervention participants completed the first NLSC appointment face-toface. The average time of consultation was 64.28 minutes (range 20–120
minutes) and the average time from baseline was 9.63 days (range 0–56
days). Four participants (13%), prior to the baseline appointment, indicated
they would be unable to return to the hospital within the next few weeks if
randomised to the intervention. Therefore, the first NLSC appointment was
planned for the same day as baseline if required. Two participants (6%) did
not present for their scheduled NLSC appointment and were eventually seen
31 and 56 days later. The average time of the second NLSC appointment was
46.13 minutes (range 19–90 minutes) and 44.31 minutes (range 15–70
minutes) for the third NLSC appointment. Four participants (13%) requested
a telephone appointment after their haematologist appointments had been
cancelled and moved to a future date. Assessment measures were completed
over the phone, and any written information requested was emailed or
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posted. Thirty participants at Time 1 and Time 2 and 29 participants at Time
3 completed all elements of the study.

Intervention group
Concerns and health goals
Half of the participants identified fear of recurrence, and one-third identified
fatigue and/or cognitive impairment as concerns on the SCPTS (Table 6.1.2).
Counselling referrals to a clinical psychologist were offered to those who
self-reported struggling with a psychosocial issue. Those who accepted a
counselling opportunity (n=4, 13%) had issues with fear of recurrence and/or
managing stress and anxiety. At study completion, one participant (3%)
continued to self-report a high / very high level of fear of recurrence on the
SF-SUNS. Fatigue was ongoing and remained a moderate to very high unmet
need self-reported on the SF-SUNS in one third of participants (n=10, 34%).
Cognition impairment likewise remained an issue with 52% (n=15) selfreporting this as a moderate to high unmet need on the SF-SUNS.

The majority of participants (n=25, 83%) wanted to increase or start physical
exercise and over half wanted to make healthy lifestyle changes (Table 6.1.2).

12Table 6.1.2 Top Five Concerns and Health Goals Identified from SCPTS
Rank Participant-identified
Concerns

N (%) Participant-identified Health
Goals

N (%)

1

Fear of recurrence or
other cancer

15 (50) Increasing or undertaking
physical activity/exercise

25 (83)

2

Fatigue

10 (33) Healthy lifestyle (including
weight loss, healthy diet,
reducing alcohol intake)

16 (53)

3

Memory and
concentration issues

9 (30) Work (balancing with life
now, taking opportunities)

13 (43)

4

Quit cigarette

4 (13) Travel

10 (33)
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smoking
5

Financial and
insurance issues

4 (13) Managing stress, anxiety and
mental health

8 (26)

A motivational chart was used as an aid to list participant likes, dislikes and
conflicts that might arise while trying to quit a particular behaviour. Four
participants (13%) used the chart to assist with smoking cessation. Three
participants (10%) were able to quit smoking by the end of the study, and
one young person had reduced smoking to social situations only. Two young
participants (6%) used the chart to address excessive or binge alcohol intake.
At study completion, one participant indicated complete abstinence and felt
this achievement had helped control other aspects of his life. The other
participant had verbalised at her first NLSC appointment: “I am sick of
cancer sucking the joy out of my life” and felt the peer pressure would be
difficult to withstand if she made lifestyle changes. At study completion, she
had reduced her alcoholic intake and acknowledged that getting healthy and
taking back control of her life had included taking herself out situations
where she felt pressured.

Assessment of the nurse-led lymphoma survivorship model of care
Survivorship unmet needs (SF-SUNS)
Friedman tests were undertaken to measure total scale and domain scores to
compare participants in the intervention group of the nurse-led lymphoma
survivorship model of care at Time 1 (pre-intervention), Time 2 (3 months'
post-intervention) and Time 3 (6 months' post-intervention). Total scale SFSUNS scores identified the highest unmet need at Time 2 (Md=22), then Time
1 (Md=18) with Time 3 (Md=16) the lowest (X2 (2, N=29) = 7.60, p=.022).
Significant results were evident in the financial concerns domain with greater
unmet need reported at Time 1 (Md=6) and Time 2 (Md=6) with Time 3
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(Md=4) the lowest X2 (2, N=29) = 6.08, p=.048. The access and continuity of
care domain demonstrated higher unmet need at Time 1 (Md=1) with Time 2
(Md=0) and Time 3 (Md=0) reporting no unmet need X2 (2, N=29) = 6.53,
p=.038. The relationships and emotional health domain identified the highest
unmet need at Time 1 (Md=12,) and Time 2 (Md=12) with Time 3 (Md=8) the
lowest X2 (2, N=29) = 6.69, p=.035. A significant difference was not reported
for the information domain (X2 (2, N=29) = 2.04, p=.360).

In the intervention group, scores decreased from Time 1 to Time 3 for total
scale (z=–2.15, p=.031, r=.28); and access and continuity of care domain scores
(z=–2.31, p=.021, r=.30) both with a small–moderate effect size. All other
results had a small effect size and were not statistically significant.

The Kruskal–Wallis test revealed no significant distribution across
lymphoma type. The intervention >60 years age group had very low scores
for access and continuity of care domain at Time 2 compared with the other
two age groups (Md=0 vs Md=2, 18–29 years and Md=2.5, >60 years; p=.012).
Although there was a disproportionate number of males to females, women
had significantly higher scores at Time 1 (Md=41 vs Md 16; p=.046),
particularly evident in the relationships and emotional health domain
(Md=21 vs Md=7; p=.007). Conversely, at Time 3, men recorded a significantly
higher median than women (Md=2 vs Md=0; p=.024) in the information
domain. The control group results revealed more unmet needs in the 30–59
years age group at Time 1 (Md=25.5 vs Md=18, 18–29 years and Md=13, >60
years; p=.016), and these were significantly higher in the financial concerns
(Md=9 vs Md=3, 18–29 years and Md=6, >60 years; p=.019) and access and
continuity of care domains (Md=2.5 vs Md=1, 18–29 years and >60 years;
p=.012). This continued to be an unmet need for this age group at Time 3 for
the access and continuity of care domain (Md=4 vs Md=1, 18–29 years and
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Md=0, >60 years; p=.023). Women in the control group had significantly
higher scores at Time 1 (Md=24 vs Md 17; p=.034), especially in the
relationships and emotional health domain (Md=13 vs Md=5.5; p=.004).

Intervention group mean scores were highest at Time 1 (M=27.33) and
continued to decrease over the study period. The domain with the most
significant decrease was the access and continuity of care domain. The
control group scores were highest at Time 2 (M=28.62); nonetheless were not
significant.

Independent t-tests, conducted to compare total scale and domain scores
across the time points, demonstrated higher mean scores in the control group
compared with the intervention group. The relationships and emotional
health domain scores for the control group increased over the study period.
All scores had a small effect size and no results were significant.

Individual items on the SF-SUNS were also assessed to identify specific
aspects of unmet need. Significant differences were found indicating that the
intervention group at Time 1 reported a higher level of need for finding
information about complementary or alternative therapies (M=0.87, SD=1.04,
Md=0) than the control group (M=0.27, SD=0.52, Md=0) [U 592, z 2.45, p=.014,
r .32]. Time 3 results indicated the control group felt less able to speak to
others about their emotions or deal with feeling depressed (Table 6.1.7).
Although not significant, six control group participants (21%) continued to
record high / very high unmet needs for fear of recurrence at Time 2 and 3.
Likewise, the control group reported more unmet cognition impairment
(n=20, 34%) at study completion. Both concerns documented by intervention
participants on the SCPTS.
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LMM analysis, adjusting for gender, lymphoma type and age, reported
group (control or intervention), time (1, 2 or 3), and lymphoma type (NHL or
HL) were not significantly associated with the SF-SUNS (Appendix L). The
LMMs for the domains (Table 6.1.3) reported a significant effect for time in
the information domain, showing Time 1 scores were higher (p=.025). The
LMM for the financial domain reported those with NHL had higher scores
compared to those with HL (p=.010). The access and continuity of care
domain LMM reported those with NHL had higher scores compared to those
with HL (p=.021) and as age increased, unmet needs in this domain
decreased (p=.039). The LMM for the relationships and emotional health
domain reported that women had more unmet needs compared to males
(p=.010).

13Table 6.1.3 Linear Mixed Model Results of SF-SUNS Domains
Variable

Information Domain
Intercept
Group—Controla
Lymphomab (NHL)
Genderc (Male)
Time 1d
Time 2d
Age
Financial Concerns
Domain
Intercept
Group—Controla
Lymphomab (NHL)
Genderc (Male)
Time 1d
Time 2d
Age
Access and Continuity
of Care Domain
Intercept

Beta
Estimate

Std.
Error

95% Confidence
Interval
Lower
Upper

P Value

3.23
0.37
0.50
–0.65
0.76
0.36
–0.02

1.00
0.67
0.81
0.66
0.33
0.33
0.02

1.20
–0.97
–1.12
–1.97
0.10
–0.30
–0.06

5.22
1.70
2.13
0.68
1.42
1.02
0.02

.002
.585
.536
.332
.025
.287
.276

7.70
–1.40
5.70
–1.56
0.83
1.00
–0.80

2.62
1.76
2.15
1.75
0.66
0.66
0.05

2.44
–4.93
1.40
–5.06
–0.47
–0.31
–0.18

12.94
2.14
10.00
1.94
2.13
2.30
0.02

.005
.434
.010
.376
.209
.133
.105

4.23

1.58

1.12

7.44

.009

159

CHAPTER 6. RESULTS

Group—Controla
–0.81
1.06
–2.93
1.31
.448
.021
Lymphomab (NHL)
3.05
1.29
0.47
5.62
c
Gender (Male)
–0.97
1.05
–3.07
1.13
.360
d
Time 1
0.94
0.48
–0.01
1.90
.053
d
Time 2
0.49
0.48
–0.47
1.44
.316
.039
Age
–0.06
0.03
–0.12
–0.00
Relationships and
Emotional Health
Domain
Intercept
20.54
4.63
11.28
29.81
.000
a
Group—Control
–1.75
3.11
–7.99
4.49
.577
b
Lymphoma (NHL)
4.59
3.79
–3.00
12.18
.231
.010
Genderc (Male)
–8.20
3.09
–14.39
–2.02
d
Time 1
0.93
1.19
–1.42
3.28
.435
d
Time 2
1.97
1.19
–0.39
4.33
.100
Age
–0.11
0.09
–0.28
0.06
.211
Note. Bolded p value indicates statistical significance p<.05; a Comparison group set
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set
to zero (Female); d Comparison group set to zero (Time 3)

Psychological distress (DASS21)
Friedman tests performed on the intervention group did not identify
significant differences on the total scale and domain scores between the three
time points. Total scale scores revealed the highest levels were at Time 1
(Md=10) and Time 2 (Md=10) with Time 3 (Md=8) the lowest (X2 (2, N=29) =
1.55, p=.462). Domain results revealed higher levels of depression at Time 2
(Md=3), then Time 1 (Md=2), with Time 3 (Md=1) the lowest (X2 (2, N=29) =
3.12, p=.210). This result was reflected in the stress domain with higher levels
identified at Time 2 (Md=5) then Time 1 (Md=4) and Time 3 (Md=4) (X2 (2,
N=29) = 4.00, p=.135). Greater levels of anxiety were identified at Time 1
(Md=3) and Time 2 (Md=3) with Time 3 (Md=2) lower (X2 (2, N=29) = 0.16,
p=.923).

A Wilcoxon Signed Rank Sum test revealed no significant differences in the
intervention group, and all results had a small effect size. There were no
significant differences in the distribution of scores across age groups, gender
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or lymphoma type in the intervention group. The control group
demonstrated a significant difference in the distribution of total scale scores
across gender at Time 2, with women reporting higher scores (Md=16 vs Md
5; p=.022). Domain scores revealed women had higher levels in the
depression domain at Time 1 (Md=2.5 vs Md 1; p=.039) and Time 2 (Md=6 vs
Md 0; p=.016), and anxiety domain at Time 2 (Md=3.5 vs Md=1; p=.017). No
significant results were reported across age group or lymphoma type. No
significant results were identified in the control group; however, total scale
scores did decrease over the study period.

Independent t-tests revealed no significant results in either the control or
intervention groups. Intervention group mean scores were highest at Time 2
(M=15.63), and although they had decreased by Time 3 (M=13.03), they
continued to reflect higher mean scores than at Time 1 (M=12.67).
Intervention group mean anxiety (M=3.53) and stress (M=6.80) domain scores
were slightly higher at Time 2, with stress mean scores higher at Time 3
(M=5.66) than at Time 1 (M=5.17). Control group mean scores revealed Time
1 (M=15.57) and Time 3 (M=15.14) scores were higher compared with the
intervention group, with the Time 2 mean anxiety domain score highest
(M=3.63) when compared with the intervention group.

Individual items on the DASS21 were assessed to detect specific traits of
psychological distress. Results did not reveal any significant differences in
the items between the two groups at any time point.

LMM examining DASS21 total scale score and domains (Table 6.1.4),
adjusting for gender, lymphoma type and age, reported no significant group
(control or intervention) or time (1, 2 or 3) effects. However, women reported
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higher scores compared with men for all DASS21 models: Total scale
(p=.013); depression (p=.032); anxiety (p=.007); and stress (p=.029).

14Table 6.1.4 Linear Mixed Model Results of the DASS21
Variable

Beta
Estimate

Std.
Error

95% Confidence
Interval
Lower
Upper

P Value

Total Scale
Intercept
17.12
5.12
6.86
27.38
.001
a
Group—Control
–2.75
3.45
–9.66
4.17
.429
b
Lymphoma (NHL)
5.77
4.20
–2.64
14.19
.175
.013
Genderc (Male)
–8.75
3.42
–15.60
–1.90
d
Time 1
0.16
1.23
–2.28
2.60
.897
d
Time 2
0.95
1.23
–1.49
3.40
.441
Age
–0.02
0.09
–0.21
0.17
.857
Depression Domain
Intercept
4.67
1.99
0.68
8.66
0.23
a
Group—Control
–1.34
1.34
–4.02
1.35
.322
Lymphomab (NHL)
2.05
1.63
–1.21
5.32
.213
c
.032
Gender (Male)
–2.92
1.33
–5.58
–0.26
d
Time 1
–0.21
0.52
–1.24
0.82
.683
d
Time 2
0.53
0.52
–0.50
1.56
.309
Age
0.01
0.04
–0.06
0.09
.744
Anxiety Domain
Intercept
3.91
1.44
1.03
6.79
.009
a
Group—Control
–0.76
0.96
–2.69
1.12
.433
Lymphomab (NHL)
1.06
1.17
–1.29
3.40
.370
c
.007
Gender (Male)
–2.70
0.96
–4.61
–0.78
d
Time 1
0.56
0.43
–0.30
1.42
.202
Time 2d
0.08
0.44
–0.78
0.94
.852
Age
0.01
0.03
–0.39
0.07
.589
Stress Domain
Intercept
8.65
2.12
4.40
12.90
.000
Group—Controla
–0.74
1.43
–3.59
2.12
.607
b
Lymphoma (NHL)
2.69
1.73
–0.78
6.17
.126
c
.029
Gender (Male)
–3.16
1.41
–5.99
–0.33
Time 1d
–0.28
0.59
–1.44
0.88
.632
d
Time 2
0.24
0.59
–0.93
1.40
.685
Age
–0.04
0.04
–0.12
0.04
.276
a
Note. Bolded p value indicates statistical significance p<.05; Comparison group set
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set
to zero (Female); d Comparison group set to zero (Time 3)
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Adjustment to cancer (Mini-MAC)
Friedman tests on the intervention group did not identify significant
differences on the total scale scores between the three time points (X2 (2,
N=29) = 3.75, p=.154). However, a significant result in the fighting spirit
domain was identified, with the highest level of fighting spirit evident at
Time 1 (Md=13) then Time 3 (Md=12) with Time 2 (Md=11) the lowest (X2 (2,
N=29) = 12.00, p=.002). Other domains reported no significant differences:
fatalism (X2 (2, N=29) = 1.35, p=.508); helplessness/hopelessness (X2 (2, N=29) =
1.12, p=.572); anxious preoccupation (X2 (2, N=29) = 0.73, p=.695); and
cognitive avoidance (X2 (2, N=29) = 0.08, p=.959).

A Wilcoxon Signed Rank test on the intervention group revealed a decrease
in scores from Time 1 to Time 2 (z –2.60, p=.009, r .34) with a small–moderate
effect size in the fighting spirit domain for the intervention group. All other
results had a small effect size and were not significant.

Those with NHL in the intervention group reported significantly lower
median scores at Time 1 on the total scale scores (Md=58 vs Md 72.5; p=.009),
in the anxious preoccupation (Md=13 vs Md 20.5; p=.010) and cognitive
avoidance (Md=8 vs Md 10; p=.037) domains. Significant results were not
identified at other time points or in gender or age groups. Conversely the
control group’s 30–59 years age group had the highest total scale scores at
each time point in comparison with the other two groups (Time 1: Md=72.5
vs Md=64, 18–29 years and Md=63, >60 years; p=.040. Time 2: Md=77 vs
Md=59, 18–29 years and Md=63, >60 years; p=.012. Time 3: Md=73 vs Md=61,
18–29 years and Md=57, >60 years; p=.019). Higher scores in this group were
notable at Time 2 in the helplessness/hopelessness (Md=15 vs Md=8, 18–29
years and >60 years; p=.011) and anxious preoccupation (Md=21 vs Md=15,
18–29 years and Md=14, >60 years; p=.011) domain scores. Anxious
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preoccupation scores at Time 3 were likewise higher (Md=22 vs Md=17, 18–29
years and Md=15, >60 years; p=.023). The cognitive avoidance domain
revealed the 30–59 years age group had the highest scores compared with the
other two groups at Time 1 (Md=12 vs Md=10, 18–29 years and Md=8, >60
years; p=.005) and Time 3 (Md=12 vs Md=9, 18–29 years and >60 years;
p=.017). One aberration to this trend was noted at Time 2 in the fatalism
domain where scores revealed those >60 years of age had significantly higher
scores compared with the other two groups (Md=16 vs Md=11, 18–29 years
and Md=14, 30–59 years; p=.029). A significant distribution of fatalism scores
revealed NHL participants recorded higher scores at Time 1 (Md=16 vs
Md=12; p=.013), Time 2 (Md=15 vs Md=10; p=.010) and Time 3 (Md=14 vs
Md=10; p=.015) compared with those diagnosed with HL. However, it should
be noted there were more NHL participants in this group than HL. The
fighting spirit domain at Time 3 showed a significant difference with NHL
participants recording a higher median (Md=12 vs Md=10; p=.039). No
significant differences in the distribution of gender scores were reported.

The fighting spirit domain in the intervention group identified a significant
decrease from Time 1 to Time 2 (p=.009). Likewise, the fighting spirit domain
(p=.002), along with anxious preoccupation (p=.037) was significant in the
control group at Time 1 to Time 3. Independent t-tests that compared both
groups at each of the three time points did not identify significant
differences. For the intervention group, total scale and domain mean scores
decreased from Time 1 to Time 3, with the exception of cognitive avoidance
domain mean score which was highest at Time 2 (M=8.80; p=.043). Results of
the independent t-tests revealed the control group had a decrease in scores
across the domains; fatalism, fighting spirit and anxious preoccupation over
the study period. Fatalism and fighting spirit scores were lower for the
control group when compared with the intervention group. In contrast, the
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helplessness/hopelessness (M=12.62 vs M=12.00) and cognitive avoidance
(M=10.14 vs M=8.52) domain scores continued to increase and were highest
in this group when compared with the intervention group at Time 3;
however, the results were not significant.
Individual items on the Mini-MAC were evaluated to detect any specific
areas where either group had greater concerns. Significant differences were
found at Time 2 indicating the control group struggled more with having a
cancer diagnosis and trying not to think about it (Table 6.1.7). For the control
group, trying not to think about having cancer was still an issue at Time 3
(Table 6.1.7).

LMM analysis of the Mini-MAC and domains fighting spirit and fatalism,
adjusting for gender, lymphoma type and age, reported group (control or
intervention), gender and lymphoma type were not significant contributors
(Table 6.1.5). For all Mini-MAC models, total scale (p=.020), fatalism (p=.035)
and fighting spirit (p=.029) domain scores were higher at Time 1 (Table 6.1.5).
In addition, for the LMM fatalism domain, scores increased as age increased
(p=.005). For the fighting spirit domain, a significant interaction between
group and time was found, reporting that the control group had a higher
fighting spirit domain score at Time 2 (p=.049). No significant results were
found in the LMM for other domains; helplessness/hopelessness, anxious
preoccupation and cognitive avoidance (Appendix L).

15Table 6.1.5 Linear Mixed Model Significant Results of Mini-MAC
Variable

Total scale
Intercept
Group—Controla
Lymphomab (NHL)

Beta
Estimate

Std.
Error

67.65
1.38
0.09

5.49
3.70
4.51

95% Confidence
Interval
Lower
Upper
56.65
–6.04
–8.93

78.64
8.80
9.12

P
Value

.000
.711
.983
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Genderc (Male)
–5.29
3.67
–12.64
2.07
.155
.020
Time 1d
2.93
1.25
0.46
5.40
d
Time 2
1.97
1.25
–0.50
4.44
.117
Age
–0.03
0.10
–0.23
0.17
.780
Fatalism Domain
Intercept
10.87
1.17
8.53
13.21
.000
a
Group—Control
–0.65
0.79
–2.23
0.92
.411
b
Lymphoma (NHL)
0.01
0.96
–1.91
1.93
.992
c
Gender (Male)
–0.40
0.78
–1.96
1.16
.609
.035
Time 1d
0.69
0.32
0.05
1.33
d
Time 2
0.57
0.32
–0.07
1.21
.081
.005
Age
0.06
0.02
0.02
0.11
Fighting Spirit Domain
Intercept
11.71
0.95
9.82
13.61
.000
a
Group—Control
–.031
0.70
–1.70
1.09
.665
b
Lymphoma (NHL)
1.09
0.76
–0.44
2.62
.159
Genderc (Male)
0.36
0.62
–0.89
1.60
.571
d
.029
Time 1
0.83
0.38
0.08
1.58
d
Time 2
–0.24
0.38
–0.98
0.51
.531
Age
–0.02
0.02
–0.06
0.01
.211
a
d
Group—Control * Time 1
0.38
0.53
–0.68
1.43
.480
a
d
.049
Group—Control * Time 2
1.06
0.53
0.01
2.12
a
Note. Bolded p value indicates statistical significance p<.05; Comparison group set
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set
to zero (Female); d Comparison group set to zero (Time 3)

Patient empowerment (PES)
No significant difference was reported on the Friedman test conducted on
the intervention group. Results identified an increase from Time 1 (Md=49) to
Time 2 (Md=51) with Time 3 (Md=52) the highest empowerment scores (X2 (2,
N=29) = 4.71, p=.095). A Wilcoxon Signed Rank test revealed no significant
increase in empowerment scores at Time 1 to Time 2 or Time 1 to Time 3 in
the intervention group; all results had a small effect size.

The distribution of scores from the intervention group, as measured by the
Kruskal–Wallis test, was similar across the age groups, gender and
lymphoma types. In the control group, results indicated a significant
distribution of higher scores for the >60 years age group at Time 1 (Md=54 vs
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Md=46, 18–29 years and Md=47, 30–59 years; p=.010), Time 2 (Md=50 vs
Md=44, 18–29 years and 30–59 years; p=.011) and Time 3 (Md=51 vs Md=44,
18–29 years and Md=45, 30–59 years; p=.024), demonstrating more
empowerment. At Time 2, men had the highest scores (Md=48 vs Md=44;
p=.036). Those with NHL had the highest scores at Time 1 (Md=50.5 vs
Md=43.5; p=.010) and Time 2 (Md=48 vs Md=42; p=.014).

Paired-sample t-tests indicated the highest level of empowerment in the
intervention group was at Time 2 and Time 3; however, these were not
significant results. Whereas control group results identified a significant
decrease from Time 1 to Time 2 (p=.005) in the level of empowerment this
group recorded. Although not significant, the lowest scores were recorded at
Time 3. The highest empowerment scores were identified in the intervention
group compared with the control group at Time 2 (M=49.50 vs M=45.79;
p=.016). No further significant results were identified.

Individual items on the PES revealed significant differences for the control
group. The results indicated the control group felt less adept at making
lifestyle changes at Time 2 and Time 3 and at Time 1 indicated a need for
support from family and friends. This was in contrast to the intervention
group where results indicated they had all the information they needed to
manage their health and adapt to and make lifestyle changes at Time 2 and
Time 3 (Table 6.1.7).

The LMM for the PES, adjusting for gender, lymphoma type and age,
reported no significant group (control or intervention), lymphoma, gender or
time (1, 2 or 3) effects (Table 6.1.6). However, a significant group x time
interaction was reported indicating Time 1 scores were higher in the control
group (p=.013) and then decreased over the study period.

167

CHAPTER 6. RESULTS

16Table 6.1.6 Linear Mixed Model Results of PES
Variable

Beta
Estimate

Std.
Error

95% Confidence
P
Interval Value
Lower
Upper
Intercept
45.19
2.07
41.05
49.32
.000
a
Group—Control
–2.71
1.55
–5.79
0.38
.085
b
Lymphoma (NHL)
0.95
1.65
–2.36
4.26
.569
Genderc (Male)
1.70
1.35
–1.00
4.40
.213
d
Time 1
–1.76
0.90
–3.55
0.04
.055
d
Time 2
–0.59
0.90
–2.38
1.20
.516
Age
0.06
0.04
–0.01
0.14
.093
.013
Group—Controla * Time 1 d
3.21
1.28
0.68
5.74
a
d
Group—Control * Time 2
–0.83
1.28
–3.36
1.71
.521
a
Note. Bolded p value indicates statistical significance p<.05; Comparison group set
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set
to zero (Female); d Comparison group set to zero (Time 3)
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17Table 6.1.7 Assessment Measure Items that Demonstrated a Statistically Significant Difference between Control and Intervention
Groups
Measure
Time
Item

Control
Group
Mean (SD)
Median

Intervention
Group
Mean (SD)
Median

Test Pool Effect*

Effect
Size #

SF-SUNS
Time 1
Finding information about complementary or alternative therapies

0.27 (0.52) 0

0.87 (1.04) 0

U 592, z 2.45, p .014

r .32

Time 3
Telling others how I was feeling emotionally

1.10 (1.01) 1

0.21 (0.82) 0

U 186.50, z –4.25, p .000

r .55

Dealing with feeling depressed
Mini-MAC
Time 2
I have difficulty believing this happened to me

1.24 (1.33) 1

0.62 (0.98) 0

U 302.50, z –1.99, p .047

r .26

2.76 (0.95) 3

2.20 (1.03) 2

U 301, z –2.11, p .035

r .27

I deliberately push all thoughts of cancer out of my head

2.59 (0.98) 3

2.03 (0.96) 2

U 301, z –2.12, p .034

r .28

Time 3
Not thinking about it helps me cope

2.48 (0.98)3

1.97 (0.98) 2

U 296, z –2.03, p .042

r .27

2.48 (0.87) 3

2.03 (1.02) 2

U 297, z –2.00, p .046

r .26

I deliberately push all thoughts of cancer out of my head
PES
Time 1
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I need the support of family and friends

3.77 (0.43) 4

3.43 (0.73) 4

U 338, z –1.99, p .047

r .26

Time 2
I have all the information I need to manage my illness

3.03 (0.63) 3

3.47 (0.63) 4

U 590, z 2.66, p .008

r .35

I can adapt to changes in my lifestyle

3.03 (0.78) 3

3.40 (0.68) 3

U 553, z –1.98, p .048

r .26

Health professionals are happy to include me in decisions related
to my illness

3.28 (0.53) 3

3.53 (0.82) 4

U 570, z 2.33, p .020

r .30

I accept that I have to change my lifestyle

2.86 (0.74) 3

3.30 (0.65) 3

U 568, z 2.28, p .023

r .30

Time 3
I am capable of handling my illness

3.28 (0.59) 3

3.62 (0.49) 4

U 547, z 2.24, p .025

r .29

I have all the information I need to manage my illness

3.14 (0.64) 3

3.59 (0.57) 4

U 577, z 2.17, p .007

r .36

I am capable of helping health professionals reach decisions related
to my illness

3.31 (0.54) 3

3.62 (0.56) 4

U 546, z 2.23, p .026

r .29

I accept that I have to change my lifestyle

2.83 (0.89) 3

3.34 (0.67) 3

U 556, z 2.29, p .022

r .30

U 564, z 2.45, p .014
I have a lot of confidence in my local GP
3.03 (0.98) 3
3.59 (0.63) 4
r .32
#
Note. Significance level 0.05 (2-tailed); *Mann–Whitney U test; Effect size r=z/square root N (total number of cases). Therefore r=z/7.7 (60 cases),
7.68 (59 cases), 7.6 (58 cases). 0.2=small effect, 0.5=moderate effect, 0.8=large effect
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6.2 Results of the General Practitioner
Evaluation
Statistical Techniques
The data collected from the GP evaluations were analysed using descriptive
statistics and content analysis for open-ended items. A Likert-type scale was
used to assess four items on the usefulness of the SCPTS content (1=very
poor, 2=poor, 3=adequate, 4=good, 5=very good). Cronbach’s alpha of 0.93
indicated these items were reliable.

Results
Twenty-eight GPs who had received an SCPTS six months previously for
intervention participants were sent the SCPTS evaluation. Although the
study randomised 30 participants to the intervention group, two participants
did not have a GP during the study. One GP had two participants in the
study and chose only to respond once. Five further participants had not seen
their GP during the study; however, two GPs sent back an evaluation stating
they had not seen the participant. The overall response rate was 64% (18
evaluations returned). A number of strategies were employed to maximise
evaluation return such as follow-up phone calls which resulted in one
evaluation return. Although five medical practices were faxed another copy
of the documents, this did not result in the return of an evaluation.
Participants were also encouraged to remind the GP to fill out an evaluation.
Three patients requested a copy of the evaluation they could personally hand
over at their next GP visit, this resulted in one evaluation returned.
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Of the GPs who did not return an evaluation (n=10, 36%), seven were male,
eight had metropolitan medical practice addresses and two were regional.
No further information was collected.

Of the GPs who did return an evaluation (n=18, 64%), 11 (61%) were male,
and the majority were metropolitan based (n=16, 89%). The range of years
practicing as a GP were; 6–14 years (n=2, 11%), 15–20 years (n=6, 33%) and
25–30 years (n=10, 56%). Responses to use of the SCPTS are reported in Table
6.2.1.
18Table 6.2.1 Responses to Use of SCPTS (n=18)
Item

Yes

No

Not Applicable

N (%)

N (%)

N (%)

Seen patient in last 6
months

16 (89)

2 (11)

Received SCPTS

16 (89)

2 (11)

Read on receipt

16 (89)

1 (5.5)

1 (5.5)

GP initiated appointment

6 (33)

11 (61)

1 (5.5)

Participant initiated
appointment

7 (39)

10 (55)

1 (5.5)

Participant brought SCPTS

8 (44)

7 (39)

3 (17)

11 (61)

4 (22)

3 (17)

9 (50)

6 (33)

3 (17)

SCPTS discussed with
participant
GP Initiated Support

GPs' perception of the usefulness of the SCPTS was evaluated. Sixteen GPs
responded to this section and responses are reported in Table 6.2.2.
Responses ranged from adequate to very good. As indicated, the majority of
GPs (n=13, 81%) perceived the SCPTS was good to very good.

An open-ended section investigated what further information GPs would
like on the SCPTS. Ten (56%) GPs provided responses which included:
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haematologist contact details or other treatment details (psychological
support implemented or planned); frequency of haematology review; what
blood tests the GP needed to order; drug names written in full rather than
use

of

acronyms;

vaccination

schedule

post-autologous

transplant;

peripheral neuropathy management; potential fertility issues; and ‘brain
training’ (? for cognitive impairment).

19Table 6.2.2 Description of GP Responses (n=16)

Usefulness of treatment
information

Raw Scoring (N)

Mean (SD) [Range]

Adequate (2)

4.25 (0.68) [3–5]

Good (8)
Very good (6)

Usefulness of survivorship
care plan information

Adequate (3)

4.19 (0.75) [3–5]

Good (7)
Very good (6)

Usefulness of patient-derived
health concerns, goals and
actions
Usefulness of SCPTS for
patient

Adequate (1)

4.13 (0.50) [3–5]

Good (12)
Very good (3)
Adequate (2)

4.19 (0.66) [3–5]

Good (9)
Very good (5)

Total combined scores

16.75 (2.38) [12–20]

GPs were queried if any information was not required on the SCPTS; n=6
(34%) responded: four (67%) indicated no information needed to be
removed; one GP wrote it was ‘all good’, and one indicated the information
‘was really well presented’.

Over half of GP respondents (n=10, 56%) took up the opportunity to make
additional comments. Responses were dichotomised as: positive (“As far as
questionnaires go this was excellent. Concise and brief”, “Great idea”);
neutral (“Rang when I learnt of diagnosis to offer follow-up. I did not ring
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again when I got the plan”, “Diagnosed the lymphoma and not seen him
since”, “nothing further to add”); or negative (“Not clear what you expect GP
to follow-up [or] what follow-up provided by haematology clinic. I expect a
letter with instructions once you discharge from your service”, “further
comments are pointless”).

GPs were solicited if they would like further education on the management
of haematology survivors, n=13 (72%) responded (yes=4, 31%, no=9, 69%).
Those who responded ‘yes’, indicated they would like education either in a
workshop or online n=1, online or a learning package n=1, online n=2. Three
GPs indicated they would like further education on other haematology
malignancies, case studies, post-treatment vaccinations.
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6.3 Results of Qualitative Interviews
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Qualitative Results from a Phase II Pilot Randomised
Controlled

Trial

of

a

Lymphoma

Nurse-led

Model

of

Survivorship Care.

Abstract
Purpose: To explore and describe lymphoma survivors’ thoughts and
perceptions of the components of a nurse-led lymphoma survivorship clinic
intervention.

Methods: An exploratory, qualitative descriptive study using interviews
from 10 participants who had transitioned post-treatment into the
survivorship

phase

via

a

nurse-led

lymphoma

survivorship

clinic

intervention.

Results: Thematic analysis revealed three major themes: Reassurance and
individualised

care;

Information

and

support;

and

Empowerment.

Participants described the reassurance they gained from having contact with
a health professional post-treatment who individualised information and
support. A survivorship care plan and treatment summary was developed
for this study and was believed to be very patient-centred and helpful. This
enabled participants to take back control of their health and well-being and
to rebuild confidence.

Conclusions: In this study, participants expressed a need for patient-centred
follow-up care that addressed their concerns and supported them in the
survivorship phase to get their life back on track. Nurse-led follow-up may
offer a viable model of post-treatment survivorship care to lymphoma cancer
survivors.
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Introduction
Lymphomas are haematological cancers that originate from the lymphatic
system, and are mainly categorised as either Hodgkin (HL) or non-Hodgkin
lymphoma (NHL) (American Cancer Society, 2014). Worldwide, lymphomas
represent the sixth most commonly diagnosed cancer (Surveillance
Epidemiology and End Results (SEER), 2014). Australian incidence is
increasing with an estimated 6,323 cases expected in 2017, which will equate
to 4.6% of all cancer cases (Cancer Australia, 2017). However, developments
in treatment and supportive care options such as chemotherapy,
haematopoietic stem cell transplantation, radiotherapy and targeted
therapies have improved five year survival to 76% (Cancer Australia, 2017).
With increased remission and survival rates, many survivors experience
issues and concerns, called unmet needs, which can impact quality of life and
well-being (Carey et al., 2012; Sant et al., 2014). These can relate to issues
such as: fatigue; poor nutrition; exercise capacity; cognition impairment; fear
of recurrence; fertility, relationships; finances; employment; and insurance
(Taylor et al., 2015; van der Poel et al., 2014). Health can be further
compromised by late effects of treatment such as cardiovascular disease and
second cancers (Grinyer, 2010; Ng et al., 2011; Travis et al., 2012), often
experienced earlier than the general population (Panek-Hudson, 2013).

Haematological survivorship studies mainly report on mixed haematological
samples regardless of variations in clinical features, treatment, curability and
relative survival (Hall, Campbell, et al., 2013; Lobb et al., 2009; McGrath,
2014). A study of lymphoma (n=236) and myeloma (n=178) survivors on
anxiety, depression and unmet needs in the early survivorship period (under
two years) reported decreasing anxiety and depression rates in the myeloma
cohort and increasing rates in the lymphoma cohort (Oberoi et al., 2017). The
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authors indicated a need for cohort specific studies, especially in the early
survivorship period (Oberoi et al., 2017) to ensure targeted support.
Lymphoma only studies often reflect a survivorship period beyond two
years at assessment (Ferrer, Huedo-Medina, Johnson, Ryan, & Pescatello,
2011; Friedman et al., 2010; Oerlemans et al., 2014), which may not reflect the
unique needs of those who have recently completed treatment, limiting
generalisability. A recent study by the authors (Monterosso et al., 2017)
reported on focus groups with lymphoma survivors (n=17), the majority
(n=13, 76%) who were 12–30 months post-treatment completion. Participants
recounted unmet needs related to information, coping strategies and
support, especially when transitioning into survivorship. Findings suggested
cancer nurse coordinators could be a feasible approach to delivering
structured, individualised support early post-treatment (Monterosso et al.,
2017).

Nurse-led models of survivorship care have been proposed to transition
patients post-treatment and have demonstrated acceptable outcomes in
haematology cohorts (Gates et al., 2015; Howell et al., 2012; John & Armes,
2013). As a minimum, nurse-led models should include: administration of
survivor-specific needs assessments to identify patient concerns (McDowell
et al., 2010; Stricker et al., 2011); development and delivery of a survivorship
care plan and treatment summary (SCPTS), to guide holistic follow-up
(Clinical Oncology Society of Australia, 2016; MacMillan Cancer Support &
NHS Improvement, 2010; McCabe, Bhatia, et al., 2013); and support to assist
survivors to take ownership of their health and well-being (Bodenheimer et
al., 2002; Kuijpers et al., 2013). To date, studies that have tested nurse-led
models of care have focused on survivors of common cancers (breast,
prostate, colon) (Jefford et al., 2016; Maly et al., 2017; Taylor et al., 2015), been
based in acute care settings, used long consultations, and involved more
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frequent patient contact (Cooper et al., 2010; De Leeuw & Larsson, 2013),
which may preclude generalisability to other cancers or limit economic
viability.

In order to provide lymphoma survivors with specific and responsive
supportive care, the unique issues and unmet concerns of this cohort need to
be assessed in the early survivorship period (under one year). The aim of this
sub-study was to provide qualitative semi-structured interview data from a
sample of participants who had been randomised to the intervention group
of the Care After Lymphoma (CALy) phase II randomised controlled trial
study (RCT) (Taylor et al., 2016). The RCT aimed to develop and test a nurseled lymphoma survivorship clinic (NLSC) intervention to assist participants
transitioning from treatment completion into the early survivorship phase.
This study will add to the limited literature that exists in lymphoma specific
early survivorship.

Methods
Methodological framework
A

qualitative

descriptive

methodology was

utilised to

provide

a

comprehensive summary of a specific experience by the participants
(Neergaard, Olesen, Andersen, & Sondergaard, 2009; Sandelowski, 2000),
using a semi-structured interview design. The interview schedule consisted
of the same open-ended questions and was developed by the researchers. To
ensure participants felt able to express themselves and their perceptions
freely, interviews were conducted by an experienced independent
researcher.
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Sample and setting
A purposive sample of lymphoma patients from a large tertiary hospital
cancer centre in Perth, Western Australia were recruited from the
intervention group of the RCT. A non-probability purposive sampling
provides rich information from participants who have the greatest amount of
in-depth knowledge and experience of a particular circumstance or event
(Patton, 2014). Only participants who had completed all aspects of the NLSC
intervention were approached by the survivorship cancer nurse conducting
the clinic intervention. These participants had completed four measures:
Short-Form Survivor Unmet Needs Survey (SF-SUNS); Depression Anxiety Stress
Scale (DASS21); Mini Mental Adjustment to Cancer Scale (Mini-MAC); and
Patient Empowerment Scale at three time points; baseline (prior to
randomisation), 3 months and 6 months. At the first NLSC appointment
(approximately one week after baseline), participants completed and
received an individualised lymphoma SCPTS, developed for this study
(Taylor et al., 2016). Participants’ GP were sent a copy. A motivational
interview technique was used to provide evidenced-based information,
advice and support at the first intervention appointment and reinforced with
additional resources and support as required over the next two
appointments.

All participants approached agreed to be interviewed. Each participant was
nine months’ post-treatment completion and the sample reflected an equal
gender distribution and range of ages. Data saturation was achieved after ten
interviews.

Interviews
The study was approved by the relevant hospital and university human
research ethics committees. Informed written consent was obtained by all
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participants prior to interview scheduling. Interviews were conducted from
February 2016 to May 2017 and occurred after the last NLSC appointment.
Telephone interviews were conducted at a time convenient for the
participant and were digitally recorded. The following are examples of the
interview questions: ‘Did you have any concerns or needs not addressed by
any of the questions?’; ‘What aspects of the clinic would you want to stay the
same for future patients?’; ‘Would you recommend the clinic to other
patients finishing treatment?’; ‘How do you feel about having the health
concerns, goals and actions individualised to yourself?’; and ‘Overall how
useful was the SCPTS to you?’ Interviews were transcribed verbatim, deidentified and an identifier code applied. Digital recordings and transcribed
interviews were saved in a password-protected file on a secure server. After
the first three interviews, the question order was slightly altered to enhance
the flow of the interview.

Data Analysis
Interview transcripts were imported into NVivo 11 (NVivo 11, 2016) to
facilitate management of data and completion of the analysis. Thematic
analysis was used to establish patterns and themes within the text (Grbich,
1998; Patton, 2014; Smith, 2007). Thematic analysis allows for participant
diversity of ideas and perceptions (Smith, 2007), thus providing a depth of
information regarding the personal impact of the NLSC on the participant.
Subthemes were developed from the data and allowed for a logical
organisation of the themes that emerged. The criteria of credibility,
auditability and fittingness were applied to the data analysis process to
ensure rigor (Beck, 1993). Credibility was maintained by triangulation with
another member of the research team (Beck, 1993) to ensure independent
reading and analysis of the transcripts by KT and CB who allocated codes
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and themes to the generated data (Braun & Clarke, 2006). The researchers
met to discuss the codes and any discrepancies before consensus on
emerging themes was reached. The ample use of extracts or quotes from the
data demonstrated fittingness to the agreed codes. A comprehensible audit
trail maintained auditability, demonstrated by documentation of research
planning through to analysis, and through a reflective discourse and debrief
process with colleagues.

Results
Participants
Ten semi-structured interviews were conducted with all participants willing
to share an opinion for each of the interview guideline areas. Demographic
and disease information is shown in Table 6.3.1. There were equal numbers
of males and females, with similar age range (24 –74 years) and lymphoma
type. The majority of participants resided within the metropolitan area (n=8,
80%), were working (n=6, 60%), were married or defacto (n=6, 60%) and had
a university degree or trade qualification (n=8, 80%).

Time elapsed from end of study to interview ranged from 1 to 26 days (mean
6.5 days, SD 7.8 days). The majority of interviews (n=8) were done within 5
days. No time limit was set and interviews ranged from 17 minutes through
to 48 minutes (mean 30.5 minutes).
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20Table 6.3.1 Demographic Characteristics for Interview Participants (n=10)
Characteristics

Males n=5
(50%)

Females n=5
(50%)

24–25

2

2

48

1

1

65–74

2

2

Non-Hodgkin

2

2

Hodgkin

3

3

Secondary school or less

1

1

Trade/vocational college

2

2

University

2

2

Working

4

2

Retired

1

2

No return to work date

–

1

Single

1

2

Married/defacto

4

2

Divorced

–

1

Metropolitan

4

4

Regional

1

1

Age group at baseline

Lymphoma diagnosis

Highest level of education

Employment status

Marital status

Residence

Themes
Three major themes emerged from analysis and coding of data: reassurance
and individualised care; information and support; and empowerment.
Subthemes have been included to add clarity.

Reassurance and individualised care
Overall, the NLSC was well received and deemed a positive experience for
participants, although it would have been reassuring to know about the
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clinic intervention during treatment. The assessment questionnaires and the
SCPTS were perceived to facilitate individualised care.

Timing of support
Most participants indicated they would have liked knowledge of the clinic
intervention during treatment so they could feel reassured that someone was
still interested in supporting them and they were ‘not going to be
abandoned’. This would take the form of a contact person they could trust.

“Just knowing that I was still going to get some support” F_25yo_HL

“But to know that look, don’t worry, after treatment you are going to see a
nurse, that would have been very calming for me” F_64yo_HL

The use of questionnaires to elicit unmet needs and concerns
Questionnaires were used to elicit unmet needs and areas of concern that
could be discussed with participants at the NLSC appointment. Participant
responses served as a focus for the follow up appointment. Feedback about
the questionnaires indicated some questions were hard to answer.

“Sometimes I found that I couldn’t say yes or no to the questions, because they
didn’t apply I suppose, and I had to answer” F_64yo_HL

Nonetheless, the questionnaires were able to cover aspects thought to be
important to participants’ overall wellbeing, as one said,

“They covered a multitude of the different things like your emotional well-being,
mental well-being and physical well-being, all the things that you know you can
struggle with” F_24yo_HL
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The supportiveness of the intervention
All participants wanted the intervention structure to remain the same,
describing the one-to-one, personalised nature of the intervention a valuable
opportunity to talk to someone who was not family, friends or a doctor. They
described being listened to and ‘feeling safe’ to ask questions on a range of
topics, especially questions they felt they could not ask their haematologist.
Participants indicated support was individualised and felt reassured they
could get their life back on track.

“The one-on-one was really helpful because then you felt like you could pretty
much ask anything, or talk about anything, and you didn’t feel like there would
be other people around to listen to your private conversations. A safe space, ask
questions and get reassurance and the right answers. That was good”
F_24yo_HL

“Someone that you can speak to and address the problems that you don’t get the
time with the doctors to talk about” F_64yo_HL

Another participant also commented on how he could discuss other aspects
of the cancer experience. He said,

“What I particularly liked was the opportunity to have a conversation around
things other than treatment. Dealing with some of the fears that you may have
that you didn’t feel like you could ask your specialist about. Or where do I go for
complementary therapies. The kind of questions that specialists I don’t think are
necessarily geared for. Or don’t have time really to cover. The ability to have a
chat to a nurse that can help you through the next part of the journey”
M_48yo_NHL
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A couple of participants indicated that the intervention should have been
conducted according to patient preferences. This included a preference for
the NLSC to be away from the hospital and closer to their home.

“We should be providing services close to home where possible and I think there
are some really great opportunities for the survivorship study to get out into the
community even though they are still run by the hospital” M_48yo_NHL

Although two participants found returning to the hospital traumatic, they
felt the NLSC experience helped them to overcome their aversion as it was
felt to be a safe place they could communicate their fears and receive
reassurance.

“The torture as a result of the treatment – going back to the hospital made me
feel all that. It actually helped me deal with the fact that I can go to the hospital
and not feel sick – so there was a positive to” M_48yo_NHL

Nurse contact and rapport
It was also felt contact should have been more frequent with telephone
support between face to face visits, to provide extra support and to ‘check-in’
with the participant.

“I think you need to make them a bit closer together – a bit more frequent. And
also make it where patients can choose. Make it more patient-driven - where the
patient tells you how often they want to see or talk to someone” F_48yo_NHL

There was also an indication that many wanted the contact to go beyond the
study timeframe. As one participant said,
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“I don’t feel like I am on my own steam yet. I am thinking 2 years before I have
got my confidence and hopefully my health back” F_64yo_HL

All participants described the relationship with the nurse who ran the
intervention as comfortable and flexible, and felt they could call or speak to
her with any issues if they wanted to. Participants provided comment and
perceptions of the nurse as follows:

“And she did explain things so that I understood them more. She was really
good at making you feel relaxed” F_48yo_NHL

“You felt like you had enough time to talk about and ask questions you didn’t
feel rushed and I think that was really good” F_24yo_HL

Survivorship care plan and treatment summary
The written patient-centred SCPTS was described as reassuring when it
guided follow-up and for keeping on track with healthy lifestyle behaviours.

“Yes, it was good because it is reassuring, it is a guideline of what to do which I
needed and knowing what to look out for and should be doing” F_64yo_HL

Feedback from participants regarding the SCPTS being sent to the GP
indicated only two GPs discussed the SCPTS with them. Other participants
indicated they either had not seen the GP or the GP acknowledged receipt
but did not discuss.

Information and support
Participants appreciated the opportunity to discuss, record and receive
written individualised information, support and resources. Although some
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information such as late effects was confronting at the time, it was
nevertheless appreciated. All felt the information received at the NLSC was
relevant and appropriate because it was tailored to their unique needs. Most
felt they had not received this information or support from the treating team,
however, it was acknowledged that possibly verbal information had been
given but not retained.

Individualisation of the SCPTS
Participants liked the individualisation of the health concerns, goals and
actions, and the accompanying written information and/or contacts.
“When I did have a concern, I was given printed notes about those issues and I
think that is really good. Because I do have trouble with my memory now, and I
can go back over those notes and sometimes it is like reading it anew, you know”
F_64yo_HL

The treatment summary was well-received with most participants describing
it as ‘good to have’, especially as a tool for communication with other health
professionals.

“I think it was useful to sit down and have that initial meeting. I think it was
really good that it was sent to my GP” F_25yo_HL

However, one participant was unsure of the value to himself,

“But I think this kind of treatment summary is the sort of thing I would give to
my GP, or if I am seeing a new Dr, or if I was travelling and I got sick. I almost
feel like it’s less useful for me, but more useful for other people” M_24yo_HL
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One participant felt the terminology related to the disease location could
have been put in simpler language and this helpful recommendation was
utilised for subsequent treatment summaries.

“Sometimes you don’t always understand the medical terms so I think putting it
into more simpler language would be a bit more helpful” F_48yo_NHL

Late effect information
The potential late effect information given on the SCPTS was individualised
to each participant. It came as a shock to many that heart disease and other
cancers, for example, were possible consequences of the treatment received.

“Well that was a bit of a shock to me because they hadn’t been mentioned prior
to the treatment. … but at the same time, it was probably easier on me not
knowing anyway” F_64yo_HL

Participants appreciated having the information and felt it could help with
GP consultations, specifically around planning of health management into
the future.

“That gave me something to go to my GP with and go okay I think I need to
monitor this and this. And it helped me set out a care plan with my Dr as well”
F_48yo_NHL

“It is always a bit overwhelming, but I think it is a good way to highlight the
possible things that could happen. I think it reduces you’re stress because you
are not just in the dark about it. I think it is really important for yourself and the
GP. If anything does change you know at least you are going to get it early”
F_24yo_HL
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One participant indicated they had heard the potential late effect information
at diagnosis and another described being told there were some possible late
effects after she had completed treatment,

“Oh, he just briefly spoke about ‘you just need to be careful, you need to look
after your skin, you need to do annual breast checks, you need to look after your
heart. You know there is a possible risk you could get these problems in the
future’. That is sort of how he mentioned it” F_24yo_HL

Neither participant had received written information and did not feel they
knew how to follow-up these risk factors. This was an important
consideration when developing the SCPTS to ensure follow-up suggestions
for the GP and participant were given.

“[GP] just asked me to come in and discussed it with me and then he kind of just
saved it and then he linked me in with support services to make sure I was
monitoring all of my side-effects, so I think he thought it was good” F_25yo_HL

Empowerment
Most participants perceived the intent of the NLSC was to assist with
transitioning away from a reliance on the treating team, to taking
responsibility for monitoring and seeking support.

Nurturing empowerment
All participants described the SCPTS as useful and perceived it as a means to
remind them to ‘stay on track’ with healthy lifestyle behaviours or for
encouragement with achieving their goals.
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“It just kind of helped remind me of my goals, and every time I had the meeting
with [KT], it was like a kind of thing to remember my goals and I thought was a
really beneficial thing” M_24yo_HL

Although one participant described the initial discussion and plan as helpful,
she felt she should not have had to seek out services and arrange
appointments.

“Maybe actually getting linked into the services they talk about. Rather than
just getting the information and being left with it, it was kind of like I had to go
and seek it out myself. I think it would have been really helpful to have someone
contact me” F_25yo_HL

It appeared she did not want to take responsibility for her follow-up care.
The remaining participants described understanding and appreciating the
need to take back control of their health and well-being. They described the
opportunity to discuss and write down their own health concerns, health
goals and the actions they planned to take with a health professional as
confidence building and assisted in increasing their positivity post-treatment
completion.
“There are definitely days where you go thru and you start to question yourself,
but being able to talk to someone about it made me feel more confident about
being finished” M_25yo_HL

“I started thinking a bit more positive” M_71yo_HL

Participants noted that having the opportunity to record and discuss
participant-specific issues had personalised both the appointment and the
SCPTS.
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“It identified what you personally were worried about and it wasn’t just a
general thing that everyone can be worried about, but it was specific to you. And
then having the specific needs addressed with a certain plan or the actions
column that you could put in place. I think that was really helpful because you
see how you could be proactive about things” F_24yo_HL

Monitoring progress
Participants felt the follow-up over the next six months in the NLSC allowed
them to monitor their progress and see how they were going.

“That was good. It was something to monitor my progress and it feels more
personal” M_25yo_HL

“It sort of crystallises your thinking for the future. If you don’t do something
like that you tend to drift along day to day” F_74yo_NHL

Receiving written and contact information for support allowed participants
to engage and take ownership for how and when they dealt with their goals
and concerns. Even when issues remained unmet, having the issue
normalised was equally important.

“Well the fatigue and the memory [problems] I have still got. It was useful to
find that other people suffer the same things, that I am not alone on that!”
F_64yo_HL

Usefulness of general health information
Participants received general health and screening information and felt it
was helpful. Most read it again at home, then put it aside. They felt the value
was in having it to refer to if needed.
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“I think that it is really good to get the information and just have it there. I
thought that was very handy” F_24yo_HL

This document was not sent to the GP, as GPs involved in evaluating the
SCPTS for content clarity, internal consistency and content validity, indicated
they knew this information and did not want it. It was noteworthy that two
participants had given it to the GP and it had guided follow-up care.

“I basically took all the information into my GP and let him read thru it and he
used it to help guide my care plan in the right direction” F_48yo_NHL

Discussion
This study contributes to the growing body of cancer-specific survivorship
literature. The current model of specialist follow-up care for cancer survivors
is inadequate, with many survivors experiencing unmet needs that can
remain poorly addressed throughout the survivorship continuum (De Leeuw
& Larsson, 2013). It is essential survivorship care incorporates an awareness
of treatment and disease, long-term and late effect risks, as well as healthy
lifestyle behaviours (Taylor et al., 2015), and facilitates communication
amongst all health professionals and the patient and family. Expertise in the
provision of health promotion, support and information has always been the
purview of cancer nurses (Jackson et al., 2013), therefore nurse-led models
should be considered within any proposed model of survivorship care.

This study involved a cohort of lymphoma participants and specifically
targeted those in the early survivorship phase (first nine months’ posttreatment). Studies that involve a single subtype of haematological cancer are
important in ascertaining the psychosocial and supportive care interventions
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that are specific and most appropriate (Oberoi et al., 2017). Assessing and
providing an intervention in the early survivorship period has been shown to
lead to a reduction in the unmet needs as survivors continue beyond five
years (McDowell et al., 2010).

Participants described having time within the NLSC appointment to ask
questions and seek individualised support as fundamentally helpful. An
important point of difference with medical follow-up where participants
perceived the specialist as too busy, or perhaps not interested when they
were seeking reassurance and support. Interestingly, some participants
would have preferred a follow-up appointment away from the hospital, an
important

consideration with future

planning

of

nurse-led clinics.

Participants had not previously met the nurse who provided the
intervention, she is however, a cancer nurse coordinator with extensive
haematology/oncology

nursing

and

counselling

experience

and

qualifications. A health professional who can quickly build a strong and
positive rapport allows participants a greater opportunity to explore their
own unmet needs (Ross, 2013). This may be why participants responded
favourably to the intervention and is important when considering nurse-led
models of survivorship care.

Empowering participants with an individualised SCPTS that provided
disease

and

treatment

knowledge,

and

allowed

them

to

assume

responsibility for their future health and well-being (Taylor & Monterosso,
2015), was described as helpful from all participants. The expectation of
younger survivors living longer with potential issues is important (Jabson &
Bowen, 2013), nevertheless all participants in this study, regardless of age,
appreciated the follow-up guidance they could discuss and implement with
their GP. Information on general health and screening allowed participants a
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sense of independence of when and how they would seek follow-up. Of
particular importance to participants was the opportunity to personalise the
SCPTS and concentrate on what was important to them as they moved
forward after treatment had completed. Conversely, our study revealed a
small subset of participants who were not ready to take back control of their
future health and well-being. It is important to acknowledge those patients
and provide individualised support that meets their needs at the time,
without building further dependency in the survivorship phase.

Survivorship literature highlights the concept of ‘teachable moments’ (Alfano
et al., 2012; Grant & Economou, 2008; Hewitt et al., 2005; Panek-Hudson,
2013) at the end of active treatment to support and promote patient
participation in healthy lifestyle behaviours. It was thought that participants
in this study would need to be encouraged to engage in healthy lifestyle
behaviours. However, it was evident that participants did feel a need to
improve their health, and for some, change their lifestyle to adopt healthier
lifestyle behaviours they had not been able to do during the stress of
treatment. These participants particularly described the opportunity to
revisit the SCPTS over the preceding months allowed them to monitor and
reflect on their achievements and help them to keep focused on their goals.

Limitations
This study reflects the views of a subset of lymphoma participants who
underwent a nurse-led clinic survivorship intervention and therefore could
not be generalisable to the wider survivorship population who have
experienced a nurse-led clinic. Nonetheless, the use of qualitative interview
research allowed an opportunity to gain a deeper understanding of the
experiences of this select group. The findings are presented to help build
research that is based on patient experience and feedback. The small number
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of participants is not a methodological limitation in qualitative research
when data saturation is reached.

Conclusion
The interviews were conducted to ascertain the participant’s perception of
the efficacy and value of the components of the nurse-led intervention and to
highlight any issues or challenges for this cohort that could be better
addressed in the future. Survivorship care offered by nurses may address the
patient-perceived unmet needs at the conclusion of active treatment.
Participants indicated the need for security in knowing there would be
support when treatment completed and would likewise value the
opportunity to have their concerns heard. An individualised SCPTS that
empowers survivors to address healthy lifestyle issues and provide a followup guide for late effects of the disease and treatment assists in refocusing
responsibility back to the patient. Nurse-led survivorship care may offer an
acceptable model to deliver patient-centred post-treatment follow-up. This
model allows the time required to individualise and tailor supportive
survivorship care.
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6.4 Results of Test–retest of the SF-SUNS
Analysis
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Test–retest Reliability of the Short-Form Survivor Unmet Needs
Survey.

Abstract
Background: Reliable and valid needs assessment measures are important
assessment tools in cancer survivorship care. A new 30-item short form
version of the Survivor Unmet Needs Survey (SF-SUNS) was developed and
validated with cancer survivors, including haematology cancer survivors,
however test–retest reliability has not been established.

Aim: To assess test–retest reliability of the SF-SUNS with a cohort of
lymphoma survivors (n=40).

Design: Test–retest reliability of the SF-SUNS was conducted at two time
points; baseline (time 1) and five days later (time 2).

Methods: Test–retest data was collected from lymphoma cancer survivors
(n=40) in a large tertiary cancer centre in Western Australia. Intra-class
correlation (ICC) analyses compared data at time 1 (baseline) and time 2 (5
days later). Cronbach’s alpha analyses were performed to assess internal
consistency at both time points.

Results: The majority (23/30, 77%) of items achieved test–retest reliability
scores .429–.757 (fair to good). A high degree of overall internal consistency
was demonstrated (time 1=.918, time 2=.945), with scores .646–.942 across
subscales for both time points.
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Conclusions: Mixed test–retest reliability of the SF-SUNS was established.
Our results indicate the SF-SUNS is responsive to the changing needs of
lymphoma cancer survivors. Routine use of cancer survivorship specific
needs-based assessments are required in oncology care today. Nurses are
well placed to administer these assessments and provide tailored
information and resources. Further assessment of test–retest reliability in
haematology and other cancer cohorts is warranted.

Introduction
Lymphoma blood cancers are malignant T or B cell lymphocytes in the
lymphatic system and are categorized under two main types: non-Hodgkin
lymphoma (NHL) and Hodgkin Lymphoma (HL). NHL represents
approximately 88% of all lymphomas, while HL is predominately diagnosed
in the adolescent and young adult population (Howlader et al., 2016).
Combined, they represent the sixth most common cancer diagnosis
worldwide (Howlader et al., 2016). Consistent with worldwide trends, the
incidence of lymphoma in Australia is increasing, and with a projected
diagnosis of 6232 cases in 2017, this equates to 4.6% of all cancer cases
(Cancer Australia, 2017). An estimated mortality rate of 1481 equates to 3.1%
of all deaths from cancer in 2017 (Cancer Australia, 2017). Projected figures
for 2017 in the USA have a similar expected incidence of lymphoma of 4.8%
and mortality of 3.6%. (Howlader et al., 2016). Treatment for lymphoma
generally

comprises

high-dose

chemotherapy

and/or

targeted

immunotherapy agents and may include radiotherapy and hematopoietic
stem cell transplants (Carey et al., 2012). These treatments have resulted in an
improvement to overall survival of approximately 76% at five years
compared with 52% at five years in the 1980s (Cancer Australia, 2017).
Notwithstanding the positive impact treatment has had on survival rates
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(Sant et al., 2014), the consequences of disease and treatment continue long
after treatment completion (Campbell et al., 2014). Long-term and late effects
may produce ongoing unmet needs such as fear of recurrence, fatigue, poor
nutrition, exercise, fertility, relationship, financial, employment, and
insurance issues (Taylor et al., 2015).

To provide optimal supportive cancer care to lymphoma survivors, the
identification of patients’ perceived concerns and level of support needed is
required (Campbell et al., 2014). This is especially important for younger
patients (18–45 years of age) where the expectation of long-term remission
can raise additional concerns and unmet needs (Arden-Close et al., 2011).
Receiving relevant information and practical support soon after treatment
ends, especially resources related to healthy lifestyle behaviours (ArdenClose et al., 2011; Boyes et al., 2012; Hall, Campbell, et al., 2013; Hjermstad et
al., 2003; Lobb et al., 2009), can help mitigate the impact of disease and
treatment and lead to fewer unmet needs further along the survivorship
continuum (Aziz, 2007; McDowell et al., 2010). A qualitative study with
lymphoma cancer survivors (n=17) undertaken in Western Australia
(Monterosso et al., 2017) reported unmet informational and practical needs as
participants transitioned from treatment to the survivorship phase. The
findings suggested tailored post-treatment support and interventions are
fundamental components of excellent survivorship care.

The measures used to assess unmet needs are equally important. Generic
cancer measures which comprise items related to diagnosis and treatment
are often not specific enough for the survivorship phase (Taylor &
Monterosso, 2016). Comprehensive, relevant, reliable, and validated needs
assessment measures that are survivor-specific are essential to capture unmet
needs that become evident when treatment ends (Taylor & Monterosso,
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2016). These measures can guide health professionals in providing
individualised information, support, and resources (Campbell et al., 2014;
Taylor & Monterosso, 2016). Two recent systematic reviews (Jiao et al., 2017;
Taylor & Monterosso, 2016) revealed that needs assessment tools are varied
and may not capture all the possible unmet needs patients may have. The
reviews likewise found validity and reliability evidence limited. The
Survivor Unmet Needs Survey (SUNS) was identified as a measure that had
strong psychometric properties and was developed and psychometrically
tested with a large cross-sectional sample of cancer survivors (n=550)
including a small cohort of haematology cancer participants (n=31, 5.6%)
(Campbell et al., 2010). Campbell et al. (2010) confirmed a high overall
internal consistency of items for their study with an overall Cronbach’s alpha
of 0.99. The authors also reported high test–retest reliability although the
results were not published (Campbell et al., 2010). Internal consistency of the
SUNS was further tested in two studies of haematological cancer survivor
cohorts. A cross-sectional study with 529 haematological cancer survivors
(Hall, D’Este, Tzelepis, Sanson-Fisher, & Lynagh, 2014) demonstrated overall
Cronbach’s alpha values >0.9, and a weighted Kappa coefficient score of >0.6
for test–retest reliability; acceptability was reported for 40/89 (45%) items.
Qualitative data from 17 semi-structured interviews indicated that the SUNS
was considered relevant by this cohort of haematological cancer survivors
(Hall, D’Este, et al., 2014). A cross-sectional study of haematological cancer
survivors from Australia and Canada (n=437) reported similar levels of
unmet needs across the two cohorts using the SUNS, with fatigue (n=76, 17%)
and financial concerns (n=39, 9%) rated as high unmet needs (Hall, Campbell,
et al., 2013). Despite the clinical utility of the original SUNS, it was
considered potentially burdensome for use in the clinical setting given the
large number of items (n=89). In 2014, the 30-item short-form-SUNS (SFSUNS) was developed and validated with a mixed sample of cancer
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survivors (n=1589), including haematological cancer survivors (n=84, 5%)
(Campbell et al., 2014). Construct validity and intraclass correlation
coefficients (ICCs) of the SF were similar to those of the original SUNS.
Cronbach’s alpha scores for the final four domains were ≥0.85, and ICCs for
the three domains from the original SUNS (financial concerns, information,
and access and continuity of care) and the SF-SUNS were high (>0.9).
Discriminant validity demonstrated the SF-SUNS ability to discriminate
between individuals who had recently received treatment and those who had
not. The authors recommended further testing of the SF-SUNS for test–retest
reliability (Campbell et al., 2014). The 30-item SF-SUNS was therefore judged
to be more practical and likely to be completed by participants in our larger
study, particularly as the SF-SUNS was one of four measures to be
administered to participants in a pilot randomised trial to measure the effect
of a nurse-led survivorship model of care (Taylor et al., 2016).

For researchers and clinicians to develop targeted follow-up support for
cancer cohorts underrepresented in survivorship literature, such as
lymphoma (Swash et al., 2014), cohort-specific studies in the early
survivorship phase are required (Oberoi et al., 2017). Therefore, this study
recruited only those with a lymphoma diagnosis who had completed
treatment. Discerning the issues and concerns of this group requires
survivor-specific measures that are psychometrically sound and fully tested.
The SF-SUNS has been used within the clinical setting; however, since test–
retest reliability of the SF-SUNS had not been established, the aim of the
present study was to establish test–retest reliability of the SF-SUNS to add to
the psychometric data available in the published literature on this
instrument.
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Methods
Design
Test–retest reliability of the SF-SUNS was conducted at two time points:
baseline (time 1) and 5 days later (time 2). This time frame was chosen to
reduce recall bias and change in the level of unmet needs (Terwee et al.,
2007). Ethical approval to conduct the study was obtained from the human
research ethics committee of the study site (2015-020) and university
(015007F).

Population and setting
A convenience sample of 40 lymphoma cancer patients who were 3 months’
post-treatment completion were recruited from the haematology department
of a large tertiary hospital in Western Australia. Inclusion criteria were
pathologically confirmed new diagnosis of NHL or HL; completed first-line
curative-intent chemotherapy or second-line curative-intent autologous stem
cell transplant within the previous 3 months; no radiological evidence of
lymphoma posttreatment (on positron emission tomography [PET] scan);
able to understand and read English; and over 18 years of age. Participants
were excluded if they had not been treated with chemotherapy; had received
further treatment at another hospital (as experiences or interventions may
have introduced bias); or were cognitively impaired or experiencing an acute
mental health condition that prohibited the provision of informed consent.

Sample size
The sample size calculation was derived from Walter et al. (1998) and used a
fixed alpha of .05 from two observations with reliability values of R0=.6
(acceptable) and R1=.8 (expected), indicating a minimum sample size of n=39.
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Short-Form Survivor Unmet Needs Survey
The SF-SUNS assesses unmet needs across four domains: information needs
(3 items); work and financial needs (8 items); access and continuity of care
needs (6 items); and coping, sharing, and emotional needs (13 items). Patient
self-reported concerns and the level of support required are measured using
a Likert-type scale: 0—no unmet need, 1—low unmet need, 2—moderate
unmet need, 3—high unmet need, and 4—very high unmet need. Domain
scores are generated by adding each item score and dividing by the total
number of domain items (Filsinger, Burkhalter, & Campbell, 2011).

Procedure
The researcher identified and approached eligible participants after
treatment completion to discuss the study and provide them with a
participant information and consent form. Following informed consent,
demographic and baseline (time 1) SF-SUNS questionnaires were then
administered to participants. After completion of the questionnaires,
participants were provided with another blank copy of the SF-SUNS
accompanied by instructions to complete the questionnaire at home 5 days
later and post back using the supplied reply-paid addressed envelope.
Participants were advised to record the date of completion if this differed
from the specified due date.

Data collection
At the request of the research team’s haematologist, baseline demographic
and SF-SUNS data were collected from consenting participants 3 months
post-treatment completion and PET scan to confirm the absence of disease.
Demographic information obtained included lymphoma type, stage of
disease, type of treatment received (chemotherapy +/− radiotherapy), date of
diagnosis, time since diagnosis, comorbid conditions, gender, age, weight,
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marital status, age of children (if any), postcode, occupation, income level,
education level, and health behaviours such as smoking and alcohol
consumption. Participants then completed the SF-SUNS at time 2 (5 days
following time 1 completion) at home.

Data Analysis
All analyses were performed using IBM SPSS Statistics Version 25 data
analysis software (IBM Corp, 2017). Descriptive statistics were used to
analyse all data. Descriptive analyses were used to analyse and describe
demographic data. To assess for absolute consistency of SF-SUNS items for
test–retest reliability data, an ICC with a random-effects model was used to
compare each item at time 1 and time 2. The ICC measure was chosen for its
ability to discriminate between sets of scores ranked in the same order but
not necessarily in agreement and adjusts for the degree of test–retest
agreement expected by chance (Bujang & Baharum, 2017; Cicchetti, 1994).
The closer the value of the ICC to 1.0, the greater the reliability of the item or
measure (Weir, 2005). The guidelines developed by Cicchetti and Sparrow
(1981) were used to determine the level of clinical significance of the ICC
values obtained: <.40 = poor, .40–.59 = fair, .60–.74 = good, and >.75 =
excellent. For this study, items classified as achieving “fair to excellent”
reliability, ICC >.40 (Rosner, 2016), were reported. Cronbach’s alpha, a
measure of internal consistency, was used to measure the scale reliability.

To examine the distribution of unmet needs, the five levels of unmet need
were collapsed to three levels. A score of 0 (no unmet need) remained the
same. Scores of 1 or 2 (low and moderate unmet need) were reclassified as 1
(low–moderate unmet need), and scores of 3 or 4 (high and very high unmet
need) were classified as 2 (high–very high unmet need).
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Results
Participant characteristics
There were slightly more male (n=22, 55%) participants, and a greater
number of participants with NHL (n=29, 72.5%) compared with HL (n=11,
27.5%) (Table 6.4.1). This was in keeping with the current disease statistics
which reflect a greater number of NHL than HL diagnoses (Howlader et al.,
2016). Almost one-third of participants were aged between 18 and 39 years
(32.5%), and a greater proportion had a university qualification (n=6, 40%)
(Table 6.4.1). Although the majority of participants were currently working
(n=15, 37.5%) and had been throughout their treatment, 30% (n=12) were
looking for work or had no return to work date set. Over half the participants
had a partner (n=25, 62.5%). Forty participants completed both time 1 and
time 2 SF-SUNS. The majority of participants (n=35, 87.5%) completed time 2
SF-SUNS 5 days after time 1 (range 4–7 days).

21Table 6.4.1 Baseline Participant Demographic and Disease Characteristics
(n=40)
Characteristics
Gender
Male
Female
Age group (years)

N (%)
22 (55.0)
18 (45.0)

18–39
40–59

13 (32.5)
12 (30.0)

60–74

9 (22.5)

75+
Marital status

6 (15.0)

Single

10 (25.0)

Married/de facto
Divorced

25 (62.5)
3 (7.5)

Widowed

2 (5.0)

Lymphoma diagnosis
Non-Hodgkin

29 (72.5)
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Hodgkin
Highest level of education

11 (27.5)

Secondary school or less

11 (27.5)

Trade, vocational college

13 (32.5)

University or higher
Employment status

16 (40.0)

Working

15 (37.5)

Retired

13 (32.5)

Looking for work/no return to work date

12 (30.0)

Test–retest
ICCs, 95% confidence intervals, and clinical significance are shown in Table
6.4.2. One (3%) item met the “excellent” criteria for clinical significance;
Finding car parking I can afford at the hospital or clinic. Twelve (40%) items
met the “good” criteria (.60–.74) and 11 (37%) items met the “fair” criteria
(.40–.59). In summary, test–retest data showed “fair” to “good” reliability for
the majority of items (23/30, 77%).

Internal consistency
Overall Cronbach’s alphas were .918 at time 1 and .945 at time 2, with
subscales (Table 6.4.2) ranging from .744 and .695 for information needs, .646
and .828 for work and financial needs, .891 and .853 for access and continuity
of care, and .897 and .942 for coping, sharing, and emotional needs,
respectively. These results support strong internal consistency for the overall
scale. Item-to-total correlations between .40 and .70 indicate that items are
not redundant or measuring needs similar to other items within the
instrument (Leong & Austin, 2006). Using this criterion, the SF-SUNS
demonstrated item-to-total correlations between .40 and .70 at time 1 for 24
items (80%) and at time 2 for 19 items (63%) (Table 6.4.2). The majority of
items were considered relevant and to be measuring unique needs.
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22Table 6.4.2 Item Test–retest Reliability and Internal Consistency (n=40)
Domain
(n=4)

Item Description

Information
needs

Items (n=3)
Finding information about complementary or alternative
therapies
Dealing with fears about cancer spreading
Dealing with worry about whether treatment has worked
Items (n=8)
Worry about earning money
Having to take a pension or disability allowance
Paying household bills or other payments
Finding what type of financial assistance is available and
how to obtain it
Finding car parking that I can afford at the hospital or
clinic
Understanding what is covered by my medical insurance
or benefits
Knowing how much time I would need away from work
Doing work around the house (cooking, cleaning, home
repairs, etc.)
Items (n=6)
Having access to cancer services close to my home
Getting appointments with specialists quickly enough

Work and
financial
needs

Access and
continuity of
care

ICC (95% CI)

Level of
Clinical
Significance

Cronbach’s
Alpha
Time Time
1
2
.744
.695

.694 (.490–.825)

Good

.304

.504

.560 (.304–.740)
.568 (.316–.746)

Fair
Fair

.589
.654

.626
.714

.631 (.401–.787)
.390 (.093–.623)
.692 (.488–.825)
.700 (.499–.829)

Good
Poor
Good
Good

.486
.446
.550
.668

.466
.384
.597
.713

.757 (.586–.864)

Excellent

.018

.455

.314 (.007–.568)

Poor

.203

.060

.736 (.553–.851)
.366 (.065–.606)

Good
Poor

.545
.122

.501
.701

.437
.701

.619
.436

.646

.891
.446 (.159–.663)
.377 (.078–.614)

Fair
Poor

Item-to-total
Correlation
Time
Time
1
2

.828

.853
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(oncologist, surgeon, etc.)
Getting test results quickly enough
Having access to care from other health specialists
(dietitians, physiotherapists, occupational therapists)
Making sure I had enough time to ask my doctor or nurse
questions
Getting the health care team to attend promptly to my
physical needs
Coping,
Items (n=13)
sharing and
Telling others how I was feeling emotionally
emotional
Finding someone to talk to who understands and has been
needs
through a similar experience
Dealing with people who expect me to be “back to
normal”
Dealing with people accepting that having cancer has
changed me as a person
Dealing with reduced support from others when treatment
has ended
Dealing with feeling depressed
Dealing with feeling tired
Dealing with feeling stressed
Dealing with feeling lonely
Dealing with not being able to feel “normal”
Trying to stay positive
Coping with having a bad memory or lack of focus
Dealing with changes in how my body appears
Note. ICC: Intraclass correlation; CI: Confidence interval

.662 (.444–.806)
.526 (.260–.718)

Good
Fair

.569
.508

.507
.671

.579 (.329–.753)

Fair

.590

.477

.529 (.264–.720)

Fair

.592

.497

.429 (.140–.651)
.329 (.023–.578)

Fair
Poor

.577
.449

.476
.573

.620 (.386–.780)

Good

.568

.768

.509 (.239–.707)

Fair

.681

.812

.673 (.406–.813)

Good

.824

.824

.734 (.550–.850)
.487 (.211–.692)
.552 (.294–.735)
.715 (.522–.838)
.475 (.196–.683)
.628 (.397–.785)
.639 (.412–.791)
.275 (–.037–.537)

Good
Fair
Fair
Good
Fair
Good
Good
Poor

.535
.566
.780
.527
.570
.548
.496
.229

.720
.712
.691
.615
.697
.646
.864
.244

.897

.942
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Discussion
Our study is the first to report test–retest data for the SF-SUNS. The majority
of items met absolute consistency for reliability ICC scores of >.40 for test–
retest, categorized as “fair” to “good.” An “excellent” clinical significance
score was achieved for only one item (3%), related to car parking costs which
are unlikely to change over time. Needs-based instruments such as the SFSUNS measure the degree of an individual’s perceived unmet need at one
point in time. Importantly, Cronbach’s alpha scores at time 1 and time 2
demonstrated a high degree of internal consistency and high item-to-total
correlations, confirming that items in the tool were reliable.

A criterion for psychometrically sound needs-based tools is the requirement
for an instrument to be responsive to changes over time (DeVellis, 2012;
McDowell, 2006; Streiner & Norman, 2003). Although our ICC results may
reflect the responsiveness of the SF-SUNS to changes in need over the data
collection period, further research is required to detect clinically meaningful
change for patients (Jiao et al., 2017). All participants completed the time 2
questionnaire at home, well away from the haematology clinic where the
time 1 questionnaire was completed. It is possible that participants may have
had additional time to more accurately reflect on the level of unmet need.
Similarly, time 1 scores may have been impacted by participants’ anxiety at
the hospital appointment where patients often worry about test results and
potential relapse (Thewes et al., 2012). In addition, fatigue is a recognized
effect of lymphoma treatment (Arden-Close et al., 2011), and may have
potentially affected participant responses at either time point. Finally, most
items were similarly balanced for both time points from “no unmet need” to
“low unmet need” or “low unmet need” to “no unmet need.”
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It is important to allow cancer survivors the opportunity to self-identify
unmet needs and issues of concern. Survivorship needs-based instruments
provide a consistent method for this purpose (Hawkins et al., 2008).
Furthermore, it is important that any tool is responsive to change as
individuals’ issues, concerns, thoughts, and feelings can change from day-today (McDowell, 2006; Streiner & Norman, 2003), particularly during
survivorship transition as individuals move on with their lives after cancer
treatment. Such reliable and valid instruments can facilitate individualized
survivorship care and tailored support and resources (Taylor & Monterosso,
2016).

It is important to note that the original SUNS demonstrated low test–retest
reliability acceptability (Hall, D’Este, et al., 2014), with the authors
suggesting that the test–retest timeframe was too long at 28 days. Since our
study was part of a larger study involving an intervention group, a 5-day
later test–retest assessment was deemed an appropriate timeframe to ensure
completion of the time 2 SF-SUNS before the implementation of any needsbased interventions associated with the larger study (Taylor et al., 2016).
Importantly, this time period was also in keeping with the recommended 2–
14-day time period for test–retest procedures (DeVellis, 2012; McDowell,
2006; Streiner & Norman, 2003).

A limitation of this sub-study may have been the sample size of 40
participants, despite sample size calculations indicating that this number
would be sufficient to adequately perform test–retest reliability with
confidence.

Many

participants

(n=16,

40%)

attended

the

baseline

appointment, where time 1 SF-SUNS was administered, accompanied by a
support person (partner or family member). We acknowledge this may have
influenced time 1 responses. Likewise, time 2 responses may have similarly
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been influenced as the SF-SUNS was completed at home. We can confirm
that participants did not receive any needs-based interventions between time
1 and time 2 completion of the SF-SUNS.

Conclusion
We suggest that needs-based assessments should be used routinely during
the survivorship period to facilitate survivorship care that is tailored and
responsive to individuals’ changing needs. Valid and reliable survivorspecific measures are essential for routine screening and follow-up. Nurses in
particular are a valuable resource in the survivorship phase to assess for
areas of concern or unmet needs and for the provision of information,
support, and resources that are tailored to the individuals’ unique needs.
Further testing of the SF-SUNS is recommended in haematology and other
cancer

populations

to

further

understand

and

demonstrate

the

responsiveness of this instrument to changes in need over the survivorship
period.
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Chapter Summary
This chapter has documented the analysis and findings of data collected in
Phases Three and Four of this study and reports possibly the first published
data from a pilot RCT to test a nurse-led lymphoma survivorship model of
care.

Results from the pragmatic RCT showed the proposed conceptual
framework could guide a survivorship model of care that empowered
survivors to make changes to improve their quality of life and engage in
healthy lifestyle behaviours. This model allowed participants the time to
individualise and tailor their own supportive survivorship care needs.
Randomisation was found to be effective as both groups were well-matched
for

demographic

variables.

Univariate

and

multivariate

analyses

demonstrated that intervention participants who received the nurse-led
lymphoma survivorship model of care had lower levels of unmet
informational and practical needs and lower levels of depression, anxiety
and stress at study completion compared to the control group participants.
Likewise, better adjustment to the cancer diagnosis and self-empowerment
was shown in those randomised to the intervention group.

Findings from Phase Four GP evaluations indicated that GPs made use of
and were satisfied with the unique lymphoma SCPTS they received for
intervention participants.

As previously stated the nurse-led lymphoma survivorship model of care
used with this lymphoma cohort had not been previously reported in the
published literature and was a new undertaking at the study site. Therefore,
it was considered important to understand the experiences and perspectives
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of intervention participants from a qualitative perspective. The qualitative
study (Phase Four) provided strength to the quantitative data collected
during the pragmatic RCT by documenting and analysing the personal
experiences and perceptions of a group of intervention participants. Results
demonstrated participants needed support when treatment finished. In
particular, they valued: the opportunity to discuss and record their concerns
on the individualised SCPTS; the record of treatment and guidelines for
follow-up with the GP; and promotion of their engagement in healthy
lifestyle behaviours. Likewise, participants appreciated the one-to-one nature
of the appointments and the additional information and further support
provided.

As mentioned, test–retest reliability data for the SF-SUNS measure had not
been previously published, and it was considered important to undertake
this additional step during the pragmatic RCT. Findings indicated the
majority of the SF-SUNS items achieved ‘fair’ to ‘good’ for reliability with
this cohort. This published manuscript is considered an important
contribution to the cancer survivorship literature.

The following chapter provides a discussion of the results from this study
including the pragmatic RCT, GP evaluations and qualitative interviews with
intervention participants. The chapter will begin with a summary of findings
from Phase One and will conclude with a discussion of the limitations and
strengths of the thesis research.
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Chapter Seven — Discussion
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7.0 Discussion
The following discussion will present and explore the relevance of the major
findings from this study in relation to theoretical and clinical issues. This will
be followed by a discussion on the limitations and strengths of the study. The
final chapter will present the conclusions from this study in addition to
implications and recommendations for nursing practice, education and
future research.

The principal research question developed and tested in this study was that
it might be possible to decrease the number and level of unmet
informational, practical and emotional needs that may occur when
lymphoma patients finish treatment, and promote self-empowerment using a
nurse-led lymphoma survivorship model of care. This research was
undertaken in four phases, and development of the components of the nurseled lymphoma survivorship model of care and their implementation are
reported in detail in this thesis.
It was intended that this study would build on Australian cancer
survivorship research, in particular, lymphoma-specific survivorship. The
conceptual framework for this study was based on Bandura’s theory of selfefficacy. This was considered the most appropriate framework to guide the
development of the nurse-led lymphoma survivorship model of care since it
emphasises the importance of individual empowerment to enable the patient
to take responsibility for their future health and well-being. In addition,
providing support and encouragement may assist with better adjustment to
having cancer and resumption of normal activities of daily living. To achieve
this aim, a pragmatic RCT to examine a nurse-led model of survivorship care
was conceptualised, developed and delivered to a cohort of lymphoma
survivors at a large tertiary cancer centre in Perth, Western Australia. The
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intervention comprised a patient-centred survivorship care plan and
treatment summary (SCPTS), motivational interviewing to empower
survivors to make healthy lifestyle changes and individualised support and
tailored resources. To date, no RCTs have been published that report a nurseled survivorship model of care using a lymphoma survivor cohort.

This study utilised and collaborated with a multidisciplinary advisory
committee that included lymphoma survivor consumers. It was particularly
important that this research engaged with consumers who had undergone
previous lymphoma treatment at the study site and were thereby able to
have input into the design, delivery and evaluation methods of this research.
This research is, therefore, able to address the Australian Commission on
Safety and Quality in Health Care, National Safety and Quality Health
Service (NSQHS) Standard 2, Partnering with Consumers (Australian
Commission on Safety and Quality in Health Care, 2017). Likewise, this
research addresses the NSQHS Standard 5, Comprehensive Care, as it
ensured the care given to participants was individualised and considered the
impact of the disease and treatment on their health, quality of life and wellbeing (Australian Commission on Safety and Quality in Health Care, 2017).

A diagnosis of cancer is the beginning of a profound and life-changing
experience that can have a long-lasting effect on the remainder of a person’s
life and the lives of their family and friends (Corner & Bailey, 2009). Research
is constantly striving to improve the treatment offered and therefore overall
survival rates (Hewitt et al., 2005; Wait et al., 2017); however, a valuable
opportunity is missed in supporting the quality of survival once treatment is
completed (McConnell, White, & Maher, 2017). A cancer-free future may
often be characterised by ongoing physical and psychosocial health concerns
(Aaronson et al., 2014). Post-treatment, health professionals have an
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opportunity to provide support for a range of biopsychosocial issues and
have a positive effect on facilitating a change or improvement in healthy
lifestyle behaviours. There is increasing evidence that a healthy lifestyle
reduces the risk of morbidity and mortality and many interventions, such as
exercise, are safe and effective (Aaronson et al., 2014); however, promotion
and referral for these interventions is low (Boyes et al., 2012).

The rationale for Phase One (the systematic and integrative reviews) was to
examine: how lymphoma survivorship follow-up is occurring and the
models of care currently in use; the use of survivorship care plans and/or
treatment summaries with this cohort; and the assessment measures that are
used to determine survivorship unmet needs. This was followed by Phase
Two where components of the intervention were developed for use in Phase
Three which comprised the pragmatic RCT. In Phase Four additional
evaluation of the model of care and the SCPTS was conducted with GPs and
a subset of intervention participants.

A full discussion related to each of the three literature reviews, qualitative
interviews with intervention participants and the SF-SUNS test–retest results
is in each published article. The first section of this chapter will provide a
summary of the three literature reviews. This will be followed by a
presentation and exploration of the relevant major findings from the
pragmatic RCT and GP evaluations. Furthermore, a summary of the
qualitative interviews and the SF-SUNS test–retest is provided in this
chapter. This chapter concludes with a consideration of the limitations and
strengths of this thesis.
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Summary of the Phase One Literature Reviews
Published models of post-treatment cancer follow-up and/or survivorship
care was explored in the models of survivorship care provision in adult patients
with haematological cancer: an integrative literature review (Taylor et al., 2015).
This review found a lack of guidance and consensus for follow-up care
including determination of the appropriate health professional/s to deliver
survivorship care. The review likewise highlighted a lack of consensus
regarding the type of care model most appropriate for the early survivorship
period. It was also evident that further lymphoma-specific models of
survivorship care research are required. This particular cohort of cancer
patients has different needs (Parry et al., 2010) than those of the more
prevalent cancers such as breast, prostate and colorectal. These cancer types
have similar trajectories of treatment and care and generate the most
survivorship model of care research. Any model of care proposed for early
lymphoma survivors needs to be offered in addition to haematologist followup as the risk of lymphoma recurrence in the first two years' post-treatment
is very high (Lymphoma Association, 2017).

Haematology follow-up for at least five years appears the norm in the
published literature (Franco et al., 2017); and concurs with follow-up
provision undertaken by the haematology department in Western Australia
where this research was undertaken. In this follow-up period other health
professionals, including GPs, may be involved in care provision and
therefore open and effective communication is essential (Dicicco-Bloom &
Cunningham, 2013). Nurses have been proposed as a conduit to transition
survivorship care from the treating team to the GP (Cooper et al., 2010). This
will necessitate the communication of potential late effects of disease and
treatment and the recommended surveillance and management. Research
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has indicated many GPs may not be provided with this vital information
(Hall, Lynagh, et al., 2013). Nurses may similarly have an important role in
normalising post-treatment effects (Franco et al., 2017) and encouraging
survivors to seek information and support on healthy lifestyle behaviours
and how to return to "normal functioning" sooner (Cooper et al., 2010). These
findings were the basis for conceptualising and developing a nurse-led
lymphoma survivorship model of care.

A key recommendation of the Institute of Medicine for survivorship care was
the dissemination of SCPTS to all cancer survivors (Hewitt et al., 2005). The
survivorship care plans and treatment summaries in adult patients with hematologic
cancer: an integrative literature review (Taylor & Monterosso, 2015), reported a
lack of evidence on their use with lymphoma survivors and furthermore on
the most appropriate methods of developing and delivering this document.
The reviewed literature (Taylor & Monterosso, 2015) and the researcher's
recent search for newly published literature on lymphoma SCPTS usage
demonstrated a continued lack of routine use.

Experienced oncology nurses are able to provide holistic and individualised
information provision and have therefore been recognised as a practical
solution to the creation and delivery of SCPTS (Jackson et al., 2013; Marbach
& Griffie, 2011). To provide timely information and resources, two authors
(Curcio et al., 2012; Sabatino et al., 2013) proposed that dissemination of
SCPTS should occur soon after treatment completion. This recommendation
was endorsed by a recent qualitative study with lymphoma patients
undertaken at the same treatment centre as this research. These participants
indicated a lack of information and support when treatment ended
(Monterosso et al., 2017). In the present study, delivery of the SCPTS to
participants randomised to the intervention group occurred three months
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after treatment completion to facilitate early identification of issues and
concerns and provision of appropriate support, information and resources.
The SCPTS review likewise reported a lack of detail on how standardised
templates were completed and the evidence-based guidelines that were used.
This was addressed in the development of a unique lymphoma-specific
SCPTS for this thesis. A recent study with breast cancer participants (Mayer
et al., 2016), as outlined in the literature review update in Chapter Two,
reported a decrease in levels of anxiety in patients when SCPTS provision by
a nurse was coupled with GP follow-up to discuss the SCPTS contents.
Although this finding had not been available when this thesis was
developed, participants in the present study who had received an SCPTS
were encouraged to discuss the contents with their GP after the first NLSC
appointment and then at each subsequent GP visit. Qualitative results from
this thesis reported that participants experienced feelings of shock when
potential late effects information was given. However, participants indicated
an appreciation of this knowledge to empower them to follow-up in the
future (Ng, 2014). This finding confirmed those of previous studies that
reported tailored SCPTS could empower survivors to assume responsibility
for future surveillance and disease management (Hill-Kayser et al., 2013;
Jabson & Bowen, 2013; Jackson et al., 2013).

Nurses and health professionals require reliable, validated and accurate
measures to assess survivors for unmet issues and concerns once treatment
has completed (Muzzatti & Annunziata, 2013). Early identification is
important to ensure management and support is delivered effectively and
appropriately (Girgis, Delaney, & Miller, 2015). The systematic review of the
tools used to assess the informational and practical needs of the acute leukaemia and
lymphoma survivors (Taylor & Monterosso, 2016) in this thesis reported a need
for survivorship-specific needs assessment measures that had been used in

221

CHAPTER 7. DISCUSSION

lymphoma survivor cohorts. Likewise, early assessment to mitigate unmet
needs in the future was reported (McDowell et al., 2010) and considered
applicable for this research. Therefore, a post-treatment timeframe of three
months for baseline assessment was established. As the review found limited
published literature on survivorship-specific measures to assess unmet needs
in lymphoma survivor cohorts, this is an area that requires further research.

In developing the SCPTS for this study, it was important to seek and act
upon the feedback given by clinicians and survivors. GPs indicated a
preference for a succinct treatment summary, a finding supported by a recent
study delivering an SCP to primary care physicians (Ezendam et al., 2014).
Therefore, a concise document was developed that was deliberately patientcentred and only reported possible late effects that were pertinent to each
participant. The SCPTS literature review undertaken as part of this thesis
reported on large templates which covered all potential late effects and were
therefore not tailored to the individual. As reported by Klemanski et al.
(2016), the American Society of Clinical Oncology (ASCO) has recently
reduced their SCPTS templates to two pages, in line with Commission on
Cancer standards which clarified the type of information that an SCPTS was
to include (Klemanski et al., 2016). The minimum information required is
similar to that included in the SCPTS developed for this study (Deline, 2016);
however, the care plan element differs. The new ASCO SCPTS templates
provide a list of problem areas encountered by survivors, whereas
participants in this study were able to generate their own lists.
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Discussion of Phase Three Pragmatic Randomised Controlled
Trial
This pilot study contributes evidence-based data to the emerging body of
nurse-led survivorship research, and in lymphoma-specific care. In Western
Australia, the current model for all haematology cancer survivorship followup is haematologist-led, however many survivors experience a range of
unmet needs that may be poorly identified and addressed throughout the
survivorship period (De Leeuw & Larsson, 2013; Monterosso et al., 2017).
Health care providers need to recognise the importance of survivorship care
as a standard component of optimal holistic cancer care that involves
patients and families, along with other health professionals, including
primary care. The objective of the study was to assist participants,
randomised to the intervention, to transition from the end of treatment into
follow-up care, often referred to as the early survivorship phase, up to two
years' post-diagnosis (Aziz, 2007; McDowell et al., 2010). The aim was to
assess if the intervention reduced the number and level of self-reported
unmet informational, practical, emotional needs, depression, anxiety and
stress and increased adjustment to cancer and patient empowerment.
Additionally, the study assessed the use of an individualised SCPTS as a
resource for participants and their GPs to have a written record of their
disease, treatment and future surveillance of potential late effects (Taylor et
al., 2015). Notably, the SCPTS was also a tool for participants to record their
three most important concerns and three most important health goals, along
with the actions required to deal with concerns and achieve health goals. The
intervention likewise utilised the ‘teachable moment’ (Alfano et al., 2012;
Panek-Hudson, 2013) that presents at treatment completion, to support and
encourage healthy lifestyle behaviours (Taylor & Monterosso, 2015). This
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was particularly salient for the younger participants, as there was an
expectation of a longer survivorship period (Jabson & Bowen, 2013).

The early survivorship phase was chosen to provide responsive, supportive
care for the unique concerns and unmet needs of this cohort. A prospective
longitudinal study found 30% (n=353) of survivors had five or more unmet
needs at treatment completion that did not improve after six months (Armes
et al., 2009). This concurs with research which has suggested less unmet
needs were evident in the extended survivorship phase (over five years) if
assessments and interventions were undertaken in the early survivorship
phase (up to two years' post-diagnosis) (McDowell et al., 2010). It is possible
this thesis study may have also decreased the feelings of abandonment
survivors often feel at treatment completion (Matheson et al., 2016;
Monterosso et al., 2017; Taylor, Monterosso, & Bulsara, 2018).

The present pilot study suggests that survivors do have issues and concerns
post-treatment that can remain unresolved over time. This may impact
quality of life (QoL) (Hansen et al., 2013). Although statistical significance
was not reached in this pilot study, a comparison of the mean results
obtained from the two groups indicated a trend towards lower unmet needs
in the intervention group at Time 3 with higher levels of empowerment
revealed. Overall, those reporting no unmet needs at the completion of the
study on the SF-SUNS (n=5, 9%) was very low. In contrast, a study of
Canadian and Australian haematological survivors, one to 60 months' postdiagnosis, found 21% (n=71) reported no unmet needs (Hall, Campbell, et al.,
2013). As a pilot study in the early survivorship phase, it is difficult to
compare findings with larger studies with variable survivorship periods that
found low levels of unmet needs in haematological survivor cohorts
(Campbell et al., 2014; Hall, D'Este, et al., 2014).
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The most endorsed concerns on the SCPTS were fear of recurrence, fatigue
and cognition impairment. These findings are consistent with current
research. A recent study of leukaemia and lymphoma survivors (n=477)
reported the prevalence of fear of recurrence was higher in females and
younger participants (Jones et al., 2015). This finding was supported by a
study of different cancer types (n=2615) including lymphoma survivors
(n=379), that found those in active follow-up and the early survivorship
phase (0 to 5 years' post-diagnosis), experienced more fear of recurrence (van
de Wal et al., 2016). Nonetheless, this study revealed satisfaction with
information provision led to less reported fear of recurrence (van de Wal et
al., 2016). This was reflected in the present study, where only one
intervention participant recorded a high/very high level of unmet need for
fear of recurrence at Time 2 and 3, compared with six control group
participants at Time 2 and 3.

A recent study of Dutch HL survivors compared with a normative
population revealed higher fatigue prevalence (41–43% vs 23–28%). Those
with fatigue also had higher levels of anxiety (23% vs 13%) and depression
(18% vs 12%) (Daniels et al., 2014). The authors suggested coping strategies
may provide a clinically meaningful reduction in fatigue (Daniels et al.,
2014). There may also be an association of fatigue with increasing age that
may affect the ability to recover from fatigue (Kreissl et al., 2016). The present
study found fatigue was still prevalent at nine months' post-treatment (Time
3), with participants continuing to report a moderate to very high unmet
need.

Cognitive impairment is a condition that is not fully understood (Mojs et al.,
2017), however, is described as a treatment side-effect (Zimmer et al., 2015).
A recent review of psychological outcomes found cognitive decline can range
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from mild attention, memory and thinking problems to severe impairment
such as dementia (Mojs et al., 2017). A recent study of lymphoma patients
(n=262) demonstrated significantly lower cognitive scores (p .018) and greater
frequency of impairment when compared with healthy controls (32% vs 7%)
(Krolak et al., 2017). This was supported by a smaller study (n=30 vs n=10
controls) which found a significant difference on objective and subjective
cognition tests for lymphoma patients who were within 3 months of
treatment completion (Zimmer et al., 2015). At the completion of the present
study, cognition impairment remained an issue for many participants across
both groups, however the control group reported more unmet need at the
end of the study. This may indicate that normalisation, information and
support may assist lymphoma survivors to cope with this condition.

Survivorship unmet needs
Participants in the intervention group demonstrated an increase in total scale
median scores at Time 2, suggesting more unmet needs were evident in this
group at this time point. However, all scores were lowest at Time 3 perhaps
implying participants needs were met by study completion. Significantly,
those participants aged >60 years had the lowest scores, and this may be due
to their life stage where some practical issues such as finances, employment,
relationship and emotional concerns are less of a concern than for younger
age groups. Women in both groups had the highest Time 1 total scale median
scores which concur with other Australian research indicating women had
higher levels of unmet need (Lobb et al., 2009; Sanson-Fisher et al., 2000). In
contrast, men in the intervention group at Time 3 had the highest median
scores for the information domain, a finding reflected in a study of gender
differences and survivorship follow-up which likewise found men had more
unmet informational needs (Arden-Close et al., 2011). Unmet needs
decreased across the study period suggesting intervention participants were
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able to have their needs, issues and concerns resolved suggesting this may
have been attributable to the nurse-led lymphoma survivorship model of
care intervention. The control group scores were significantly higher in the
30–59 years age group suggesting this age group may require more support
when treatment ends to facilitate return to “normal” functioning and may
warrant further exploration in future research. This finding concurs with
those of a study that reported follow-up services should account for the
distinctive burden of supportive care needs in different age groups (Sharp et
al., 2014). The majority of results in the control group (total scale and domain
mean scores) decreased by Time 3, however, were higher than intervention
group scores at Time 3. Although not statistically significant, likely due to
this pilot study being underpowered, the researcher suggests these higher
scores may reflect a lack of targeted support when treatment completed.
Conversely, the relationships and emotional health domain mean scores
increased over the study period. Talking about emotions and depression
were endorsed as a moderate to high unmet need by the majority of
participants in the control group and the researcher proposes this may be an
area that requires support at treatment completion to assist in mitigating
escalating or unresolved unmet need. Those with NHL had significantly
higher scores in the financial and access and continuity of care domains than
those with HL across both groups at all time points suggesting a need for
targeted support to this cohort when treatment completes.

Psychological distress
Scores on the three domains of the DASS21 remained similar for both cohorts
across the study. The majority of domain scores were below population norm
scores outlined in the DASS scoring manual: depression <4.5; anxiety <3.5;
and stress <7.0 (Lovibond & Lovibond, 1995) and suggests the lymphoma
cohort under study had good psychological coping mechanisms. Participants
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in the intervention group showed a decrease in all scores by Time 3. This
downward trend suggested psychological distress concerns were no longer
evident and likely resolved at study completion. The data revealed an
increase in the intervention group mean scores at Time 2, and although they
had decreased by Time 3, they were nonetheless higher than Time 1 scores.
The researcher proposes this may be due to discussions around these issues
in the nurse-led lymphoma survivorship clinic (NLSC) appointment. Anxiety
and stress were the highest at Time 2, and stress continued to be elevated at
Time 3, an area highlighted as a concern in research with cancer survivors
(Marker, 2015).

Women in the control group, when compared with men, had higher total
scale and anxiety median scores at Time 2, and higher depression scores at
Time 1 and Time 2. This concurs with the findings from the SF-SUNS of
unmet needs in the anxiety and depression domain. Although statistical
significance was not reached, the direction of change revealed total scale
mean scores decreased over the study period and remained higher in
comparison with the intervention group mean scores. This was especially
evident with anxiety being higher in the control group compared with the
intervention group at Time 2. These findings concur with research that
indicated depression and anxiety is a common psychological problem in
haematology cancer survivors (Hall et al., 2016; Lobb et al., 2009; Mitchell et
al., 2011).

Mental adjustment to cancer
Fighting spirit is described as a combination of optimism and confidence that
the effects of cancer are controllable and the individual can actively deal with
the situation (Wills & O'Carroll Bantum, 2012). Participants in the
intervention group revealed significantly lower fighting spirit domain scores
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at Time 1 and Time 2. These participants were given an opportunity to
debrief about their diagnosis and treatment experiences and, therefore, the
researcher suggests these participants may have felt they no longer had to
‘fight’ or ‘beat’ their cancer. Helplessness/hopelessness, defined as a sense of
incapacity or ‘giving into the cancer’ (Czerw et al., 2015), showed a decrease
from Time 1 to Time 3 in the intervention group and may indicate this group
were not incapacitated by having had cancer. The anxious preoccupation
domain can be understood to reflect preoccupation with the cancer that
cannot be controlled by the individual (Czerw et al., 2015; Watson et al.,
1994). The intervention group had a slight increase in median scores by Time
3 revealing this group were thinking about the cancer more. However, these
participants were also aware this was their last appointment in the NLSC
and may have been experiencing some anxiety about the completion of this
individualised support. Participants with NHL in the intervention group had
the lowest total scale, and median anxious preoccupation and cognitive
avoidance (defined as a tendency to avoid actively thinking about the cancer
and its implications (Watson et al., 1994)) domain scores, perhaps reflecting
this group's ability to think beyond the cancer after treatment has been
completed.

The 30–59 years age group in the control group had the highest median
scores across all time points. Helplessness/hopelessness at Time 2, anxious
preoccupation at Time 2 and Time 3, and cognitive avoidance at Time 1 and
Time 3 had significantly higher median scores. These results may indicate
that this age group, who continued with usual care, were not able to find
ways to discuss their cancer concerns and were trying to actively avoid
thinking about the cancer without success. Those control participants aged
>60 years had significantly higher fatalism domain median scores at Time 2.
The level of fatalism is said to impact whether an individual can control or
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influence their cancer (Park, Edmondson, Fenster, & Blank, 2008), and may
indicate the older age group felt they were not able to influence the
diagnosis, perhaps due to age. Control participants with NHL had
significantly higher median scores, especially in the fighting spirit domain at
Time 3 suggesting the cancer was seen as a challenge they were still
overcoming.

Fatalism, fighting spirit and anxious preoccupation mean scores decreased
and helplessness/hopelessness and cognitive avoidance scores increased in
the control group over the study. This may suggest a sense of powerlessness
in coping with the cancer diagnosis, regardless of treatment completion and
remission status. This is reflected in mean fatalism and fighting spirit scores
which were lower than those of the intervention group. In addition, the
suggestion of a sense of powerlessness is supported by the majority of the
control group participants (compared with the intervention group) at Time 2
who significantly endorsed the items related to difficulty believing cancer
had happened to them and trying to push all thoughts of cancer away, and at
Time 3 indicating they did not want to think about cancer and were pushing
thoughts of cancer away.

Self-empowerment
Participants in the intervention group demonstrated an increase in scores for
self-empowerment from Time 1 through to Time 3. This study also found
those >60 years of age, regardless of group allocation (intervention or
control) were more empowered, especially compared with those in the 30–59
years age group. The researcher suggests this may, in part, be due to the life
experiences and previous exposure to adversity older adults may have
encountered. At Time 1 and Time 2 those with NHL, characteristically a
disease of older age (Cancer Australia, 2017), had higher median scores. The
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researcher suggests these participants may have already been more
empowered due to age. Conversely, mean scores in the control group were
lowest at Time 3. This finding suggests this group of participants felt less
able to control aspects of their cancer and move on with their life, although
further research is required to explore this trend.

The most endorsed items indicated the intervention group felt they had all
the information they needed, were able to adapt and make changes to their
lifestyle, felt health professionals included them in discussions and by Time 3
were more confident in their GP. The researcher suggests this may be due to
the

SCPTS

sent

to

their

GPs

which

outline

future

follow-up

recommendations.

Nurse-led lymphoma survivorship model of care
While this pilot study was not sufficiently powered to demonstrate a
significant effect between the two groups, the direction of change in the
results suggests the nurse-led lymphoma survivorship model of care may be
an effective intervention for targeted cancer cohorts. For some participants in
the intervention, one or two appointments in the NLSC would have been
sufficient to impart the SCPTS and give individualised and tailored resources
as these survivors do not require intensive support (Campbell et al., 2014).
However, those with high levels of unmet need after the provision of the
SCPTS and resources may need more support. This was evidenced by the
increase in needs at Time 2. These needs had diminished in the most part by
Time 3 indicating a sustained follow-up may not be warranted.

Participants who utilised the motivational chart to make healthy lifestyle
changes reported pressure to cease smoking or reduce alcohol during
treatment. However, these participants indicated adequate support was not

231

CHAPTER 7. DISCUSSION

provided at such a high-stress time. The participants acknowledged the
motivational chart and support as a useful way to explore the unhealthy
behaviour and their motivations in continuing. Likewise, these participants
felt the motivational interviewing assisted them to be empowered to quit or
reduce the unhealthy behaviours. Further study would be required to
ascertain sustained change over a longer period than the study timeframe of
six months.

Discussion of the Phase Four General Practitioner Evaluations
Data from the GP evaluations indicated the SCPTS had been received, read
and in some cases prompted the GP to make an appointment (n=16, 89%)
with the patient. However, not all GPs indicated they had discussed the
SCPTS with their patient during the trial (n=11, 61%). Discussion of the
SCPTS between participants and their GPs was encouraged; however, the
participant could choose when and if they discussed the SCPTS during the
trial. Five intervention participants indicated at the completion of the study
they had not visited or discussed the SCPTS with their GP. As a copy of the
SCPTS is held by the participant and his/her GP, it is envisaged the
document could potentially be used at future appointments.

Of those GPs who completed the Likert-type scale, the majority (n=13, 81%)
found the SCPTS useful and rated it as good to very good. Just over half of
GP responders (n=10, 59%) requested further haematology or medically
related information be included on the SCPTS, perhaps indicating
insufficient

information

was

communicated

from

the

haematology

department. As a treatment summary document, it was not the intent of the
SCPTS to provide all health-related information. The majority of responders
indicated they did not want further education on the SCPTS (n=9, 69%). The
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present study did not address the management of other medical conditions,
and this may be an area that would need consideration for future inclusion,
particularly in older cancer participants who have an increased likelihood of
co-morbidities.

Summary of the Phase Four Qualitative Interviews
In quantitative research, participants may not have an opportunity to
articulate their perceptions, thoughts and feelings as they complete
questionnaires with set responses. The researcher sought to avoid this
limitation by including a qualitative sub-study (Phase Four) using a cohort of
intervention participants to add depth and further explore some aspects of
the quantitative data obtained (Creswell & Clark, 2011). This process of
triangulating the data, using multiple methods of data collection,
strengthened and supported the study outcomes as a more holistic
understanding of the key findings was obtained from different sources
(Sarantakos, 2013).

Additional support is particularly valuable when patients are transitioning
from active treatment to life without treatment (Knott, Turnbull, Olver, &
Winefield, 2012). Reality, however, suggests this period is characterised by
the reduction or cessation of cancer care support in the acute setting (Rabin,
Simpson, Morrow, & Pinto, 2011). The support conceptualised for the nurseled lymphoma survivorship model of care and offered by an experienced
cancer nurse was appreciated by participants at a time when previous cancer
patients have expressed the fear they would be abandoned once treatment
had completed (Lobb et al., 2009; Matheson et al., 2016; Monterosso et al.,
2017). Participants who were interviewed highlighted both the importance of
a safe environment to ask questions and expressed the importance of trust
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and rapport developed between themselves and the researcher during the
study. The majority of lymphoma survivors wanted to make healthy lifestyle
behaviour changes; however, there were limited options that specifically
target cancer survivors. Having an opportunity to discuss preferences and
decisions with the researcher about individual goals and action plans was
seen as very helpful. This can enhance self-efficacy leading to greater
psychosocial well-being. This concurs with findings from a recent study
which revealed a positive correlation between increased levels of self-efficacy
and more emotional and functional well-being, alongside fewer cancerrelated issues (Papadopoulou et al., 2017). Participants particularly liked how
the SCPTS was personalised to them and they were able to document the
issues and concerns most important to them.

Summary of the Test–retest Reliability Analysis
The SF-SUNS test–retest reliability sub-study added psychometric data for
this measure in a lymphoma-specific cohort of survivors. The results
demonstrated the majority of items achieved fair to good reliability intraclass
correlation (ICC) scores. It is essential that survivorship-specific needs
assessment measures detect clinically meaningful changes over time in the
survivorship phase (DeVellis, 2012; McDowell, 2006; Streiner & Norman,
2003). An important consideration when issues and concerns are rapidly
changing as survivors move beyond the diagnosis and treatment phases and
begin to move forward with their lives. These results, now available in the
published literature will allow other researchers an opportunity to make
informed choices when choosing a survivorship-specific needs assessment
measure for their cohorts.
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Limitations of the Research
Specific limitations are addressed in each published manuscript. Limitations
of the pragmatic RCT included the recruitment by chance of more males than
females in the intervention group, and a disproportionate number of HL to
NHL that did not reflect current lymphoma statistics (Cancer Australia,
2017). However, it is acknowledged this is a possibility when randomisation
of groups occurs (Deaton & Cartwright, 2017). As a pilot study, a sample size
calculation was not required, and it is acknowledged that 60 participants
may not be adequate to see a true effect of the intervention. It must be
highlighted the purpose of this pragmatic pilot RCT was to generate data
that can be used to power future robust larger RCTs. This aim was achieved.

Fidelity of the intervention was maintained, and no control group participant
received the intervention while on the study. It is unknown if survivorship
information was imparted to control group participants by haematologists.
This is considered unlikely however as needs of this group were higher than
those of the intervention group.

The PhD candidate administered the intervention and entered the data from
both groups. There is a potential for bias when the researcher evaluates their
own service. Due to the constraints of a PhD which related to a lack of
funding to employ an independent experienced cancer research nurse, a
number of measures were employed to mitigate potential bias. Statisticians
reviewed data and assisted with quantitative analysis to decrease the risk of
bias in evaluation. Control group participants were only contacted by an
independent member of the research team if this was required.
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Alterations were made to how the NLSC appointments were conducted
when haematologist appointments were altered. This was required to ensure
timeframes were maintained. However, a strength of the NLSC intervention
was its ability to be flexible to accommodate the requests of participants.

As a pragmatic RCT, there was a usual care group who did not receive the
nurse-led lymphoma survivorship model of care. It is important when
examining new models that a comparison group is provided, especially as
research on the benefits of an SCPTS is limited. Future research to investigate
the provision of the intervention to the usual care group after study
timeframes are completed may provide valuable data on the benefits of
delayed delivery compared with no delivery.

Assessment measures used in this study may not have captured all the
concerns and issues that applied to lymphoma survivors. There were
limitations to using the DASS21, for example, where a control group
participant complained of a dry mouth it was unknown whether this was a
sign of anxiety or an ongoing treatment effect. This was comparably true for
the question related to lack of initiative which may have been related to
fatigue rather than a sign of depression. Some participants expressed
difficulty with answering particular questions on the Mini-MAC. Some
participants at baseline indicated that some items, for example; ‘I take one
day at a time’, ‘I am apprehensive’ or ‘I have difficulty believing that this
happened to me’, both "applied" and "did not apply". Intervention
participants who indicated similarly at the NLSC appointments were guided
to reflect on how they felt at present, as per questionnaire instructions. Many
participants at baseline needed to be reminded the assessment questionnaires
were related to the present, not how they felt during treatment.
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An economic evaluation of the cost of a nurse-led lymphoma survivorship
model of care would have enhanced the research and added information on
the viability of the model. This would correspondingly have examined the
time and cost required for nurses to deliver this model of survivorship care.
Likewise, an evaluation of lymphoma survivors’ utilisation of the primary
healthcare system from Medicare data could have examined if there was an
increase in GP visits with the intervention group participants who were
encouraged to see the GP compared with control group participants who
were not given any post-treatment support. The time constraints of this PhD
thesis prevented this lengthy form of evaluation. Further, as the study was
only conducted with participants from one haematology department, it
would be difficult to generalise the findings of this thesis to the other two
public tertiary haematology departments in Perth Western Australia.

The time constraints of a PhD candidacy, as well as the significant size of this
thesis, prevented an examination of the experience and needs of carers of
RCT study participants. This is an important aspect of care and should be
considered a potential future area for research. No data were collected from
patients who declined the research. Therefore, it is unknown if these patients
had more or diverse issues and unmet needs. Providing a nurse-led followup appointment to all lymphoma patients when they complete treatment as
standard practice may contribute to supporting patients who would
otherwise not seek assistance.

Finally, GP feedback could be improved with an investigation into whether
and why some GPs did not receive the SCPTS. All medical centres were
contacted if evaluations were not received with faxed copies being sent if
medical practices indicated non-receipt. Whether the participant’s GP did
eventually receive the SCPTS and evaluation remains unknown. Further,
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some GPs may have chosen not to return the evaluation. Nevertheless, the
response rate for evaluation returns was considered acceptable at 64%
(Livingston & Wislar, 2012).

Strengths of the Research
The major strength of this research and a key aspect was the tailored and
personalised nature of the nurse-led lymphoma survivorship model of care,
delivered by one experienced cancer nurse clinician (the PhD candidate).
This ensured consistency and accuracy of all data. Information provision that
is tailored to the patient’s perceived needs is a significant factor in
survivorship care, support and empowerment (Bulsara & Styles, 2013; Hall,
D'Este, et al., 2014; Husson et al., 2013). Equally important was the early
knowledge of late effects that may assist in timely follow-up with the GP
when haematology department surveillance ends (Ng et al., 2011). An
additional strength of this research was the lymphoma-specific cohort which
allowed the researcher an opportunity to assess needs that were diseasespecific (Oberoi et al., 2017). The nurse-led survivorship model of care was
developed for lymphoma survivors in the early survivorship period, a time
when studies have indicated there is an increase in distress as treatment
completes (Girgis & Butow, 2009; Hewitt et al., 2005; Jefford et al., 2008) and
survivors may feel abandoned by the treating team (Matheson et al., 2016;
Monterosso et al., 2017).

Recent studies have indicated survivors want more detail and more
information on healthy lifestyle behaviours, psychological support and
resources (Keesing, McNamara, & Rosenwax, 2015; Mayer, Birken, et al.,
2015). A strength of the conceptualised model was to develop information
that was delivered as part of the general health aspect of the SCPTS and
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within the resource pack developed for the study. GP evaluations on the
SCPTS indicated a content rating of good to very good from the majority of
GP respondents. Therefore, the researcher suggests the nurse-led lymphoma
survivorship model of care was able to accommodate the needs of both
survivors and GPs.

Assessment measures were utilised to assess and evaluate survivorship,
distress, adjustment and coping and empowerment post-treatment at three
time points. This assisted with discussion and targeting of resources during
the

nurse-led

lymphoma survivorship

clinic appointments for the

intervention group. It may have also assisted those in the usual care (control)
group to identify areas they may have discussed with their haematologist or
GP. The unique lymphoma SCPTS was patient-centred and allowed
intervention participants an opportunity to seek support on the issues and
health goals that were important to them at their life stage. This has not been
a feature of any SCPTS found in the published literature at the time of
development. Motivational interviewing techniques require a particular skill
set, and fortunately, the researcher was competent in this area. Utilising this
skill and assisting the intervention participants to understand the impact of
continuing unhealthy lifestyle behaviours, was an important promoter for
change that they were empowered to make. This was an important element
of the conceptual framework developed when the research was planned to
aid recovery of health and well-being and engagement in healthy lifestyle
behaviours to improve quality of life.

The research allowed participants an opportunity to debrief after a lifechanging and often traumatic experience, such as a cancer diagnosis. This
was an aspect that was highlighted in the qualitative interviews and
anecdotally to the researcher during the face-to-face appointments. The
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nurse-led lymphoma survivorship model of care provided normalisation of
some of the long-term effects such as fatigue, fear of recurrence and/or
cognitive impairment, with provision of further information. This was
likewise perceived by many participants as missing from haematology
follow-up care. The researcher suggests debriefing and normalisation, along
with information, resources and support may help to mitigate these issues
continuing in the longer-term.

Lastly, an important strength was the use of and collaboration with the
haematology survivorship research advisory committee which consisted of
academic, clinical health and community support group professionals and
lymphoma survivor consumers. The input of the consumers provided
significant insight into current lymphoma post-treatment follow-up and on
gaps they perceived in their own cancer survivorship journey.

Chapter Summary
This chapter summarises the key findings from the four phases of this thesis
study. In keeping with a pilot pragmatic RCT design, the small numbers of
participants recruited limited the power of this study to potentially
demonstrate statistically significant results. Nevertheless, this study provides
a valuable contribution for future rigorous testing of nurse-led survivorship
models of care to transition patients from treatment into the survivorship
phase. The large body of work presented in this PhD thesis by publication
exceeds the minimum requirement of four published manuscripts. The final
publication, currently undergoing preparation for publication will report the
LMM data from the pragmatic pilot RCT and provide evidence to generate
sample size calculations to support future RCT studies.
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Providing individualised and tailored information, support, resources and a
patient-centred survivorship care plan and treatment summary in the early
survivorship period may lead to less unmet needs and better recovery of
health and well-being in the future.

The final chapter will conclude this thesis and discuss the implications of this
type of research. Furthermore, it will provide recommendations for clinical
nursing, future research and education in survivorship care for nurses who
are a valuable and integral component of high-quality supportive
survivorship care.
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Chapter Eight — Conclusion

“But to know that look, don’t worry, after treatment you are going to see a
nurse, that would have been very calming for me” F_64yo_HL
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8.0 Implications and Recommendations
Implications
Provision of evidence-based cancer survivorship care must be a common
goal throughout the healthcare system, as cancer diagnoses and survival
rates continue to increase. The impact of cancer does not end with active
treatment as cancer survivors continue to have numerous diverse and varied
needs at different time points along the survivorship trajectory. Efficient
targeting and provision of clinical services is key to meeting and improving
the care of cancer patients at all stages.

This study was based on the assumption that the current model of
lymphoma follow-up, which is haematologist-led, has been unable to
comprehensively provide the supportive care required to transition patients
from the treatment phase into the survivorship phase. Consequently, a
nurse-led lymphoma survivorship model of care was conceptualised,
successfully developed and tested within this research.

Sixty lymphoma patients from one haematology department in Perth,
Western Australia were recruited and randomised. While not the aim of a
pilot study, many findings were not statistically significant, likely due to the
small number of participants. The intervention participants did demonstrate
less unmet informational and practical needs, less depression, anxiety and
stress while demonstrating higher levels of coping and empowerment
compared with the control (usual care) group. As intended, the study did
produce data that can be used to power larger randomised trial studies for
future competitive funding applications.
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Psychological concerns among patients are often not addressed by clinicians
in follow-up due to a number of limitations on their time and the availability
of routine screening mechanisms. Clinicians will often assess for signs of
depression, which is common following a cancer diagnosis (Mitchell,
Ferguson, Gill, Paul, & Symonds, 2013) without addressing the levels of
anxiety and stress which can be a major concern for cancer survivors
(Marker, 2015; Mitchell et al., 2011). Findings from this study suggest anxiety
and stress can remain elevated over time and was notable in the control
group where scores were higher in comparison with the intervention group
who had an opportunity to discuss concerns and issues. Therefore, future
interventions may need to consider anxiety-related issues such as fear of
recurrence, thereby normalising the need for psychosocial support when
developing cancer survivorship support and resources.

Participants in the 30–59-year-old age group across both the control and
intervention groups exhibited higher levels of unmet practical concerns and
less empowerment, a finding that corresponds to this life stage where
patients are often juggling family, employment and financial issues. This
study has confirmed the need that lymphoma patients require support and
resources that are targeted to their life stage, and which can support them to
re-establish their lives post-treatment. A finding supported by the qualitative
interviews which revealed patients appreciated the individualised aspect of
the nurse-led lymphoma survivorship model of care, valued the opportunity
to discuss their concerns and issues and had a plan for monitoring potential
late effects in the future, regardless of their age and life circumstances.

Lack of resources and support for survivors was evident in Phase Two of this
study when a resource pack was developed. It would be difficult in the
limited time survivors have in their haematologist appointments to provide

244

CHAPTER 8. CONCLUSION

and discuss all the information and support an individual lymphoma
survivor might need at that time. Therefore nurse-led survivorship models of
care may provide the time and space to assist with this issue.

Recommendations
The results of this cancer nursing thesis have provided phase II evidence of
the need for future research on nurse-led survivorship models of care in
unique and rarer cancer groups such as lymphoma. The research highlighted
the need for nurses to consider the whole cancer trajectory, not just the
diagnosis and treatment phases of cancer care. The wider implications of the
long-term and late effects of diagnosis and treatment for cancer survivors are
equally imperative. Delivering cancer survivorship care that is evidencebased, holistic, cost-effective and adaptable to different health care settings is
a continual challenge. Regardless of this, the provision of quality care and
improvement in overall quality of life should be a greater focus in effective
healthcare initiatives than just successful medical treatment. The following
recommendations could enhance research in the area of cancer survivorship.

Clinical Nursing


Experienced and senior cancer nurses should provide training and
education on the use of assessment measures in survivorship to all nurses
working in cancer care.



Cancer nurses should be encouraged to identify and refer patients to
appropriate health care providers for psychological and emotional
support.



Cancer nurses should be encouraged to undertake research and
professional development to address the gaps in information and
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resources provided to patients during their treatment and survivorship
phases.


Experienced cancer nurses should be provided with additional time to
provide holistic follow-up on survivorship needs post-treatment.



Cancer nurses should be offering educational forums to survivors to
enhance post-treatment coping skills, healthy lifestyle behaviour choices
and normalisation of treatment effects.



Cancer nurses should be encouraged to provide input into the
development and delivery of SCPTS for all cancer survivors.



Cancer nurses should find opportunities to communicate with GPs to
ensure survivorship needs will be addressed in the future.

Research


Further research should be undertaken to promote and support the
development, testing and evaluation of survivorship models of care.



Further research on nurse-led survivorship models of care should be
undertaken with survivors of:
o Other haematological cancers
o Other cancers.



Further research should include the recruitment of cancer patients from
rural/regional areas and evaluate the provision of localised support.



Exploring options for providing targeted support to carers during cancer
treatment and post-treatment requires further investigation.



Further examination of debriefing mechanisms during and after
treatment for patients is required.



Research that encourages advocacy and peer support among survivors is
required:
o Investigation of the types of peer support mechanisms currently
available
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o Development of peer support for patients of all stages of the cancer
trajectory.


Longitudinal studies are required to determine:
o If participants follow through recommendations with their GP
when haematologist follow-up is completed


If this impacts earlier diagnosis and management of late
effects

o If healthy lifestyle choices were maintained and how motivation to
continue was sustained.


Future studies in the primary care arena to deliver nurse-led survivorship
models of care would be valuable.



Larger phase III multi-centre studies are required to explore nurse-led
survivorship models of care that deliver patient-centred options for
frequency and type of contact, such as face-to-face or telephone support.



Further studies in the development and examination of psychometrically
sound measures that capture the unique needs of survivors of less
common cancers, such as lymphoma are essential.

Education


Findings from this study could be used to increase public awareness of
resources that can normalise and provide support for the issues and
concerns that occur post-treatment.



Findings from this study could be used in hospitals to provide greater
awareness of community-based support organisations
o Carer support mechanisms.



An awareness of and provision of multi-cultural support and information
requires further development and testing.
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Further education is necessary to provide relevant information and
support resources to regional and rural Australia to enable improved
referral pathways and communication between health care providers.



Further research and education is required to increase support for
employees and employers where identified employment concerns may
arise
o Provide access to information on support services and employee
entitlements
o Identify barriers that inhibit employers from implementing
supportive policies in the workplace
o Provide better mechanisms for transitioning back into the
workforce or retraining.



Increased flexibility in accessing financial government funding and
effective utilisation.



Promotion of the re-evaluation of funding allocation for rarer cancers is
required by cancer agencies and professional health organisations to
ensure equity of research and services.
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Appendix A
A.1 Models of Survivorship Care Provision in Adult Patients
with Haematological Cancer: An Integrative Review
The final publication is available at link.springer.com and permission was
granted on the 13 March 2018 by Springer Nature and the Supportive Care in
Cancer Journal License Number: 4307370922040 to include the authors'
personal copy as part of this thesis.
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A.2 Survivorship Care Plans and Treatment Summaries in Adult
Patients with Hematologic Cancer: An Integrative Literature
Review
Permission to use the article was granted on the 13 March 2018 by the
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Appendix D
Patient Information and Consent Form
SIR CHARLES GAIRDNER HOSPITAL
Participant Information Sheet/Consent Form
Effect of a Nurse-Led Lymphoma Survivorship Clinic: A Pilot Randomised
Controlled Trial
Protocol Number: 2015-020
Project Sponsor: University of Notre Dame Australia
Coordinating Principal Investigator: Professor Leanne Monterosso
Principal Investigator: Karen Taylor
Associate Investigators: Dr David Joske, Violet Platt, Kendall Stratton, Professor
Max Bulsara
What does my participation involve?
You are invited to take part in this research project, which is called the effect of a
nurse-led lymphoma survivorship clinic. You have been invited because you have
received treatment for lymphoma cancer: either Hodgkin’s lymphoma or NonHodgkin’s lymphoma. This research is specifically for patients who have completed
treatment and are entering into the post treatment or ‘survivorship’ phase. Your
haematologist has recommended you and has provided your contact details as you
are about to, or have already finished treatment.
This Participant Information Sheet/Consent Form explains the processes involved
with taking part. Knowing what is involved will help you decide if you want to take
part in this study.
Please read this information carefully. Ask questions about anything that you don’t
understand or want to know more about. Before deciding whether or not to take part,
you might want to talk about it with a relative, friend or your treating doctor.
Your participation is voluntary. If you don’t wish to take part, you don’t have to.
If you decide you want to take part, you will be asked to sign the consent section. By
signing it you are telling us that you:
• Understand what you have read
• Consent to take part in this research
• Consent to be involved in the research described
• Consent to the use of your personal and health information as described.
You will be given a copy of this Participant Information and Consent Form to keep.
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What is the purpose of this research?
“Survivorship” is a term that is commonly used to describe the experience of living
with, through and beyond a diagnosis of cancer. People who have completed
treatment for a blood (haematological) cancer such as lymphoma can have
problems that impact on the practical, physical and emotional quality of their life.
This study will test a nurse-led lymphoma survivorship clinic that will provide
information, education and practical support to people like yourself who have just
finished treatment. This will help in moving (transitioning) on from hospital care.
Information will also be passed onto your General Practitioner (GP) about the
treatment you have received and what to expect in the future. This will be in the form
of a survivorship care plan treatment summary, which has been suggested as a way
to help patients and GPs find out about the treatment received and the issues that
may require further assessment and support with.
Western Australia has no formal survivorship care and this research aims to identify
whether a survivorship clinic would be acceptable to patients like yourself to help
reduce the number of problems encountered after treatment ends and to provide
information to enable a healthy lifestyle. This pilot research will form the basis for
future expansion of survivorship care for all blood cancer survivors across Western
Australia.
Who is organising and funding the research?
This research is being conducted by Karen Taylor who is a PhD student at the
University of Notre Dame Australia, under the supervision of the coordinating
principal investigator Professor Leanne Monterosso. Karen is an experienced
haematology cancer nurse. Other members of the research team include Dr David
Joske from the SCGH Haematology Department, Violet Platt, Director of Nursing at
the WA Cancer and Palliative Care Network, Kendall Stratton from the Youth
Cancer Service and Professor Max Bulsara who is a leading biostatistician. This
research is funded by the University of Notre Dame Australia.
No member of the research team will receive a personal financial benefit from your
involvement in this research project.
What does participation in this research involve?
Consent
If you decide to participate in this study, please sign the consent form and bring it to
your next haematologist appointment at SCGH. Karen will contact you on that day
either before or after your appointment. Karen will need to check that you are
eligible for the study by asking about your diagnosis and treatment. Your medical
records will need to be accessed, but this will not occur without your consent.
Once you have consented, Karen will ask you to fill out four (4) questionnaires.
These will be used to assess whether you have any particular needs related to
practical, physical, emotional or social issues that are known to possibly affect
patients after treatment for cancer such as lymphoma. These questionnaires my
take up to an hour to complete.
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Study Design
This study is called a randomised controlled trial. This means half the participants
will get usual care with their haematologist and the other half will receive usual care
and will participate in the nurse-led lymphoma survivorship clinics. This will be
decided randomly. Once you have completed the questionnaires you will be asked
to open a sealed envelope which will identify the group to which you will be
assigned.
Control Group
If you open an envelope that indicates you are part of the control group you will be
sent the same set of four (4) questionnaires at 3 months and 6 months. We ask that
you complete them at home as soon as possible and send them back in the replypaid envelope. If we haven’t received them in two weeks’ time, another research
team member will call to check you have received them and that you have filled
them in. At 6 months, once you complete the last set of questionnaires, your
participation in the study will stop. All questionnaires will be checked by Karen once
they are sent back and if at any time you have indicated you are struggling with an
issue or concern, contact will be made with your haematologist to let them know so
they can follow up with you.
Intervention Group
If you open an envelope that indicates you are part of the intervention group, an
appointment will be made with you to come to the first of three (3) nurse-led
lymphoma survivorship clinics run by Karen. The first clinic session will take place
within a week of the initial questionnaires being completed. You are welcome to
bring a partner, friend or family member to all the nurse-led lymphoma survivorship
clinics. At the first clinic appointment any issues or concerns that you have
highlighted on the questionnaires will be discussed. During this clinic, education on
healthy lifestyle behaviours will be provided. You will also receive a resource pack of
information designed to meet your individual needs or concerns. A survivorship care
plan treatment summary will be completed by yourself and Karen to ensure you
agree with the contents. How these documents will help you will be explained. The
survivorship care plan treatment summary will also be sent to your GP and you are
asked to take this document with you if you see your GP. At three and six months
after baseline, you will be asked to return to the nurse-led lymphoma survivorship
clinic and the same four questionnaires will be filled in by yourself and any issues or
concerns discussed and support and information given.
After the six month clinic appointment, if you have consented to an interview, you
may be contacted to give some feedback on the value, function and benefit of the
nurse-led lymphoma survivorship clinic. Approximately 10 participants will be asked
for this feedback in a telephone interview at a time that is convenient to you. It is not
anticipated that this interview will take longer than an hour. This interview will be
digitally recorded and typed into a document. All names and identifying information
will be removed to protect your identity before analysis takes place.
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We ask that you do not share the resources, information, survivorship care plan
treatment summary with any other patients in the haematology clinics as this will
affect the study results.
Monitoring of the study
This study will be monitored in accordance with the research protocol and the
National Statement on Ethical Conduct in Human Research (2007) and the
Australian Code for the Responsible Conduct of Research (2007).
Venue and Commitment required
The study will be conducted onsite at Sir Charles Gairdner Hospital (SCGH) and we
ask that you complete all aspects of the study including: completing all
questionnaires; returning questionnaires promptly and attending all clinic
appointments as required. Questionnaires may take up to 30 minutes to complete.
The nurse-led lymphoma survivorship clinics including questionnaire completion will
be approximately one(1) hour. This study requires a commitment of six months.
Access to Personal Records and Confidentiality
Your medical records will need to be accessed to gain the information required to fill
in the treatment summary and partially fill the survivorship care plan prior to the first
nurse-led lymphoma survivorship clinic. This includes information such as your
name, date of birth, address, gender, marital status, education, diagnosis and
treatment.
Bias
This research project has been designed to make sure the researchers interpret the
results in a fair and ethical way.
Costs
There are no direct costs associated with participating in this research project, nor
will you be paid. If required, you may be asked to give up your time to travel to the
first nurse-led lymphoma survivorship clinic and group session, which may incur
travel and parking costs. The second and third nurse-led lymphoma survivorship
clinic appointments will be scheduled to coincide with your routine three (3) monthly
haematologist review appointments.
Do I have to take part in this research project?
Participation in any research project is voluntary. If you do not wish to take part, you
do not have to. If you decide to take part and later change your mind, you are free to
withdraw from the project at any stage.
Your decision whether to take part or not, or to take part and then withdraw, will not
affect your routine care, your relationship with professional staff or your relationship
with Sir Charles Gairdner Hospital.
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What are the possible benefits of taking part?
We cannot guarantee or promise that you will receive any benefits from this
research. However, possible benefits may include identification of issues and
concerns earlier in the post treatment period and referral to services that may assist
with these issues.
Participant Information Sheet/Consent Form 22 August 2016 Version 6 It is intended the findings
from this research will guide the development of expanded nurse-led survivorship
clinics for all haematology patients and an expansion to other cancer patient.
What are the possible risks and disadvantages of taking part?
You may feel that some of the questions we ask are upsetting. If you do not wish to
answer a question, you may skip it. If you become upset or distressed as a result of
your participation in the study, the research team will arrange for counselling or
other appropriate support. This will be provided free of charge by qualified staff who
are not members of the research team.
What if I withdraw from this research project?
If you decide to withdraw from the project, please notify Karen. She will not collect
additional information from you, although personal information already collected will
be retained to ensure that the results can be measured properly and to comply with
the law. You should be aware that data collected up to the time you withdraw will
form part of the research project results. If you do not want your data to be included,
you must tell Karen when you withdraw from the research project.
What happens when the research project ends?
At the end of the study Karen will send you a summary of the study results. The
results may not be available for up to 2 years after the study has finished for you as
it depends on the length of time it takes to recruit all the patients required and for
Karen to complete her PhD studies.
What will happen to information about me?
By signing the consent form you consent to the collection and use of your personal
information for the research project. Your information will only be used for the
purpose of this research and will only be disclosed with your permission, except as
required by law. All information will remain confidential and will be kept in the locked
office of Professor Leanne Monterosso at the University of Notre Dame Fremantle
campus during the study. Information will be de-identified and stored in a locked
archive for 15 years from the time the study is closed and published. After that time
it will be destroyed.
Your health records and any information obtained during the research project are
subject to inspection (for the purpose of verifying the procedures and the data) by
the relevant authorities and authorised representatives of the Sir Charles Gairdner
Hospital Human Research and Ethics Committee, relevant to this Participant
Information Sheet, or as required by law. By signing the Consent Form, you
authorise release of, or access to, this confidential information to the relevant
research personnel and regulatory authorities.
Participant Information Sheet/Consent Form 22 August 2016 Version 6
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It is anticipated that the results of this research project will be published and/or
presented in a variety of forums. In any publication and/or presentation, information
will be provided in such a way that you cannot be identified, except with your
express permission.
In accordance with relevant Australian and/or Western Australian privacy and other
relevant laws, you have the right to request access to the information about you that
is collected and stored by the research team. You also have the right to request that
any information with which you disagree be corrected. Please inform the research
team member named at the end of this document if you would like to access your
information.
Complaints and compensation
Any complaint or concern will be treated in confidence and fully investigated. You
will be informed of the outcome. In the unlikely event that you experience any
research-related harm as a result of taking part in this study, you will be provided
with medical treatment/care at no cost to you. The term “research-related harm”
means both physical and mental injury caused by the study drug, study product or
study procedures required by the trial. Your consent to participate in this study does
not affect your right to pursue a legal remedy from any party involved with the study,
in respect to an injury alleged to have been suffered by you as a result of your
participation.
Who has reviewed the research project?
All research in Australia involving humans is reviewed by an independent group of
people called a Human Research Ethics Committee (HREC). The ethical aspects of
this research project have been approved by the HREC of Sir Charles Gairdner
Hospital and the University of Notre Dame Australia. This project will be carried out
according to the National Statement on Ethical Conduct in Human Research (2007).
This statement has been developed to protect the interests of people who agree to
participate in human research studies.
Further information and who to contact
The person you may need to contact will depend on the nature of your query. If you
want any further information concerning this research or if you have any problems
which may be related to your involvement, you can contact the researcher
Karen Taylor Survivorship Cancer Nurse Coordinator, Telephone contact: 0428 411
309, Email: Karen.Taylor@health.wa.gov.au Or Professor Leanne Monterosso (ph)
9433 0103.
Complaints contact person
If you have any complaints about any aspect of the project, the way it is being
conducted or any questions about being a research participant in general, then you
may contact the Executive Officer of the Sir Charles Gairdner and Osborne Park
Health Care Group Human Research Ethics Committee on (08) 6457 2999,
HREC.SCGH@health.wa.gov.au. Or the Executive Officer of the Human Research
Ethics Committee, Research Office, The University of Notre Dame Australia, on (08)
9433 0943, research@nd.edu.au
Participant Information Sheet/Consent Form 22 August 2016 Version 6
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Consent Form
Effect of a Nurse-Led Lymphoma Survivorship Clinic: A Pilot
Randomised Controlled Trial
Protocol Number: 2015-020
Project Sponsor: University of Notre Dame Australia
Coordinating Principal Investigator: Professor Leanne Monterosso
Principal Investigator: Karen Taylor
Associate Investigators: Dr David Joske, Violet Platt, Kendall Stratton, Professor
Max Bulsara
Declaration by Participant
I have read the Participant Information Sheet or someone has read it to me in a
language that I understand.
I understand the purposes, procedures and risks of the research described in the
project.
I have had an opportunity to ask questions and I am satisfied with the answers I
have received.
I freely agree to participate in this research project as described and understand that
I am free to withdraw at any time during the project without affecting my future care.
I understand that I will be given a signed copy of this document to keep.

Signature

Date

Declaration by Researcher†
I have given a verbal explanation of the research project, its procedures and risks
and I believe that the participant has understood that explanation.
Name of Researcher (please print)

Signature

Date

†

An appropriately qualified member of the research team must provide the explanation of, and
information concerning, the research project.

Note: All parties signing the consent section must date their own signature.
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Appendix E
Assessment Measures
E.1 Demographic Questionnaire
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E.2 Short-Form Survivor Unmet Needs Survey
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E.3 Depression Anxiety Stress Scale
DASS21

Name:

Date:

Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the
statement applied to you over the past week. There are no right or wrong answers. Do not
spend too much time on any statement.
The rating scale is as follows:
0
1
2
3

Did not apply to me at all
Applied to me to some degree, or some of the time
Applied to me to a considerable degree, or a good part of time
Applied to me very much, or most of the time

1

I found it hard to wind down

0

1

2

3

2

I was aware of dryness of my mouth

0

1

2

3

3

I couldn't seem to experience any positive feeling at all

0

1

2

3

4

I experienced breathing difficulty (eg, excessively rapid
breathing,
breathlessness in the absence of physical exertion)

0

1

2

3

5

I found it difficult to work up the initiative to do things

0

1

2

3

6

I tended to over-react to situations

0

1

2

3

7

I experienced trembling (eg, in the hands)

0

1

2

3

8

I felt that I was using a lot of nervous energy

0

1

2

3

9

I was worried about situations in which I might panic and make
a fool of myself

0

1

2

3

10

I felt that I had nothing to look forward to

0

1

2

3

11

I found myself getting agitated

0

1

2

3

12

I found it difficult to relax

0

1

2

3

13

I felt down-hearted and blue

0

1

2

3

14

I was intolerant of anything that kept me from getting on with
what I was doing

0

1

2

3

15

I felt I was close to panic

0

1

2

3

16

I was unable to become enthusiastic about anything

0

1

2

3

17

I felt I wasn't worth much as a person

0

1

2

3

18

I felt that I was rather touchy

0

1

2

3

19

I was aware of the action of my heart in the absence of physical
exertion (eg, sense of heart rate increase, heart missing a beat)

0

1

2

3

20

I felt scared without any good reason

0

1

2

3

21

I felt that life was meaningless

0

1

2

3
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E.4 Mini Mental Adjustment to Cancer Scale
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E.5 Patient Empowerment Scale
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Appendix F
F.1 Lymphoma Survivorship Care Plan and Treatment Summary
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F.2 Content Validity Evaluation Form
Validation of the Survivorship Care Plan Treatment Summary (SCP TS)
for use with lymphoma cancer survivors
The Survivorship Care Plan Treatment Summary (SCPTS) has been
developed by the chief investigator Karen Taylor (Cancer Nurse Coordinator
Survivorship, Western Australia Cancer and Palliative Care Network
(WACPCN) & PhD candidate, University of Notre Dame Australia (UNDA)).
The principal supervisor for this research, Professor Leanne Monterosso
PhD, BNurs(Hons) and the associate clinical investigator, Professor David
Joske have assisted with the development, content and structure of the
SCPTS.
To assist in ensuring this document is clear, consistent and valid for use with
lymphoma survivors, I would like to invite you to assist in this process by
answering a number of questions that relate to each of the areas this SCP
TS covers. This will determine the content clarity, apparent internal
consistency and content validity of the Survivorship Care Plan Treatment
Summary (SCP TS) that has been developed for use with lymphoma cancer
survivors.
If you have any questions before or after you have completed this
questionnaire,

please

contact

Karen

Taylor

0428

411

309

or

Karen.Taylor@health.wa.gov.au
Please read the following directions carefully and fill in all sections of the
table.
Your participation in this part of my research project is invaluable and greatly
appreciated.
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Evaluation of the Survivorship Care Plan Treatment Summary (SCP TS)
The components of this questionnaire will be scored as either a Yes/No
answer or on a 4-point Likert-type scoring scale:
1. Clarity - refers to whether each item is clearly defined – Y = yes or N =
no
2a. Apparent internal consistency – refers to whether each item belongs
in the SCPTS – Y = yes or N = no
2b. Apparent internal consistency – refers to whether each item generally
belongs within the SCPTS – Y = yes or N = no
3. Content validity index – refers to the level of relevance each item has
when assessing the question inclusion for the SCPTS.
Please score in this column according to the following 4-point Likert-type
scoring scale
Not
Relevant=1

Somewhat
Relevant=2

Quite
Relevant=3

Highly
Relevant=4

The tables are divided into three sections:


Table 1 refers to the Survivorship Care Plan section



Table 2 refers to the Treatment Summary section



Table 3 refers to the General Health and Screening section

Please look at the section each table refers to and use the following table to
assess each item.
Please add any comments/suggestions in the box provided.
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Table 1 Survivorship Care Plan
Content

1. Is this
heading/infor
mation clear?
Y/N

2a. Should
this
information
be included
in a
survivorship
care plan?
Y/N

2b. Does this
information
generally fit
with the other
information
Y/N

3. How
relevant is
this
information
for a
survivorship
care plan?
Score
between 1-4

Please indicate
whether you are:
Lymphoma
Survivor (LS);
GP (GP);
Haematologist
(H) or Nurse (N)

Comments

Possible late effect
column
Follow-up
recommended
Discussion notes
My main health
concerns
My main health
goals
Haematologist
details
Survivorship
coordinator details
GP details
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Table 2 Treatment Summary
Information

1. Is this
information
clear?
Y/N

2a. Should
this
information
be included
in a treatment
summary?

2b. Does this
information
generally fit
with the other
information?
Y/N

Y/N

3. How
relevant is
this
information
for a
treatment
summary?
Score
between 1-4

Please indicate
whether you are:
Lymphoma
Survivor (LS);
GP (GP);
Haematologist
(H) or Nurse (N)

Comments

Date of diagnosis
Age at diagnosis
New or relapse
Subtype
Location of disease
Extra-nodal sites
Major co-morbid
conditions
Goal of treatment
Chemotherapy
regimen
Clinical trial
Chemotherapy
start date
Chemotherapy end
date
Number of cycles
planned
Number of cycles
given
Reasons for
stopping
Planned
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maintenance
Blood product
support
Toxicities
Major side-effects
Current sideeffects
Treatment drug
summary
Radiotherapy start
date
Radiotherapy end
date
Region treated
Dose
Response
Contact details
Stem cell
transplant
Allied health
providers
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Table 3 General Health and Screening
Information

1. Is this
information
clear?
Y/N

2a. Should
this
information
be included
in general
health and
screening?
Y/N

2b. Does this
information
generally fit
with the other
information?
Y/N

3. How
relevant is
this
information
for general
health and
screening?

Please indicate
whether you are:
Lymphoma
Survivor (LS);
GP (GP);
Haematologist
(H) or Nurse (N)

Comments

Score
between 1-4

New symptoms to
watch for
Possible effects of
treatment
Staying healthy table
Diet
Exercise
Sun Smart
Weight
Alcohol
Smoking
Screening
Mental health
Resources
General screening
recommendations
Thank You for taking the time to fill in this questionnaire
Your contribution will assist in improving patient services/outcome
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Appendix G
Control Group Letter

Sir Charles Gairdner Hospital
Haematology Clinic

[Date]

Dear [insert name],
Nurse-led Lymphoma Survivorship Trial
You have agreed to be part of a study to test the effect of a nurse-led
lymphoma survivorship clinic against the usual standard of follow-up care.
As part of your commitment to this research, we are asking you to fill in the
same 4 questionnaires you did 3 months ago and return them in the provided
reply-paid envelope. We would ask you to do this as soon as possible after
receiving them.
We appreciate your participation as your commitment to this research will
assist in the development of survivorship services in Western Australia.
If you have any questions or would like further information then please do not
hesitate to contact me on 0428 411 309.
Yours sincerely

Karen Taylor
Survivorship Cancer Nurse Coordinator
PhD Candidate
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Appendix H
GP Letters and Evaluation
H.1 GP cover letter for SCPTS

Sir Charles Gairdner Hospital
Haematology Clinic

[Date]

Dear Doctor [insert name]
Lymphoma Survivorship Trial
Your patient, [insert name] s participating in a randomised controlled trial to test the effect of
a nurse-led lymphoma survivorship clinic against the usual standard of follow-up care. This
clinic is for lymphoma patients who have finished their chemotherapy treatment. As part of
this clinic intervention a “Survivorship Care Plan & Treatment Summary” has been
developed in conjunction with the Consulting Haematologist, the patient and myself.
Survivorship care plans and treatment summaries have been proposed as a way to improve
communication between clinicians and the patient. Cancer patients treated with
chemotherapy may be at increased risk of certain health problems. The purpose of this
document is to:
 summarise the treatment given;
 list possible current and late effects of treatment and recommended follow-up;
 identify the patient’s major health concerns and goals; and
 provide general health information to promote wellness.
The patient may make an appointment to meet with you to discuss their recommended
follow-up care.
If you have any urgent clinical concerns these should be directed to the Haematology
Department at SCGH who will continue to follow up this patient and send their usual clinic
letter documentation.
EviQ can be accessed to provide further up to date, evidence-based cancer treatment
information. Free access is available at: www.eviq.org.au. Username: phc. Password: phc.
As part of the assessment of this Survivorship Care Plan & Treatment Summary, an
evaluation form will be sent to you in six months to gauge your use of the Survivorship Care
Plan & Treatment Summary, and your thoughts on its usefulness.
If you have any questions or would like further information about this survivorship study,
please do not hesitate to contact me.
Yours sincerely

Karen Taylor
Survivorship Cancer Nurse Coordinator/PhD Candidate
Karen.Taylor@health.wa.gov.au
0428 411 309
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H.2 GP Cover Letter for Evaluation

Sir Charles Gairdner Hospital
Haematology Clinic

[Date]

Dear Doctor [insert name]
Lymphoma Survivorship Trial
Your patient [insert name] has been part of a randomised controlled trial to
test the effect of a nurse-led lymphoma survivorship clinic against the usual
standard of follow-up care.
We would like your feedback as to whether the information we provided in
the Survivorship Care Plan & Treatment Summary has been helpful to you. A
plan for this patient should have been posted to you six months ago when the
patient commenced in the trial. A copy has been attached with this letter.
Please complete the attached questionnaire and return in the provided replypaid envelope. Alternatively, it can be faxed back “Attention Karen Taylor
Survivorship CNC” to 6457 4432 or scanned to the email address below.
We appreciate all the information that you are able to give as this will assist
in the evaluation of survivorship services.
If you have any questions or would like further information then please do not
hesitate to contact me.
Yours sincerely

Karen Taylor
Survivorship Cancer Nurse Coordinator
PhD Candidate
Karen.Taylor@health.wa.gov.au
0428 411 309
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H.3 GP Evaluation of SCPTS
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Appendix I
Interview Questions
Interview guide for patient participants
Thank you for volunteering for this interview and for participating in the
survivorship study. I would like to talk to you about your experience of the
survivorship clinic and record your thoughts about this and any suggestions
you may have to improve the experience for future patients. As you may be
aware, the study involves a ‘nurse-led cancer survivorship clinic’ – something
that hasn’t been offered to cancer patients before. The study was focusing on
the development and testing of this new form of cancer survivorship or followup care after treatment has finished.
From your perspective what are your thoughts about
questionnaires you were asked to complete at each clinic visit?

the

1. Did you have any concerns or needs that weren’t addressed by any of the
questions?
- if yes, can you please tell me what these were?
2. The time it took to answer all the questions?
3. Did you think any questions were too intrusive?
We are hoping survivorship care will become routine for all cancer
patients when they finish treatment at the hospital. As you know at the
moment the survivorship clinic is offered after all treatment is
completed.
4. Would you have preferred to know about this clinic after diagnosis or
earlier in the treatment phase?
- would this have helped you think beyond the treatment phase
to what
comes after treatment finishes?
- why do you feel this way, can you explain?
5. What aspects of the clinic would you want to stay the same for other
cancer patients in the future?
6. Can you please describe the difference (if any) this clinic has made for you
after finishing your treatment phase?
6.1 What do you consider the best part of coming?
6.2 Were there are any downsides to coming?
6.3 If you could change anything about the clinic, what would you
change?
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7. Would you recommend the clinic for other patients who are about to finish
treatment?
- why or why not?
Now I would like to ask some questions on your thoughts of the
survivorship care plan and treatment summary you received. This is the
document Karen gave you.
8. Did you find the treatment summary section a helpful summary of your
diagnosis and treatment? (This is page 1)
- would you like to see more information on that part?
- did you feel any information was not explained enough or
difficult to
understand?
9. What were your thoughts and reactions to the potential late effects
information you were given? (These are on the first page under the treatment
summary).
- were they as you expected?
- did they add to your worry about the cancer treatment?
- had this information been given to you before by your
doctors?
10. How did you feel about having the health concerns, goals and actions
individualised to yourself? (This was the second page).
- did you find it useful to explore your needs in this way?
- were you concerned this information would be shared with
your medical team?
11. Do you have any thoughts on the general health and screening
information? (This was the 2 page sheet).
- did you find it useful?
- were there parts you found more useful than others?
12. Did you discuss the survivorship care plan and treatment summary with
your GP?
- did they have any thoughts on this document they shared with
you?
13. Overall how useful was the survivorship care plan and treatment
summary to you?
Thank you for patience, these few questions relate to finding out about
the study.
14. Did your haematology Dr mention the study to you prior to the researcher
Karen contacting you?
14.1 Did your haematology Dr discuss the survivorship care plan and
treatment summary with you?
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Lastly these questions are about Karen’s nurse-led clinic – these are
not about the treatment clinic or Dr appointments.
From your perspective what are your thoughts about:
15. Its location? Would you have preferred to be away from the hospital?
16. The timing of the visit?
5.1 Do you have any thoughts about when the clinic should
commence?
- just before the last treatment?
- immediately after the last treatment?
- later than 3 months after treatment has completed?
17. The length of each clinic visit?
18. The information you were given?
- was it too much or too little?
- was the timing of the information right?
- how relevant was the information to you?
19. Do you have any other thoughts or issues to raise that we haven’t
discussed today?
I appreciate the time you have given today and your insights and
thoughts in relation to your experience. Thank you for agreeing to this
interview, and for your participation throughout

Intervention Participant Interview V8 10/6/2016
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Appendix J
J.1 Checklist for Nurse-led Lymphoma Survivorship Clinic
Appointment
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J.2 Motivational Chart
Motivational chart
Behaviour/Problem: LIKE

Stay the Same

List what you like about List what you don’t like
the behaviour

Change

DISLIKE

about the behaviour

List what you think will List what you think will
be better

be difficult
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Appendix K
K.1 SPIRIT Checklist for Protocol
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K.2 CONSORT Statement for Pragmatic RCT
CONSORT 2010 checklist of information to include when reporting a randomised trial
Item
Section/Topic

Reported

No

Checklist Item

on Page No

1a

Identification as a randomised trial in the title

1b

Structured summary of trial design, methods, results, and conclusions

Background

2a

Scientific background and explanation of rationale

and objectives

2b

Specific objectives or hypotheses

7

3a

Description of trial design (such as parallel, factorial) including allocation ratio

8

3b

Important changes to methods after trial commencement (such as eligibility criteria),

Title and abstract
i
11

Introduction
2-6

Methods
Trial design

NA

with reasons
Participants
Interventions

4a

Eligibility criteria for participants

131

4b

Settings and locations where the data were collected

131

5

The interventions for each group with sufficient details to allow replication, including

137-138

how and when they were actually administered
Outcomes

6a

Completely defined pre-specified primary and secondary outcome measures, including

127-128

how and when they were assessed
6b

Any changes to trial outcomes after the trial commenced, with reasons

NA

412

Sample size

7a

How sample size was determined

133

7b

When applicable, explanation of any interim analyses and stopping guidelines

NA

8a

Method used to generate the random allocation sequence

136

8b

Type of randomisation; details of any restriction (such as blocking and block size)

136

9

Mechanism used to implement the random allocation sequence (such as sequentially

136

Randomisation:
Sequence
generation
Allocation
concealment

numbered containers), describing any steps taken to conceal the sequence until

mechanism

interventions were assigned
10

Implementation
Blinding

Who generated the random allocation sequence, who enrolled participants, and who

136

assigned participants to interventions
11a

If done, who was blinded after assignment to interventions (for example, participants,

NA

care providers, those assessing outcomes) and how
11b

If relevant, description of the similarity of interventions

Statistical

12a

Statistical methods used to compare groups for primary and secondary outcomes

methods

12b

Methods for additional analyses, such as subgroup analyses and adjusted analyses

170

13a

For each group, the numbers of participants who were randomly assigned, received

149

146-148

Results
Participant flow
(a diagram is
strongly

intended treatment, and were analysed for the primary outcome
13b

For each group, losses and exclusions after randomisation, together with reasons

149

14a

Dates defining the periods of recruitment and follow-up

148

recommended)
Recruitment
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14b

Why the trial ended or was stopped

Baseline data

15

A table showing baseline demographic and clinical characteristics for each group

151-152

Numbers

16

For each group, number of participants (denominator) included in each analysis and

154-155

analysed
Outcomes and

148

whether the analysis was by original assigned groups
17a

estimation

For each primary and secondary outcome, results for each group, and the estimated

156-173

effect size and its precision (such as 95% confidence interval)
17b

For binary outcomes, presentation of both absolute and relative effect sizes is

156-173

recommended
Ancillary

18

analyses
Harms

Results of any other analyses performed, including subgroup analyses and adjusted

175-212

analyses, distinguishing pre-specified from exploratory
19

All important harms or unintended effects in each group

20

Trial limitations, addressing sources of potential bias, imprecision, and, if relevant,

NA

Discussion
Limitations

234-237

multiplicity of analyses
Generalisability

21

Generalisability (external validity, applicability) of the trial findings

Interpretation

22

Interpretation consistent with results, balancing benefits and harms, and considering

223
223-232

other relevant evidence
Other information
Registration

23

Registration number and name of trial registry

Protocol

24

Where the full trial protocol can be accessed, if available

Funding

25

Sources of funding and other support (such as supply of drugs), role of funders

122
122-143
xxii

414

APPENDICES

Appendix L
Quantitative Analysis Tables
23Table 1 Reliability of Assessment Measures
Measure Domain

SFSUNS

Information (3 items)

Original
study
Cronbach’s
alpha
0.85a

Current study Cronbach’s
alpha
Time 1 Time 2
Time 3
N=60
N=59
N=58
0.70

0.80

0.82

Financial Concerns (8
0.90a
0.74
0.90
0.88
items)
Access and Continuity of
0.90a
0.89
0.85
0.88
Care (6 items)
Relationships and
0.95a
0.92
0.96
0.96
emotional health (13 items)
DASS21 Depression (7 items)
0.94b
0.90
0.93
0.92
b
Anxiety (7 items)
0.87
0.79
0.79
0.83
Stress (7 items)
0.91b
0.86
0.94
0.92
c
MiniHelplessness/Hopelessness
0.87
0.89
0.87
0.90
MAC
(8 items)
Anxious Preoccupation (8
0.88c
0.87
0.88
0.92
items)
Fatalism (5 items)
0.62c
0.62
0.61
0.68
c
Fighting Spirit (4 items)
0.76
0.61
0.59
0.58
Cognitive Avoidance (4
0.74c
0.82
0.85
0.89
items)
PES
15 items
0.93d,e
0.75
0.79
079
a Campbell et al. (2014); b Antony et al. (1998); c Watson et al. (1994); d Bulsara, Styles,
Ward, and Bulsara (2006); e Pearson’s Separation Index (Cronbach’s alpha
equivalent)
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24Table 2 Intervention Group Wilcoxon Signed Rank Test
Measure
SF-SUNS
Time 1 –
Time 2 Total scale scores

Mean (SD)
Median

Wilcoxon Effect
Signed Rank
Size

27.33 (20.63) 18.50
26.27 (22.81) 22.00

z -0.35 p .726

r .05

Time 1 –
Time 2 Information

2.97 (3.18) 2.50
2.33 (2.00) 2.00

z -1.12 p .262

r .15

Time 1 –
Time 2 Financial concerns

6.70 (5.93) 6.50
7.63 (7.58) 6.00

z -0.10 p .923

r .01

Time 1 –
Time 2 Access and continuity of care

3.97 (5.88) 1.50
2.24 (3.43) 0

z -1.69 p .090

r .22

Time 1 –
Time 2 Relationships and emotional health

13.70 (10.87) 12.50
13.90 (12.75) 11.50

z -0.19 p .846

r .03

Time 1 Time 3 Total scale scores

27.33 (20.63) 18.50
21.41 (22.95) 16.00

z -2.15 p .031

r .28

Time 1 –
Time 3 Information

2.97 (3.18) 2.50
1.97 (2.34) 2.00

z -1.37 p .169

r .18

Time 1 –
Time 3 Financial Concerns

6.70 (5.93) 6.50
5.76 (6.36) 4.00

z -1.71 p .088

r .22

Time 1 –
Time 3 Access and continuity of care

3.97 (5.88) 1.50
2.24 4.75) 0

z -2.31 p .021

r .30

13.70 (10.87) 12.50
11.45 (12.28) 8.00

z -1.69 p .091

r .22

12.67 (12.01) 10.00
15.63 (15.61) 9.50

z -1.24 p .214

r .16

Time 1 –
Time 2 Depression

4.03 (4.75) 2.00
5.30 (5.78) 2.50

z -1.14 p .255

r .15

Time 1 –
Time 2 Anxiety

3.47 (3.36) 3.00
3.53 (3.67) 3.00

z -0.08 p .940

r .01

Time 1 –
Time 2 Stress

5.17 (5.05) 4.00
6.80 (6.97) 4.50

z -1.62 p .106

r .21

Time 1 –
Time 3 Relationships and emotional health
DASS21
Time 1 –
Time 2 Total scale scores
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Time 1Time 3 Total scale scores

12.67 (12.01) 10.00
15.61 (13.40) 8.00

z -0.03 p .976

r .004

Time 1 –
Time 3 Depression

4.03 (4.75) 2.00
4.14 (5.38) 1.00

z -0.05 p .957

r .006

Time 1 –
Time 3 Anxiety

3.47 (3.36) 3.00
3.45 (3.93) 2.00

z -0.05 p .961

r .006

Time 1 –
Time 3 Stress
Mini-MAC
Time 1 –
Time 2 Total scale scores

5.17 (5.05) 4.00
5.66 (5.75) 4.00

z -0.42 p .675

r .05

65.30 (12.62) 64.50
64.27 (13.44) 63.50

z -0.64 p .524

r .08

Time 1 –
Time 2 Fatalism

14.13 (3.03) 14.00
14.30 (2.81) 14.00

z -0.35 p .732

r .05

Time 1 –
Time 2 Fighting Spirit

12.40 (2.59) 13.00
11.33 (2.32) 11.00

z -2.60 p .009

r .34

Time 1 –
Time 2 Helplessness/Hopelessness

12.77 (4.88) 11.50
12.83 (4.79) 12.50

z -0.04 p .969

r .08

Time 1 –
Time 2 Anxious preoccupation

17.27 (5.84) 16.00
17 (6.07) 16.50

z -0.41 p .686

r .05

8.73 (3.17) 8.50
8.80 (3.26) 9.00

z -0.17 p .865

r .02

65.30 (12.62) 64.50
62.59 (15.03) 64

z -1.17 p .241

r .15

Time 1 –
Time 3 Fatalism

14.13 (3.03) 14.00
13.76 (3.44) 14.00

z -1.11 p .266

r .14

Time 1 –
Time 3 Fighting Spirit

12.40 (2.59) 13.00
11.55 (2.43) 12.00

z -1.80 p .073

r .23

Time 1 –
Time 3 Helplessness/Hopelessness

12.77 (4.88) 11.50
12 (4.74) 9.00

z -1.31 p .190

r .17

Time 1 –
Time 3 Anxious preoccupation

17.27 (5.84) 16.00
16.76 (6.34) 17

z -0.50 p .616

r .07

8.73 (3.17) 8.50

z -0.59 p .556

r .08

Time 1 –
Time 2 Cognitive avoidance
Time 1 Time 3 Total scale scores

Time 1 –
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Time 3 Cognitive avoidance
PES
Time 1 –
Time 2

8.52 (3.94) 8.00
48.33 (5.11) 48.50
49.50 (5.63) 50.50

z -1.16 p .246

r .15

Time 1 –
48.33 (5.11) 48.50
z -1.78 p .075
Time 3
50.21 (5.63) 52.00
Note. Significance level 0.05 (2-tailed); Effect size: 0.2=small effect, 0.5=moderate
effect, 0.8=large effect

r .23

25Table 3 Linear Mixed Model Results of SF-SUNS Total Scale
P
95% Confidence
Interval
Value
Lower
Upper
Intercept
35.79
8.93
17.91
53.67
.000
Group—Controla
–3.61
6.02
–15.67
8.45
.551
b
Lymphoma (NHL)
13.82
7.32
–0.85
28.50
.064
Genderc (Male)
–11.39
5.97
–23.35
0.56
.061
Time 1d
3.46
2.09
–0.68
7.59
.101
d
Time 2
3.79
2.09
–0.35
7.93
.072
Age
–0.27
0.16
–0.60
0.06
.109
a
b
Note. Comparison group set to zero (Intervention); Comparison group set to zero (HL);
c Comparison group set to zero (Female); d Comparison group set to zero (Time 3)
Variable

Beta
Estimate

Std.
Error
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26Table 4 Linear Mixed Model Results of Mini-MAC Domains
Variable

Beta
Estimate

Std.
Error

95% Confidence
Interval
Lower Upper

P
Value

Helplessness/Hopelessness Domain
Intercept
14.18
1.74
10.70
17.67
.000
a
Group—Control
–0.67
1.17
–3.00
1.68
.571
Lymphomab (NHL)
0.11
1.42
–2.74
2.96
.938
c
Gender (Male)
–1.97
1.16
–4.29
0.35
.094
Time 1d
0.36
0.49
–0.62
1.34
.465
Time 2d
0.43
0.49
–0.55
1.41
.383
Age
–0.01
0.03
–0.07
0.05
.735
Anxious Preoccupation Domain
Intercept
20.40
2.28
15.84
24.96
.000
a
Group—Control
1.33
1.54
–1.75
4.42
.389
Lymphomab (NHL)
–0.73
1.87
–4.48
3.02
.698
c
Gender (Male)
–2.05
1.52
–5.10
1.01
.185
Time 1d
0.96
0.49
–0.02
1.93
.055
Time 2d
0.38
0.49
–0.60
1.36
.440
Age
–0.04
0.04
–0.12
0.05
.360
Cognitive Avoidance Domain
Intercept
10.71
1.22
8.28
13.15
.000
Group—Controla
1.19
0.81
–0.44
2.82
.150
Lymphomab (NHL)
–0.38
0.99
–2.37
1.60
.700
c
Gender (Male)
–1.22
0.81
–2.84
0.40
.137
Time 1d
–0.09
0.36
–0.81
0.63
.802
Time 2d
0.30
0.36
–0.42
1.02
.409
Age
–0.02
0.02
–0.06
0.03
.387
Note. a Comparison group set to zero (Intervention); b Comparison group set to zero (HL);
c Comparison group set to zero (Female); d Comparison group set to zero (Time 3)
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27Table 5 Descriptive Data of the Multi-item Measures by Group at Each Time Point and Between Time Points
6 Months (Time 3)#

Time differences^

P value
(Cohen's d)

Control
Group*

Intervention
Group*

P value

26.53
(21.84)

27.33
(20.63)

.885
(-.04)

28.62
(27.82)

26.27
(22.81)

.723
(.09)

25.72
(25.99)

21.41
(22.95)

.506
(.18)

t (28) -0.46
p .648

t (29) 0.39 p
.698

t (28) 0.32
p .753

t (28) 1.99 p
.057

Information

3.30
(2.58)

2.97
(3.18)

.657
(.12)

3.21
(3.29)

2.33
(2.01)

.221
(.27)

2.76
(2.82)

1.97
(2.34)

.249
(.31)

t (28) 0.43
p 0.673

t (29) 1.20 p
.240

t (28) 1.36
p .185

t (28) 1.52 p
.139

Financial
concerns

7.03
(6.13)

6.70
(5.93)

.831
(.05)

6.38
(8.38)

7.63
(7.58)

.549
(-.16)

6.28
(7.77)

5.76
(6.36)

.782
(.07)

t (28) 0.62
p .538

t (29) -0.89 p
.383

t (28) 0.68
p .505

t (28) 1.02 p
.317

Access and
continuity of
care

2.60
(4.35)

3.97
(5.88)

.310
(.27)

3.28
(4.32)

2.40
(3.43)

.391
(.23)

2.34
(2.87)

2.24
(4.75)

.920
(.03)

t (28) -0.98
p .338

t (29) 1.88 p
.070

t (28) 0.34
p .737

t (28) 2.47 p
.020

Relationships
and emotional
health

13.60
(11.51)

13.70
(10.87)

.973
(.01)

15.76
(13.79)

13.90
(12.75)

.593
(.14)

14.34
(14.10)

11.45
(12.28)

.408
(.22)

t (28) -0.93
p .361

t (29) -0.19 p
.907

t (28) -0.22
p .826

t (28) 1.32 p
0.199

DASS21b

15.57
(13.91)

12.67
(12.01)

.391
(.22)

14.17
(13.67)

15.63
(15.61)

.704
(-.10)

15.14
(13.76)

13.03
(13.40)

.558
(.16)

t (28) 0.75
p .462

t (29)=-1.53 p
.136

t (28) 0.24
p .812

t (28) - 0.19 p
.853

Depression

4.33
(5.37)

4.03
(4.75)

.819
(.06)

4.59
(5.44)

5.30
(5.78)

.627
(-.13)

4.83
(5.56)

4.14
(5.38)

.633
(.13)

t (28) -0.28
p 0.79

t (29)=-1.58 p
0.13

t (28) -0.58
p 0.57

t (28) -0.06 p
0.95

Anxiety

4.60
(5.05)

3.47
(3.36)

.310
(.27)

3.63
(4.18)

3.53
(3.67)

.932
(.02)

3.55
(3.95)

3.45
(3.93)

.921
(.03)

t (28) 1.22
p .232

t (29) -0.14 p
.888

t (28) 1.38
p .179

t (28) -0.06 p
.892

6.63

5.17

.270

5.97

6.80

.617

6.76

5.66

.471

t (28) 0.67

t (29) -1.85 p

t (28) -0.22

t (28) -0.65 p

SF-SUNSa

Stress

(Cohen's d)

Intervention
Group*

Time 1 – Time 3

Control
Group*

Time 1 – Time 2

P value
(Cohen's d)

3 months (Time 2)#

Intervention
Group*

Baseline (Time 1)#
Control
Group*

Measure

Control

Intervention

Control

Intervention
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(5.15)

(5.05)

(.29)

(5.69)

(6.97)

(-.13)

(5.82)

(5.75)

(.19)

p .510

.074

p .825

.522

68.47
(12.74)

65.30
(12.62)

.337
(.25)

67.72
(15.22)

64.27
(13.44)

.359
(.24)

65.38
(15.52)

62.59
(15.03)

.489
(.18)

t (28) 0.51
p .614

t (29)=0.61 p
.547

t (28) 1.81
p .081

t (28) 1.35 p
.188

Fatalism

14.27
(3.29)

14.13
(3.03)

.871
(.04)

13.79
(3.58)

14.30
(2.81)

.547
(-.16)

13.28
(3.56)

13.76
(3.44)

.603
(-.14)

t (28) 0.80
p .428

t (29) -0.39 p
.701

t (28) 1.94
p .062

t (28) 1.13 p
.267

Fighting spirit

12.47
(2.13)

12.40
(2.59)

.914
(.03)

12.07
(2.61)

11.33
(2.32)

.257
(.30)

11.24
(2.91)

11.55
(2.43)

.661
(-.12)

t (28) 0.96
p .345

t (29) 2.80 p
.009

t (28) 3.50
p .002

t (28) 2.13 p
.042

Helplessness/h
opelessness

12.47
(4.31)

12.77
(4.88)

.802
(-.07)

12.66
(4.76)

12.83
(4.79)

.887
(-.03)

12.62
(4.41)

12.00
(4.74)

.608
(.14)

t (28) -0.04
p .968

t (29) 1.11 p
.909

t (28) 0.00
p 1.00

t (28) 1.39 p
.176

Anxious
preoccupation

19.47
(5.34)

17.27
(5.84)

.133
(.40)

18.66
(5.68)

17.00
(6.07)

.284
(.28)

18.10
(6.14)

16.76
(6.34)

.415
(.22)

t (28) 1.46
p .154

t (29) 0.33 p
.742

t (28) 2.20
p .037

t (28) 0.65 p
.521

Cognitive
avoidance

9.80
(3.13)

8.73
(3.17)

.195
(.03)

10.55
(3.25)

8.80
(3.26)

.043
(.54)

10.14
(3.06)

8.52
(3.94)

.086
(.46)

t (28) -1.68
p .105

t (29) -0.14 p
.888

t (28) -0.73
p .474

t (28) 0.16 p
.876

PESd

48.77
(6.03)

48.33
(5.11)

.765
(.80)

45.79
(5.85)

49.50
(5.63)

.016
(-.65)

47.21
(6.07)

50.21
(5.63)

.056
(-.50)

t (28) 3.06
p .005

t (29) -1.45 p
.158

t (28) 1.41
p .170

t (28) -1.97 p
.059

Mini-MAC

s

Note. *Data given as mean (SD); Bolded p value indicates statistical significance p<.05; # Independent T-test results; ^ Paired-sample T-test results; aHigher
scores represent higher levels of need; bHigher scores represent higher levels of psychological need; cHigher scores represent more endorsement of the domain
trait; dHigher scores represent more empowerment; SF-SUNS: Short-Form Survivor Unmet Needs Survey; DASS21: Depression, Anxiety Stress Scale; MiniMAC: Mental Adjustment to Cancer Scale; PES: Patient Empowerment Scale; Cohen’s d: 0.2=small effect, 0.5=moderate effect, 0.8=large effect
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28Table 6 Age Differences Across Measures at Each Time Point within the Control and Intervention Groups
Control Group
Measure

Age Group 1

Age Group 2

Age Group 3

18–29 years

30–59 years

>60 years

N=5

N=14

N=11

Mean(SD)
Median

Mean(SD)
Median

Mean(SD)
Median

17 (9.25) 18

36.36 (25.49) 25.5

18.36 (15.84) 13

2 (2.35) 1

4.57 (2.44) 4

Financial concerns

2.60 (2.07) 3

Access and continuity of
care

Group
Comparison*

Intervention Group
Age Group 1

Age Group 2

Age Group 3

Group
Comparison*

18–29 years

30–59 years

>60 years

N=8

N=12

N=10

Mean(SD)
Median

Mean(SD)
Median

Mean(SD)
Median

X2 8.31, p .016

30.50 (14.37) 34

28.75 (27.11) 15

23.10 (16.75) 18

X2 1.06, p .587

2.27 (2.24) 2

X2 5.47, p .065

4.13 (3.40) 4

3.17 (3.71) 1.5

1.80 (1.99) 1.5

X2 1.94, p .380

9.93 (7.05) 9

5.36 (4.23) 6

X 7.88, p .019

6 (3.34) 7

7.42 (8.57) 5

6.40 (3.69) 5

X2 0.57, p .751

0.80 (0.84) 1

4.57 (5.75) 2.5

0.91 (1.22) 1

X2 8.89, p .012

3.88 (3.14) 3.5

5.42 (8.30) 2

2.30 (3.71) 1

X2 1.78, p .411

11.60 (7.83) 12

17.29 (13.02) 13.5

9.82 (10.14) 5

X2 5.16, p .076

16.50 (10.94) 16

12.75 (11.16) 13.5

12.60 (11.23) 9

X2 0.68, p .713

18.60 (8.26) 17

39.31 (33.92) 28

20.55 (22.08) 12

X2 2.81, p .245

22.50 (12.81) 22

36.17 (30.94) 28

17.40 (12.20) 16

X2 2.23, p .327

Information

2.20 (1.64) 3

4.15 (3.56) 3

2.55 (3.45) 0

X 2.13, p .344

2 (1.51) 2

2.75 (2.61) 3

2.10 (2.13) 2

X2 0.83, p .662

Financial concerns

3.20 (2.59) 3

9.23 (10.16) 5

4.45 (7.10) 2

X2 2.18, p .336

4.75 (2.87) 5.5

12.08 (10.15) 13.5

4.60 (2.99) 6

X2 2.58, p .275

1 (1.73) 0

4.92 (5.20) 3

2.36 (3.38) 1

X2 3.80, p .149

2.63 (2.97) 2

4.08 (4.19) 2.5

0.20 (0.83) 0

X2 8.88, p .012

12.20 (8.20) 13

21 (16.03) 16

11.18 (10.47) 10

X2 2.43, p .296

13.13 (8.71) 12

17.25 (16.89) 11

10.50 (9.38) 9

X2 0.66, p .717

17.60 (9.94) 20

36.69 (31.32) 22

16.45 (19.76) 7

X2 4.14, p .126

14.71 (11.19) 16

26.92 (31.18) 18.5

19.50 (16.95) 14

X2 0.48, p .787

2 (1.23) 2

3.85 (3.05) 4

1.82 (2.79) 0

X 3.69, p .158

0.71 (1.25) 0

2.17 (2.92) 1

2.60 (1.96) 3.5

X2 3.76, p .153

SF-SUNS Time 1
Total scale scores
Information

Relationships and
emotional health

2

SF-SUNS Time 2
Total Scale scores

Access and continuity of
care
Relationships and
emotional health

2

SF-SUNS Time 3
Total Scale scores
Information

2
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Financial concerns

3.20 (1.92) 4

9.46 (10.30) 5

3.91 (4.4) 3

X2 1.84, p .399

2.71 (2.69) 2

8.58 (8.91) 6

4.50 (2.07) 4

X2 2.04, p .361

1 (1.23) 1

3.85 (3.24) 4

1.18 (2.14) 0

X2 7.54, p .023

0.71 (1.50) 0

3.83 (6.99) 1

1.40 (1.71) 1

X2 1.84, p .399

11.40 (9.71) 11

19.54 (16.21) 15

9.55 (11.80) 4

X2 3.16, p .206

10.57 (7.83) 11

12.33 (14.46) 8.5

11 (13.07) 6.5

X2 0.33, p .847

10 (5.79) 9

18.79 (15.72) 13

14 (13.92) 10

X2 1.87, p .392

14.63 (10.03) 12.5

12 (14.14) 8

11.90 (11.74) 7.5

X2 1.84, p .398

Depression

2 (2.35) 1

5.50 (6.19) 2.5)

3.91 (5.19) 1

X2 1.61, p .446

3.75 (3.96) 2

3.67 (5.12) 1.5

4.70 (5.25) 3

X2 1.26, p .533

Anxiety

2 (2.45) 2

5.86 (5.64) 4.5

4.18 (4.94) 3

X 2.17, p .338

4 (3.42) 3

3.42 (3.73) 2

3.10 (3.14) 2.5

X2 0.63, p .732

Stress

6 (1.58) 6

7.43 (5.60) 6.5

5.91 (5.79) 5

X2 1.03, p .599

6.88 (5.14) 5.5

4.92 (5.81) 4

4.10 (4.04) 3

X2 2.98, p .226

11.80 (7.53) 9

17.15 (15.96) 11

11.73 (13.18) 5

X2 1.27, p .530

11.75 (12.90) 6

19.33 (19.76) 10

14.30 (12.05) 13.5

X2 0.58, p .749

Depression

2.40 (3.78) 1

6.38 (6.50) 5

3.45 (4.28) 1

X2 2.07, p .355

3.50 (3.82) 1.5

6.50 (7.44) 3

5.30 (4.88) 4

X2 1.002, p .606

Anxiety

2.20 (1.79) 2

4 (4.71) 2

3.82 (4.45) 1

X 0.24, p .885

2.63 (2.93) 2

4.33 (4.72) 3.5

3.30 (2.83) 3.5

X2 0.72, p .698

Stress

7.20 (3.27) 6

6.77 (6.34) 5

4.45 (5.84) 4

X2 2.70, p .259

5.63 (6.74) 3.5

8.50 (8.43) 5.5

5.70 (5.27) 5

X2 0.37, p .831

Total scale scores

8.60 (7.67) 6

17.62 (14.97) 12

15.18 (14.44) 12

X2 1.19, p .552

12.57 (8.85) 15

12.75 (16.97) 5.5

13.70 (12.40) 8

X2 1.14, p .566

Depression

1.20 (2.17) 0

6.46 (5.88) 4

4.55 (5.75) 2

X 4.67, p .097

3.57 (3.91) 3

3.42 (5.81) 1

5.40 (5.99) 4.5

X2 0.57, p .753

Anxiety

2.20 (2.28) 2

3.85 (3.98) 3

3.82 (4.65) 2

X2 0.38, p .826

2.43 (2.51) 2

3.5 (4.52) 1.5

4.10 (4.20) 3.5

X2 0.27, p .874

Stress

5.20 (4.15) 5

7.31 (6.63) 5

6.82 (5.81) 8

X2 0.35, p .841

6.71 (4.96) 8

5.92 (7.19) 2.5

4.60 (4.58) 3.5

X2 0.64, p .728

64 (7.28) 64

74.29 (13.30) 72.5

63.09 (11.42) 63

X2 6.45 p .040

69.75 (13.42) 72.5

62 (13.67) 64.5

65.70 (10.61) 62

X2 2.05, p .358

Fatalism

11.40 (1.95) 12

14.93 (3.29) 16

14.73 (3.29) 15

X 5.28, p .071

13.75 (2.32) 14

13.17 (3.04) 13

15.60 (3.20) 15.5

X2 3.65, p .162

Fighting spirit

12.60 (1.52) 13

12.71 (1.98) 13

12.09 (2.63) 13

X2 0.22, p .896

12.50 (2.45) 12.5

12.33 (3.20) 13.5

12.40 (2.12) 12.5

X2 0.09, p .958

11.40 (4.22) 9

13.5 (4.62) 14.5

11.64 (4.01) 10

X 1.59, p .451

14 (5.76) 12.5

12.33 (5.05) 11.5

12.30 (4.24) 11

X2 0.41, p .814

19.40 (2.07) 19

21.57 (5.14) 21.5

16.82 (5.71) 18

X2 4.67, p .097

19.75 (6.86) 20.5

16.42 (5.92) 15

16.30 (4.79) 16

X2 1.46, p .481

9.20 (1.92) 10

11.57 (2.77) 12

7.82 (2.86) 8

X 10.52, p .005

9.75 (2.87) 10

7.75 (2.30) 8

9.10 (4.15) 8.5

X2 2.71, p .258

Access and continuity of
care
Relationships and
emotional health
DASS21 Time 1
Total scale scores

2

DASS21 Time 2
Total scale scores

2

DASS21 Time 3
2

Mini-MAC Time 1
Total scale scores

Helplessness/hopelessness
Anxious preoccupation
Cognitive avoidance

2

2

2

Mini-MAC Time 2
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Total scale scores

58.4 (8.26) 59

76.69 (12.33) 77

61.36 (15.71) 63

X2 8.82, p .012

67.38 (13.79) 71.5

62.83 (14.22) 61.5

63.50 (13.24) 62.5

X2 0.84, p .657

Fatalism

10.20 (1.64) 11

14.08 (2.9) 14

15.09 (4.04) 16

X 7.07, p .029

13.88 (2.85) 14

13.50 (2.36) 13.5

15.60 (3.06) 15

X2 2.62, p .270

Fighting spirit

12.20 (2.68) 11

13.15 (1.95) 13

10.73 (2.83) 12

X2 4.67, p .097

11.63 (2.07) 11.50

11/17 (2.66) 11

11.30 (2.31) 11.5

X2 0.17, p .92

Helplessness/hopelessness

9.60 (2.61) 8

15.46 (4.24) 15

10.73 (4.50) 8

X2 9.08, p .011

13.25 (3.92) 14

13.42 (5.57) 12.5

11.80 (4.73) 9.5

X2 1.20, p .550

Anxious preoccupation

17 (2.83) 15

22 (4.28) 21

15.45 (6.17) 14

X 9.07, p .011

19.13 (6.92) 20

16.25 (6.14) 16.5

16.20 (5.47) 14.5

X2 1.14, p .567

Cognitive avoidance

9.40 (2.30) 9

12 (2.35) 12

9.36 (3.98) 10

X2 4.21, p .122

9.50 (2.73) 10/5

8.50 (3.37) 8.5

8.60 (3.75) 9

X2 1.25, p .536

55.20 (14.87) 61

73.69 (14.20) 73

60.18 (13.14) 57

X2 7.97, p .019

65.43 (14.97) 71

58.92 (18.41) 54.5

65 (10.41) 65.5

X2 1.55, p .461

Fatalism

10.20 (3.42) 11

13.85 (3.85) 15

14 (2.79) 14

X 4.42, p .110

13.14 (3.29) 13

12.75 (3.67) 14

15.40 (2.91) 15

X2 2.93, p .231

Fighting spirit

10.20 (4.27) 10

12 (1.87) 12

10.82 (3.28) 11

X2 1.43, p .489

12.29 (1.70) 13

11 (3.16) 11.5

11.70 (1.83) 11.5

X2 0.73, p .694

9.80 (2.05) 9

14.46 (3.80) 14

11.73 (5.12) 8

X 5.69, p .058

12.29 (5.02) 9

11.50 (5.32) 9

12.40 (4.22) 11

X2 0.83, p .659

16.20 (5.81) 17

21.69 (4.96) 22

14.73 (5.61) 15

X2 7.51, p .023

18.29 (7.18) 20

15.33 (7.30) 12

17.40 (4.53) 18

X2 1.72, p .422

8.80 (3.11) 9

11.69 (2.75) 12

8.91 (2.74) 9

X2 8.17, p .017

9.43 (3.65) 9

8.33 (4.46) 7.5

8.10 (3.78) 8

X2 0.53, p .767

PES Time 1

45.80 (3.49) 46

46.71 (5.37) 47

52.73 (5.95) 54

X 9.13, p .010

47 (4.90) 47

49.42 (4.72) 50

48.10 (5.92) 48.5

X2 0.99, p .610

PES Time 2

45.40 (4.93) 44

42.54 (5.30) 44

49.82 (4.54) 50

X2 8.97, p .011

49.13 (4.49) 49.5

49.17 (4.91) 49.5

50.20 (7.48) 51.5

X2 0.50, p .778

PES Time 3

46 (5.66) 44

44.31 (5.19) 45

51.18 (5.4) 51

X2 7.46, p .024

49.86 (5.11) 52

51.08 (4.81) 51.5

49.40 (7.14) 51

X2 0.33, p .849

2

2

Mini-MAC Time 3
Total scale scores

Helplessness/hopelessness
Anxious preoccupation
Cognitive avoidance

2

2

2

Note. *Kruskal–Wallis test results; Bolded p value indicates statistical significance p<.05
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29Table 7 Gender Differences Across Measures at Each Time Point within the Control and Intervention Groups
Control Group
Measure

Male

Female

N=12

N=18

Mean(SD)
Median

Mean(SD)
Median

17.42 (11.07) 17

32.61 (25.24) 24

2.25 (2.22) 2.5

Group
Comparison*

Intervention Group
Male

Female

Group
Comparison*

N=22

N=8

Mean(SD)
Median

Mean(SD)
Median

X2 4.49, p .034

23.64 (20.66) 16

37.50 (17.91) 41

X2 3.98, p .046

4 (2.61) 4

X2 3.24, p .072

2.73 (3.41) 1.5

3.63 (2.50) 4

X2 1.13, p .288

6.08 (4.27) 6

7.67 (7.15) 6

X 0.05, p .815

6.45 (6.47) 5

7.38 (4.37) 7

X2 1.03, p .310

Access and continuity of care

1.92 (1.93) 1.5

3.06 (5.42) 1

X2 0.06, p .811

3.68 (5.80) 1.5

4.75 (6.43) 2

X2 0.23, p .631

Relationships and emotional health

7.17 (4.63) 5.5

17.89 (12.79) 13

X2 8.09, p .004

10.77 (10.27) 7

21.75 (8.52) 21

X2 7.18, p .007

20.73 (20.42) 16

33.44 (31.05) 24.5

X2 1.37, p .242

25.27 (24.21) 20.5

29 (19.66) 26

X2 0.67, p .412

Information

2.27 (2.65) 2

3.78 (3.57) 3.5

X2 1.26, p .261

2.36 (2.04) 2.5

2.25 (2.05) 2

X2 0.03, p .867

Financial concerns

5.55 (7.33) 2

6.89 (9.13) 3.5

X2 0.12, p .733

7.73 (7.75) 6

7.38 (7.60) 6

X2 0.002, p .962

Access and continuity of care

2.36 (3.26) 2

2.5 (3.28) 1.5

X2 0.34, p .563

2.55 (3.46) 0.5

2 (3.55) 0

X2 0.29, p .593

10.55 (8.14) 10

18.94 (15.68) 13

X2 1.48, p .224

12.64 (13.93) 9.50

17.38 (8.55) 16.5

X2 3.02, p .082

17.82 (16.41) 15

30.56 (29.81) 21.5

X2 1.37, p .242

22.81 (25.90) 17

17.75 (12.99) 14

X2 0.001, p .981

Information

2.27 (2.15) 2

3.06 (3.19) 2

X2 0.17, p .678

2.52 (2.40) 2

0.50 (1.41) 0

X2 5.12, p .024

Financial concerns

5.18 (5.76) 3

6.94 (8.88) 4

X2 0.10, p .750

6.19 (7.11) 4

4.88 (3.98) 4.5

X2 0.01, p .922

Access and continuity of care

2.09 (2.17) 2

2.5 (3.28) 1.5

X2 0.002, p .963

2.38 (5.22) 1

1.88 (3.48) 0

X2 0.20, p .654

Relationships and emotional health

8.27 (7.53) 6

18.06 (15.99) 14

X2 2.71, p .100

11.81 (13.79) 8

10.50 (7.64) 8.5

X2 0.22, p .642

SF-SUNS Time 1
Total Scale scores
Information
Financial concerns

2

SF-SUNS Time 2
Total Scale scores

Relationships and emotional health
SF-SUNS Time 3
Total Scale scores

DASS21 Time 1
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Total scale scores

9.42 (5.38) 9

19.67 (16.33) 15.5

X2 1.96, p .161

11.14 (12.67) 7.5

16.88 (9.42) 16

X2 3.71, p .054

Depression

2.17 (3.54) 1

5.78 (5.97) 2.5

X2 4.27, p .039

3.59 (5.08) 1.5

5.25 (3.69) 4

X2 3.25, p .072

Anxiety

2.33 (1.67) 2

6.11 (5.97) 5

X2 2.31, p .128

3.05 (3.30) 2.5

4.63 (3.46) 3.5

X2 2.10, p .147

Stress

4.92 (2.84) 5

7.78 (6.04) 6.5

X2 1.53, p .217

4.50 (4.98) 3.5

7 (5.07) 5.5

X2 3.14, p .077

Total scale scores

6.36 (6.20) 5

18.64 (14.89) 16

X2 5.27, p .022

13.95 (16.07) 8.5

20.25 (14.19) 22

X2 1.61, p .205

Depression

1.64 (2.54) 0

6.39 (5.98) 6

X2 5.77, p .016

4.82 (6.10) 2

6.63 (4.90) 8.5

X2 1.18, p .277

Anxiety

1.36 (1.50) 1

5 (4.70) 3.5

X 5.70, p .017

3.23 (3.88) 2

4.38 (3.11) 4

X2 1.41, p .235

Stress

3.36 (3.01) 4

7.56 (6.40) 6.5

X2 3.22, p .073

5.91 (6.64) 4

9.25 (7.70) 7

X2 1.50, p .220

Total scale scores

8.82 (7.14) 6

19 (15.50) 17

X2 2.48, p .115

12.86 (14.53) 8

13.50 (10.69) 16.5

X2 0.24, p .625

Depression

2.55 (3.08) 2

6.22 (6.32) 4

X2 1.68, p .195

4.43 (5.69) 2

3.38 (4.72) 0.5

X2 0.36, p .546

Anxiety

1.64 (1.50) 1

4.72 (4.54) 4

X2 2.41, p .121

3.10 (3.83) 2

4.37 (4.31) 4

X2 0.46, p .498

Stress

4.64 (3.41) 4

8.06 (6.66) 9.5

X2 1.12, p .289

5.52 (6.22) 3

6 (4.63) 5.5

X2 0.32, p .572

65.83 (10.21) 64.5

70.22 (14.19) 69.5

X2 1.04, p .309

63.41 (13.50) 62

70.50 (8.40) 71.5

X2 2.26, p .133

14.67 (3.09) 15.5

14 (3.48) 14.5

X2 0.28, p .594

13.55 (2.96) 13.5

15.75 (2.77) 16

X2 3.30, p .069

Fighting spirit

12.83 (1.53) 13

12.22 (2.46) 12.5

X 0.36, p .549

12.32 (2.64) 13

12.63 (2.62) 13

X2 0.05, p .832

Helplessness/hopelessness

11.33 (3.68) 10

13.22 (4.62) 15.5

X2 1.23, p .267

12.18 (4.97) 10.5

14.38 (4.53) 12.5

X2 2.30, p .130

Anxious preoccupation

18.08 (4.50) 19

20.39 (5.76) 20.5

X2 1.63, p .201

16.91 (6.14) 16

18.25 (5.15) 18.5

X2 0.60, p .437

8.92 (3.0) 9.5

10.39 (3.17) 11

X2 1.43, p .232

8.45 (3.10) 9

9.50 (3.46) 8

X2 0.11, p .739

64.64 (14.42) 64

69.61 (15.79) 67.5

X2 0.66, p .418

62.86 (13.65) 61.5

68.13 (12.91) 73

X2 1.32, p .250

Fatalism

14.36 (4.37) 15

13.44 (3.09) 14

X2 0.70, p .403

13.82 (2.54) 14

15.63 (3.25) 16.5

X2 2.49, p .114

Fighting spirit

12.36 (2.58) 12

11.89 (2.68) 12

X2 0.17, p .683

11.55 (2.15) 11.5

10.75 (2.82) 11

X2 0.44, p .508

Helplessness/hopelessness

11.36 (4.06) 10

13.44 (5.09) 14

X2 1.35, p .246

12.64 (4.95) 11.5

13.38 (4.60) 13.5

X2 0.27, p .602

DASS21 Time 2

2

DASS21 Time 3

Mini-MAC Time 1
Total scale scores
Fatalism

Cognitive avoidance

2

Mini-MAC Time 2
Total scale scores
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17 (4.90) 19

19.67 (6.02) 19.5

X2 1.17, p .279

16.41 (6.26) 15.5

18.63 (5.55) 21

X2 1.22, p .270

9.55 (3.45) 11

11.17 (3.05) 11

X2 0.99, p .319

8.45 (3.13) 8.5

9.75 (3.66) 10

X2 0.99, p .320

63.73 (12.66) 63

66.39 (17.31) 67.5

X2 0.55, p .458

60.33 (15.86) 61

68.50 (11.36) 71)

X2 1.87, p .171

Fatalism

14.45 (3.53) 15

12.56 (3.52) 12.5

X2 1.90, p .168

13.05 (3.31) 13

15.63 (3.25) 15.5

X2 2.87, p .090

Fighting spirit

12.27 (2.53) 12

10.61 (3.01) 10.5

X2 1.61, p .204

11.43 (2.62) 12

11.88 (1.96) 12.5

X2 0.06, p .806

10.55 (3.14) 9

13.89 (4.66) 13

X2 3.51, p .061

11.76 (4.80) 9

12.63 (4.84) 10

X2 0.76, p .383

Anxious preoccupation

16.27 (5.48) 17

19.22 (6.39) 20

X 1.23, p .268

16.33 (6.95) 15

17.88 (4.55) 20

X2 0.96, p .327

Cognitive avoidance

10.18 (3.16) 11

10.11 (3.09) 10.50

X2 0.19, p .666

7.76 (3.53) 8

10.50 (4.50) 11

X2 2.65, p .104

PES Time 1

50.92(6.11) 51.5

47.33(5.69) 47

X2 2.81, p .094

48.86 (5.43) 51

46.87 (4.05) 48

X2 1.72, p .279

PES Time 2

48.55(5.63) 48

44.11(5.46) 44

X2 4.40, p .036

49.41 (5.37) 49.5

49.75 (6.67) 52.5

X2 0.43, p .510

PES Time 3

47.73(6.07) 47

46.89(6.23) 46.5

X2 0.13, p .718

50.29 (4.98) 51

50 (7.46) 52.5

X2 0.05, p .825

Anxious preoccupation
Cognitive avoidance
Mini-MAC Time 3
Total scale scores

Helplessness/hopelessness

2

Note. *Kruskal–Wallis test results; Bolded p value indicates statistical significance p<.05
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30Table 8 Lymphoma Differences Across Measures at Each Time Point within the Control and Intervention Groups
Control Group
Measure

NHL

HL

N=24

N=6

Mean(SD)
Median

Mean(SD)
Median

28.17 (24.14) 23

20 (4.69) 18.5

3.38 (2.65) 3.5

Group
Comparison*

Intervention Group
NHL

HL

Group
Comparison*

N=18

N=12

Mean(SD)
Median

Mean(SD)
Median

X2 0.08, p .775

26.72 (23.56) 17.5

28.25 (16.21) 26

X2 0.55, p .459

3 (2.45) 3

X2 0.10, p .753

2.33 (3.33) 0

3.92 (2.81) 3

X2 3.28, p .070

7.92 (6.49) 7

3.5 (2.26) 4

X 3.12, p .077

7.22 (7.08) 5

5.92 (3.75) 7

X2 0.002, p .966

3 (4.78) 1.5

1 (0.89) 1

X2 0.92, p .339

4.61 (7.14) 1.5

3 (3.28) 1.5

X2 0.01, p .914

13.88 (12.68) 11.5

12.50 (5.21) 11.5

X2 0.11, p .735

12.56 (11.03) 10

15.42 (10.88) 13.5

X2 0.49, p .484

30.87 (30.71) 22

20 (8.44) 21

X2 0.003, p .957

28.72 (28.21) 19.5

22.58 (10.84) 23

X2 0.02, p .882

Information

3.48 (3.59) 2

2.17 (1.47) 2.5

X2 0.17, p .680

2.17 (2.15) 2

2.58 (1.83) 2.5

X2 0.45, p .504

Financial concerns

7.43 (9.12) 4

2.33 (1.63) 2

X2 1.50, p .220

9 (8.96) 6

5.58 (4.46) 6

X2 0.33, p .564

Access and continuity of care

3.87 (4.62) 3

1 (1.67) 0

X2 2.68, p .102

2.39 (3.87) 0

2.42 (2.81) 1

X2 0.06, p .800

16.09 (15.16) 11

14.50 (7.15) 14.5

X2 0.16, p .686

15.17 (15.11) 11

12 (8.33) 11.5

X2 0.01, p .916

27.17 (28.78) 18

20.17 (9.52) 22

X2 0.19, p .666

24.11 (27.51) 14.5

17 (12.38) 16

X2 0.06, p .805

Information

2.78 (3.10) 2

2.67 (1.51) 3

X2 0.28, p .600

2.28 (2.63) 2

1.45 (1.75) 0

X2 0.55, p .458

Financial concerns

7.22 (8.45) 4

2.67 (2.16) 3.5

X2 1.07, p .301

7.28 (7.40) 4.5

3.27 (3.00) 4

X2 2.04, p .154

Access and continuity of care

2.57 (3.12) 2

1.5 (1.52) 1.5

X2 0.20, p .654

3.06 (5.84) 1

0.91 (1.45) 0

X2 1.30, p .254

14.61 (15.36) 9

13.33 (8.62) 16

X2 0.14, p .705

11.50 (14.52) 7

11.36 (7.99) 11

X2 0.81, p .368

SF-SUNS Time 1
Total Scale scores
Information
Financial concerns
Access and continuity of care
Relationships and emotional health

2

SF-SUNS Time 2
Total Scale scores

Relationships and emotional health
SF-SUNS Time 3
Total Scale scores

Relationships and emotional health
DASS21 Time 1
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16.92 (15.12) 11

10.17 (5.19) 9

X2 0.69, p .405

12.72 (13.91) 8

12.58 (9.02) 11

X2 0.52, p .471

4.92 (5.81) 2

2 (2) 1

X2 0.12, p .732

4.56 (5.53) 2.5

3.25 (3.31) 2

X2 0.04, p .847

Anxiety

5.25 (5.34) 3.5

2 (2.53) 1

X2 1.93, p .164

3.11 (3.64) 1.5

4 (2.95) 3

X2 1.77, p .184

Stress

6.75 (5.72) 5.5

6.17 (1.72) 6

X2 0.08, p .774

5.06 (5.32) 4

5.33 (4.83) 5

X2 0.44, p .509

14.78 (14.95) 8

11.83 (7.39) 10

X2 0.11, p .746

18.11 (17.61) 10.5

11.92 (11.75) 7

X2 0.65, p .421

4.87 (5.83) 2

3.5 (3.73) 3

X2 0.19, p .661

6.28 (6.52) 3

3.83 (4.30) 1.5

X2 1.70, p .193

4 (4.57) 2

2.17 (1.60) 2

X 0.15, p .703

3.78 (4.22) 3

3.17 (2.79) 2.5

X2 0.00, p .983

5.91 (6.15) 4

6.17 (3.87) 5.5

X2 0.50, p .480

8.06 (7.60) 5.5

4.92 (5.68) 3.5

X2 0.69, p .406

16.78 (14.69) 12

8.83 (7.14) 9

X2 1.22, p .269

13.17 (15.57) 7

12.82 (9.53) 15

X2 0.25, p .620

5.39 (6.01) 2

2.67 (2.66) 2.5

X2 0.50, p .479

4.28 (6.21) 1

3.91 (3.91) 4

X2 0.04, p .835

4 (4.22) 3

1.83 (2.14) 1

X2 0.91, p .339

3.44 (4.29) 1.5

3.45 (3.47) 3

X2 0.16, p .694

7.39 (6.11) 7

4.33 (4.08) 3.5

X2 1.05, p .304

5.72 (6.34) 3.5

5.55 (4.91) 4

X2 0.00, p 1.00

68.96 (13.85) 69

66.5 (7.26) 68

X2 0.05, p .815

60.56 (12.65) 58

72.42 (8.98) 72.5

X2 6.90, p .009

15 (3.02) 16

11.33 (2.81) 12

X2 6.15, p .013

13.72 (3.20) 13.5

14.75 (2.77) 14

X2 0.76, p .383

12.79 (2.21) 13

11.17 (1.17) 11

X 3.56, p .059

12.06 (2.69) 12

12.92 (2.47) 13.5

X2 0.76, p .382

12.21 (4.48) 10.5

13.5 (3.67) 15

X2 0.52, p .472

11.94 (4.88) 10.5

14 (4.82) 12.5

X2 2.17, p .140

19.38 (5.90) 19

19.83 (2.14) 19

X2 0.00, p 1.00

15.17 (5.51) 13

20.42 (4.98) 20.5

X2 6.61, p .010

9.58 (3.28) 10

10.67 (2.50) 11.5

X2 1.45, p .229

7.67 (2.70) 8

10.33 (3.26) 10

X2 4.34, p .037

68.87 (16.04) 66

63.33 (11.73) 64

X2 0.57, p .451

62.44 (14.46) 61

67 (11.81) 70

X2 1.08, p .299

Fatalism

14.65 (3.33) 15

10.5 (2.59) 10

X2 6.62, p .010

14.17 (2.81) 14

14.50 (2.91) 15

X2 0.16, p .686

Fighting spirit

12.39 (2.76) 13

10.83 (1.47) 10.5

X2 3.03, p .082

11.44 (2.15) 11

11.17 (2.66) 11.5

X2 0.029, p .864

Helplessness/hopelessness

12.74 (5.07) 13

12.33 (3.67) 13

X2 0.003, p .956

12.44 (5.24) 11.5

13.42 (4.19) 14

X2 1.10, p .294

Total scale scores
Depression

DASS21 Time 2
Total scale scores
Depression
Anxiety
Stress

2

DASS21 Time 3
Total scale scores
Depression
Anxiety
Stress
Mini-MAC Time 1
Total scale scores
Fatalism
Fighting spirit
Helplessness/hopelessness
Anxious preoccupation
Cognitive avoidance

2

Mini-MAC Time 2
Total scale scores
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Anxious preoccupation

18.61 (6.24) 19

18.83 (3.06) 20

X2 0.06, p .808

16 (6.16) 15

18.50 (5.85) 17.5

X2 1.36, p .244

Cognitive avoidance

10.48 (3.46) 11

10.83 (2.48) 11.5

X2 0.03, p .871

8.39 (3.20) 9

9.42 (3.40) 9.5

X2 0.77, p .381

67.30 (15.46) 69

58 (14.64) 62

X2 1.54, p .215

61.67 (16.08) 62

64.09 (13.73) 70

X2 0.52, p .471

Fatalism

14.13 (3.09) 14

10 (3.69) 10

X2 5.92, p .015

13.78 (3.57) 14

13.73 (3.38) 13

X2 0.05, p .821

Fighting spirit

11.78 (2.76) 12

9.17 (2.71) 10

X2 4.26, p .039

11.56 (2.55) 12

11.55 (2.34) 12

X2 0.01, p .946

Helplessness/hopelessness

13.09 (4.80) 13

10.83 (1.60) 11.5

X2 0.82, p .367

11.94 (4.82) 9.5

12.09 (4.83) 9

X2 0.00, p 1.00

Anxious preoccupation

18.13 (6.48) 19

18 (5.10) 19.5

X 0.04, p .850

16.06 (6.28) 15.5

17.91 (6.56) 20

X2 0.74, p .391

Cognitive avoidance

10.17 (3.03) 11

10 (3.46) 11

X2 0.01, p .935

8.33 (4.10) 8

8.82 (3.84) 9

X2 0.10, p .751

PES Time 1

50.13 (5.78) 50.5

43.33 (3.56) 43.5

X2 6.62, p .010

48.89 (5.31) 50

47.50 (4.89) 48

X2 0.43, p .510

PES Time 2

47 (5.84) 47

41.17 (2.99) 41

X2 6.05, p .014

49.33 (4.91) 49.5

49.75 (6.78) 52.5

X2 0.24, p .625

PES Time 3

48.13 (5.96) 48

43.67 (5.61) 42

X2 2.80, p .094

50.56 (5.07) 51.5

49.64 (6.67) 52

X2 0.04, p .839

Mini-MAC Time 3
Total scale scores

2

Note. *Kruskal–Wallis test result; Bolded p value indicates statistical significance p<.05
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